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Abstract 
C. neoformans var. grubii is the main cause of life-threatening cryptococcal meningitis 
worldwide, especially in individuals with underlying immunosuppressive conditions such as 
HIV infection. In contrast to its sister species C. gattii which is now considered a primary 
human pathogen, C. neoformans var. grubii does not commonly infect apparently healthy 
individuals. However, it is now clear that C. neoformans var. grubii infection also occurs in 
apparently healthy individuals in Vietnam, China and elsewhere in Southeast/East Asia. This 
could be explained by two possibilities: (i) disease in the immunocompetent is associated 
with strains with increased pathogenic potential, or (ii) there are unknown immune defect(s) 
that confers increased susceptibility in affected individuals. This thesis investigates the 
former hypothesis by systematically assessing and comparing genetic composition, virulence-
associated phenotypes and transcriptomes of C. neoformans var. grubii isolates from 
Vietnam from HIV-infected and HIV-uninfected patients.  
MLST-based interrogation of population structure of clinical C. neoformans var. grubii 
isolates from Vietnam and Laos reveal that the population from Vietnam is unique and 
intermediate in composition between that from Thailand/Laos to the West/Southwest and 
China to the East/Northeast. Almost all disease in HIV-uninfected patients is associated with 
the MLST ST5 lineage.  Comparison of in vitro and in vivo (mouse and macrophage models) 
virulence-associated phenotypes reveals lineage-specific differences. Specifically, ST5 strains 
appear with more phenotypic variability, increased intracellular replication inside 
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macrophages, and induction of more robust immune responses but apparent decreased 
virulence in mice. RNAseq profiling under log-phase growth highlights genotype-specific 
differential expression of key processes which may contribute to virulence. My data suggest 
that higher ST5 prevalence in apparently immunocompetent patients in Vietnam are not 
necessarily associated with the ability to cause more severe in-host damage and mortality, 
but likely represent better adaptation to the innate immune system and establishing 
infection in immunocompetent hosts.  
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Chapter 1 
INTRODUCTION 
1.1. Overview of cryptococcosis 
Cryptococcosis is disease caused by infection with Cryptococcus fungi, most notably 
Cryptococcus neoformans and its sister species Cryptococcus gattii. The disease impacts 
various patient groups including the apparently healthy as well as those immunosuppressed 
following solid organ transplantation, HIV infection, hematological and other malignancies, 
other iatrogenic immunosuppression, and immunosenescence related to aging [1–5]. 
Globally, Cryptococcus neoformans var. grubii is mostly associated with infection in 
immunosuppressed patients, although cases due to this species in otherwise healthy people 
are occasionally reported [5,6].  It is generally considered to be an opportunistic pathogen. 
This contrasts with C. gattii, now considered a primary human pathogen, which is mostly 
frequently reported causing disease in apparently healthy people [6,7]. Of note, a 
hypervirulent lineage of C. gattii has caused an outbreak of disease in immunocompetent 
individuals in Vancouver, Canada, over the last 20 years [8].   
The most frequent presentation of cryptococcosis is a sub-acute or chronic meningitis [5,9]. 
This has a very poor prognosis, with  90 day mortality rates as high as 70% in low income 
countries, and even in rich well-resourced settings, in the order of 10 to 20% [2].  The best 
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treatment outcomes depend upon the use of the polyene Amphotericin B, which is 
associated with significant risk of renal and hematological toxicity. Moreover, it is expensive, 
requires a cold chain, and is frequently unavailable where the disease burden is most high. In 
wealthy countries, Amphotericin B is usually combined with flucytosine, both of which were 
developed over 50 years ago. There has been no significant advance in treatment since the 
development of the azole drugs in the 1980s. Of these, fluconazole is key in consolidation 
therapy and secondary prophylaxis [10]. Monotherapy with fluconazole is the only treatment 
available in many resource–poor areas; unfortunately this delivers significantly worse 
outcomes than combination therapy regiments.  
1.2. The history of cryptococcosis 
In 1894, the first cryptococcosis case in humans was observed and reported by Busse and 
Buschke, who  cultured and isolated the etiologic agent from skin eruptions of the patient 
naming it Saccharomyces, and the disease Saccharomycosis hominis (S. hominis) [11,12]. In 
that same year, Francesco Sanfelice isolated an encapsulated yeast from peach juice and 
named it Saccharomyces neoformans (S. neoformans), marking the first description of an 
environmental isolate of the fungus [13]. The fact that the pathogen can persist in nature, 
infect and cause disease in both humans and animals was supported by isolation of S. 
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neoformans from the lymph node of an ox by Sanfelice in 1895 and from a pulmonary lesion 
from a horse by Frothingham in 1902 [14]. In 1896, another human case was described by 
the French pathologist, Curtis, who named the fungal pathogen Saccharomyces 
subcutaneous tumefaciens – distinguishable from S. neoformans in morphology and virulence 
in animal models [14]. In 1901, because of their lack of ascospore formation and carbon 
fermentation capability, cardinal characteristics of the genus Saccharomyces, Vuillemin 
reallocated S. hominis and S. neoformans (seemingly two different organism) into the genus 
Cryptococcus [15].  
Cryptococcal meningitis was first described in 1914, although the causative agent was 
mistakenly named Torula histolytica and the disease named torulosis. Over the ensuing years  
C. neoformans  came to have over 40 synonyms assigned under 7 different genera, including  
S. neoformans, C. hominis, Torula neoformans and T. histolytica [16]. It was not until 1950 
that Cryptococcus neoformans  became the official name, with torulosis and torula meningitis 
being replaced by cryptococcosis and cryptococcal meningitis and [16].  
In 1970, a further varietal form was described following isolation from an African patient with 
leukemia by Gattii and Eeckels - C. neoformans var. gattii. Kwon-Chung et al. determined that 
this strain was the anamorph of Filobasidiella bacillispora and identical to the type strain of 
Cryptococcus bacillisporus. This variety, C. neoformans var. gattii has now been designated as 
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a separate species - C. gattii [17]. As causative agents for cryptococcosis and cryptococcal 
meningitis, C. neoformans and C. gattii are now officially established in the order Tremellales 
within the phylum Basidiomycota.  
1.3. The C. neoformans/C. gattii species complex 
In the 1950s it was discovered that rabbit serum could distinguish forms of C. neoformans. 
Serotyping by capsular antigen agglutination can define 5 serotypes: A, D, AD hybrid, B, and C 
[18]. In addition, it was demonstrated the biochemical characteristics including carbon and 
nitrogen assimilation, resistance to canavanine, urease production, and sporulation 
morphology could divide C. neoformans  into the 2 varieties: var. neoformans, consisting of 
the serotypes A, D and the AD hybrid, and var. gattii, consisting of serotypes B and C [14,19–
22]. Serotypes A and D were subsequently themselves classified as separate varieties of C. 
neoformans : var. grubii for serotype A and var. neoformans for serotype D[17]. The recent 
designation of C. neoformans  and C. gattii as separate species is largely based upon the 
profound differences in key aspects of genetics, physiology and biochemistry between the C. 
neoformans  and the C. gattii species complexes [23–26].  
Besides serotyping by capsular antigen agglutination, various molecular typing methods have 
been employed to study the genealogy and molecular evolution of Cryptococcus neoformans 
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species complex. These include PCR fingerprinting methods that detect polymorphisms 
among microsatellites and similar repetitive DNA elements, RAPD (Random Amplified 
Polymorphic DNA), AFLP (Amplified Fragment Length Polymorphism), RFLP (Restriction 
Fragment Length Polymorphism), and direct DNA sequencing such as Multilocus Sequence 
Typing (MLST)[27–29]. A consensus MLST typing scheme has been established by the 
Cryptococcus Species Genotyping Working Group under the auspices of the International 
Society for Human and Animal Mycology (ISHAM), to facilitate data exchange and 
comparison between different research groups worldwide [30]. Isolates from serotype A 
belong to the  VNI, VNII or VNB (so far unique to the southern Africa region) molecular types 
while serotype D isolates are molecular type VNIV [29]. Serotype B includes VGII,  VGII and 
VGII molecular types while serotype C comprises a VGIII or VGIV pattern[31].  
1.4. Ecology and environmental niches 
Even though a main niche for C. neoformans  in the environment has not been identified, it 
has been established that avian guano, especially from pigeons, is a frequent source of 
isolation in the environment [32–35]. C. neoformans  cells are able to tolerate the high 
concentrations of urea, catecholamines and other nitrogenous compounds abundant in 
desiccated pigeon guano, suggesting the medium is a potential source for enrichment of 
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Cryptococcus cells [36]. Furthermore, pigeon guano may provide a survival advantage for C. 
neoformans because it is an inhospitable environment for competitive yeasts such as Candida 
and Pichia. These yeasts are known to produce anti-cryptococcal toxins[37]. While the 
association with pigeon guano in temperate climates is the most well-established, C. 
neoformans has also been isolated from the droppings of other birds species including 
chicken, duck, goose, parrot, owl, eagle and peacock [14,38].  C. neoformans has also been 
isolated from the beaks and feet of feral pigeons, suggesting that the birds have occupied 
and possibly foraged in C. neoformans -contaminated places [39]. Both serotypes A and D 
have been isolated from soil contaminated with pigeon droppings, air above avian guano-
contaminated soil and tree swabs [40–42]. The demonstration of the presence of C. 
neoformans on the surface of pigeons, rather than solely in the guano, supports the notion 
that pigeons are implicated in the global spread of the organism, acting as carriers. Since the 
normal range of body temperature for  pigeons is 41 – 42oC, which is significantly higher than 
the optimal temperature for growth of C. neoformans , is unlikely that global dispersion is 
primarily attributed to infection of pigeons [43], but more likely due to its external carriage.  
In addition to the well-documented association between C. neoformans and pigeon guano, C. 
neoformans can also be isolated from a variety of trees in many parts of the world, including 
South America, India and Thailand in Southeast Asia [44–48].  These arboreal niches are 
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considered to be in addition to the habitats associated with frequent exposure to avian 
feeding/guano.  
1.5. Mating types in cryptococcal life cycle and their association with 
virulence 
Two sexual phases (Mating Type – MAT) of C. neoformans and C. gattii have been identified 
and characterized: MATα and MATa [49,50]. The mating type is controlled by the MAT locus 
which is large (>100kb) and consists of more than 20 genes [51–53]. Many of these encode 
both regulators of sexual development and elements of the pheromone response pathway 
[53]. The MAT locus itself is a non-recombining chromosomal fragment from which an intact 
MATa or MATα allele is included in each segregated segment during meiosis [54]. The 
product of sexual mating between two isolates of opposite mating type is the basidiospore, 
which is proposed to be an important infectious propagule for cryptococcosis in human [55]. 
The role of mating types and the stages of the life cycle of Cryptococcus neoformans are 
summarized in Figure 1.5-1. 
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Figure 1.5-1. Life cycle of Cryptococcus neoformans  
 9 | P a g e  
 
In a bipolar mating system such as that of Cryptococcus spp., an equal ratio of α:a mating 
types would be expected. However the majority of environmental and clinical isolates of C. 
neoformans were dominated by the MATα mating type [56]. In Sub-Saharan Africa, MATa 
isolates are found at a much higher frequency and population genetics analyses have 
revealed features of mating likely to involve both mating types [29,57].  
The overall bias toward MATα in nature, given that there is no apparent physiological or 
fitness difference between α and a cells, remains unexplained. One possible explanation was 
provided by Wicker et al. (1996), who reported that only MATα cells were able to undergo 
haploid fruiting under nitrogen starvation conditions in the absence of a mating partner [58]. 
While this ability first appeared to be restricted to MATα strains, it has subsequently been 
described in MATa strains, and the phenomenon of haploid fruiting is clearly independent of 
mating type [59]. Haploid fruiting, while originally thought to be strictly mitotic, has been 
shown, in vitro, to share some of the features of sexual mating, including chromosomal 
diploidization and meiosis. This implies that α-α diploid cells can undergo independent 
chromosomal rearrangement and produce haploid basidiospore progenies [60]. 
Furthermore, fusion and meiosis has been shown to occur between non-isogenic alpha 
strains, enabling genetic exchange. The progenies of such ‘same-sex mating’ show high rates 
of recombination and have novel genotypes differing from the parental genotypes [60]. 
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Phylogenetic studies of C. gattii strains form the Vancouver outbreak supports the idea that 
same sex mating also occurs in the environment [61]. It has been suggested that same sex 
mating occurring under specific environmental stresses confers an evolutionary advantage 
because the resultant recombinant basidiospores are easily aerosolized and dispersed to 
other geographical regions [61]. 
MATα has been considered the more virulent mating type based on animal studies [62,63]. 
MATα cells of C. neoformans var. grubii seemed to penetrate the CNS better during 
coinfection with congenic MATa C. neoformans var. grubii cells [63]. Notably, both bisexual 
and unisexual mating generate aneuploid progenies at similar rate [64]. This may be relevant 
because aneuploidy has been associated with variation in the expression of certain 
cryptococcal virulent factors, including  melanin [65]. Aneuploidy has also previously been 
identified as a mechanism of drug resistance during normal growth on varying 
concentrations of fluconazole [66] and variable susceptibility to fluconazole could be seen in 
aneuploid progeny generated without selection by fluconazole [67]. Interestingly, there may 
be an important role for the MAT locus outside of mating. Transcriptional profiling of C. 
neoformans during murine macrophage infection reveals that almost the entire MATα locus 
has increased expression following ingestion by macrophages, suggesting the locus has a 
particular role during infection [68]. However, the sheer complexity of the MAT locus and the 
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diverse pleiotropic functions of its encoded products make it difficult to investigate the 
contribution of individual genes to virulence [38].  
1.6. Infectious propagules for cryptococcosis in human 
As with other fungal pathogens, inhalation of airborne spores has long been considered the 
most likely  route of infection for cryptococcosis in human[69,70]. Cryptococcus spores (~1-2 
μm in diameter) are significantly smaller than yeast cells or filamentous hyphal cells, which 
likely facilitates both their ability to become airborne and their entry into the alveoli 
following inhalation [71]. In addition, spores are potentially better able to persist in any given 
environment than yeast cells, being more resistant to desiccation and nutrient starvation 
conditions [58]. The ability of spores to establish successful infection has been demonstrated 
in a murine nasal infection model. Of note, spores from different varieties/lineages may have 
different virulence potential; serotype D spores have been reported to be more virulent than 
the corresponding yeast cells; this contrasts with serotype A spores which were not found to 
be as virulent as their yeast counterparts [72,73]. Interestingly, while serotype D strains were 
more potent in terms of establishing infection, this same model found spore-associated 
mortality in mice to be lower compared with that when a yeast cell inoculum was used [72].  
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The presence and infectivity of spores does not preclude the fact that infection may also 
occur following inhalation of desiccated yeast cells. The increased size of yeasts compared 
with spores may be mitigated by the fact that in nutrient deprived and low moisture 
environments there is considerable heterogeneity in capsule production and cell size. Under 
these circumstances cells may be as small as  3μm or less in diameter, thus facilitating their 
uptake by inhalation by the host [73]. However, the relative importance of yeasts versus 
spores in human infection remains unclear; the feasibility of such yeasts as infectious 
propagules must be considered in the context of their reduced viability and potential for 
dispersal in the environment [58]. However, the relative importance of spores in causing 
human infection must be considered in the light of the fact that while spore production has 
been demonstrated in the laboratory, due to at least 2 mechanisms - same-sex mating and 
opposite-sex mating -  neither of these phenomena has been directly observed in nature, and 
population studies suggest that recombination appears to be a relatively infrequent event 
[74–77].  
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1.7. Population structure, genomic diversity and putative origin of the 
global C. neoformans var. grubii population 
1.7.1. Global population structure of VNI C. neoformans var. grubii 
C. neoformans var. grubii (serotype A) has a global distribution and is responsible for the vast 
majority of cryptococcal disease in immunocompromised hosts [78–80]. Molecular typing 
studies demonstrate that the greatest genetic diversity is found within African populations 
[23,29,81–83]. Both clinical and environmental populations are dominated by the MATα 
mating type [83–85]. The global C. neoformans var. grubii population can be divided into 3 
main lineages: VNI, VNII and VNB[29,30,86]. While VNI and VNII are globally dispersed, the 
VNB lineage is largely restricted to southern Africa, having first been identified in Botswana 
[29]. Subsequently VNB has been sporadically reported from Brazil [22,25] and as an AD 
hybrid in China, Italy and the USA[87], though with much lower frequency. Current data 
suggest that the VNB lineage is largely geographically restricted to sub-Saharan Africa. The 
restriction of the VNB lineage to southern Africa may be explained by its adaptation to a 
particular ecological niche. While  environmental isolates of VNI are often associated with 
pigeon excreta [40,88], environmental isolates from the VNB lineage are highly associated 
with a specific indigenous African Mopane tree species (Colophospermum mopane) [81,82]. 
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Comparative genomics further divided the VNB lineage into 2 subgroups: VNB-I and VNB-II 
[82,89,90].  
Xu et al., (2000) investigated a set of strains from multiple geographical locations using a 
multi gene genealogies approach and reported high divergence among strains of different 
varieties/serotypes from the same geographical region but low divergence among strains of 
the same variety/serotype from different geographical regions, which supports the 
hypothesis of a relatively recent global dispersal of C. neoformans species [23]. The global 
VNI lineage, with its relatively low overall diversity, is proposed to have emerged from a 
small founder population that may have undergone repeated bottlenecks while spreading 
across different geographical regions [90].  
A recent extensive phylogenetic study by Desjardins et al., using whole genome data (2017) 
further divided the VNI lineage into 3 distinct sub-clades with different geographical 
distributions (VNIa, VNIb and VNIc) [90]. VNIa and VNIb were globally distributed while VNIc 
was restricted to Sub-Saharan Africa [90] (Figure 1.7-1). There appears to be active 
recombination events occurring between these individual sub-clades, as evidenced by faster 
rates of linkage disequilibrium decay in the major VNI lineage compared to the individual 
sub-clades [90] (Figure 1.7-1). The finding of highly diverse progenitor African strains of C. 
neoformans var. grubii with the capacity for sexual as well as clonal reproduction, compared 
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to the largely clonal C. neoformans var. grubii strains elsewhere, suggests that the global 
population has been driven by an “out-of-Africa” dispersal [81]. The existence of the sub-
Saharan Africa endemic VNIc sub-clade and the presence of African-origin VNIa and VNIb 
strains across the globe also support this “out-of-Africa” hypothesis [90]. These and previous 
findings suggest diversification of different VNI sub-clades occurred within Africa, with 
subsequent global expansion; the mechanisms through which this dispersion occurred are 
unknown mechanisms, but postulated to be facilitated by avian migrations and human 
activities [81,91,92].  
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Figure 1.7-1. Sub-structures of the global C. neoformans var. grubii VNI population (adapted from 
Desjardins et al. (2017) [90].  
(A) Comparative genomics and phylogenetic analysis divide the global VNI population into 3 major 
sub-clades, the global VNIa and VNIb, and the Southeast African VNIc. (B) Clustering analysis in 
STRUCTURE and PCA reveal largely distinct sub-populations (VNIa, VNIb and VNIc) with a small degree 
of mixing between groups. (C) Linkage decays more rapidly in the global VNI population than in any 
individual sub-clade, suggesting the sub-populations are currently recombining with each other and 
do not represent reproductively isolated populations. 
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1.7.2. Genes under selection in C. neoformans var. grubii 
Evaluation of genes under selection in all lineages of C. neoformans var. grubii revealed that 
the sugar transporters subset of the major facilitator superfamily (MFS) transporters, 
especially transporters for inositol, xylose, maltose, α-glucosides, lactose and galactose, are 
among those under extensive positive selection [90]. Other groups of genes under selection 
include monoxygenases in VNI and β-glucosidases in VNB [90]. This finding provides insights 
into the different adaptation of various lineages of C. neoformans var. grubii to 
environmental stress that also translate to pathogenicity in human in a “by-stander effect” 
fashion [93,94]. Specifically, enrichment of inositol and xylose transporters has been 
proposed to be involved in cryptococcal growth on different species of trees [90,95,96]. On 
the other hand, selection of inositol metabolism in the VNI lineage is evidently related to VNI 
pathogenicity in human since inositol is abundant in the human brain [97] and is a known 
stimulator for cryptococcal penetration of the Blood-Brain Barrier [98].  
1.7.3. Population structure of C. neoformans var. grubii in Asia and Vietnam 
Limited data exist on the population structure of C. neoformans var. grubii in Asia, including 
reports from India [99,100], Thailand [22,92,101,102], Vietnam [103], China [104–106] and 
Japan [107]. Pan-Asia MLST-based population structure analysis revealed clustering of C. 
neoformans var. grubii isolates according to their original geographical region: cluster 1 
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mostly consists of isolates from China, Japan and a number of isolates from Thailand; cluster 
2 contains the remaining of the Thai isolates and a number of Indonesian isolates; cluster 3 
included Indian isolates and the rest of the Indonesian isolates [101]. Widespread occurrence 
and overrepresentation of genotypes derived from clonal expansion of a few dominating 
parental genotypes was implicated, similar to what have been described for other pathogens 
including Neisseria meningitides, Mycobacterium tuberculosis, Fusarium oxysporum, and 
Leishmania tropica [108]. The overwhelming presence of the MATα mating type means that 
natural bisexual reproduction is rare among C. neoformans var. grubii populations in the 
environment and the fact that C. neoformans yeasts could undergo same sex mating, as well 
as the low rate of recombination which limits genetic divergence may have been one of the 
driving forces for the observed clonality in Asia. 
Most reports of C. neoformans var. grubii population structure from Asia indicate there is 
limited population diversity compared to other parts of the world, as well as the expected 
domination of MATα in both environmental and clinical isolates [101]. For example, all the 
clinical isolates from a cohort of 120 Chinese patients were infected with the same MLST 
genotype, M5 [109], later identified as multilocus sequence type 5 (ST5) [104,106,110]. More 
than 90% of clinical C. neoformans var. grubii isolates from Japan and South Korea were also 
ST5 (designated as M5 or VNIc in the original studies) [107,111]. In contrast, most cases 
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reported from Thailand included C. neoformans var. grubii isolates from HIV-infected 
patients, which appeared to be more diverse than those from East Asia and included 3 main 
MLST genotypes: ST4, ST5 and ST6 [92,101,102].  Studies from the East Asian region (China, 
Japan, Korea), however, are complicated by a relative lack of isolates reported from patients 
with immunosuppression, in particular HIV infection. AFLP typing of the clinical population of 
VNI C. neoformans var. grubii from Vietnam separated the isolates into two distinct clusters 
with specific association with host immune type (HIV status) [103]. Specifically, the 
respective AFLP clusters were termed VNI-γ and VNI-δ, both of which were found in HIV-
infected patients though with different proportions [103]. Intriguingly, VNI-γ accounted for 
over 80% of cases in HIV-uninfected patients with no known underlying diseases [103]. VNI-δ 
infection, when found in HIV-uninfected patients, was often accompanied by other serious 
immunosuppressive conditions [103]. While the genomic divergence between the two 
clusters was apparent, their implication to virulence potential and host preferences, i.e. 
paradoxical C. neoformans var. grubii-associated infection in apparently immunocompetent 
hosts, is still unknown.  
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1.8.  Virulence in animal hosts results from adaptation for survival in the 
environment  
Because cryptococcal infection is not contagious (i.e. no host-to-host transmission), it is 
widely held that the ability of C. neoformans to cause disease is due to the coincident or 
accidental acquisition of pathogenicity as it adapts to heterogeneous environmental 
conditions – so-called bystander pathogenicity [94,112]. A variety of virulence factors have 
been identified in vitro, including the polysaccharide capsule, the ability to grow at 
mammalian body temperatures, production of laccase and melanin, and a number of 
secreted factors important in countering the host immune response, including phospholipase 
B and urease [113][14]. Almost all these previously described cryptococcal virulence factors 
can be attributed to survival functionality in the environment. For instance, encapsulated 
yeast cells are more resistant to desiccation and predation by amoeba in the environment 
[114,115]; the ability to withstand and grow at high temperature is a desirable trait for fungal 
survival in niches with extreme temperature range [116,117]; and cell wall melanization is 
associated with protection from UV and other electromagnetic radiation [118,119].  
Many virulence factors may play a role in protecting the yeast against environmental 
predation. Using Acanthamoeba castellani as an experimental host, it has been 
demonstrated that following ingestion C. neoformans undergoes intracellular replication. 
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This is accompanied by the accumulation of cytosolic vesicles containing shed capsular 
polysaccharide [115]. The intracellular growth rate of C. neoformans is impaired in mutants 
with deficient capsules or phospholipase; acapsular mutants are more readily killed following 
ingestion by the amoeba [120,121]. Interestingly, phagocytosis of C. neoformans cells by 
amoebas in the presence of divalent cations such as Mg2+ and Ca2+ enhanced yeasts killing, 
which suggests that C. neoformans-contaminated soil with increased concentration of 
divalent cations may harbor fewer number of cryptococci due to increased amoeba 
predatory activity [122]. On the other hand, melanin production may protect against 
predation by amoeba since, even in acapsular strains, melanized yeasts are more likely to 
survive ingestion [120,121]. These observations illustrate that virulence factors recognized in 
mammalian hosts, such as capsule and melanin, are likely derived from adaptations that have 
evolved to manage ecological risks. The development of such transferable intracellular 
survival skills may help to explain the broad host range of C. neoformans since all major 
mammalian immune responses rely on phagocytic effector cells.  
Despite the fact that Cryptococcus spp. can infect a broad host range (from amoebae and 
worms to mammals) it is unlikely that a susceptible host is a pre-requisite for any stage of the 
Cryptococcus life cycle. While in-host environments could lead to microevolution of infecting 
C. neoformans yeasts [123–125], it is improbable that cryptococcal virulence is a result of in 
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vivo selective pressure because the disease is not passed from host to host. Rather, current 
data support the idea that selection pressures from environmental stress and predation have 
led to the acquisition of a unique set of cryptococcal survival strategies, which just happens 
to be confer the potential for mammalian infection.  
1.9. Intracellular parasitism 
The interactions of C. neoformans with amoeba and host macrophages are strikingly similar. 
In mammals C. neoformans is a facultative intracellular pathogen, and can survive 
phagocytosis by innate immune cells and proliferate intracellularly [14]. Recently it has been 
demonstrated that there can be subsequent non-lytic extrusion of yeast cells from 
macrophages to the extracellular space or adjacent host cells (vomocytosis) [120,126–131]. 
The intracellular parasitism of host monocytes and macrophages is a likely key in enabling C. 
neoformans to disseminate and cause brain infection [132–134]. This complex pattern of 
interaction with host innate immune cells is  a key determinant of virulence - both 
Intracellular Proliferation Rate (IPR) and phagocytosis proclivity have been correlated with 
mortality and fungal clearance during antifungal treatment [133,135–137]. Cryptococcal 
interaction with phagocytic cells from the host’s innate immune system is summarized in 
Figure 1.8-1. 
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Enhanced ability to survive and replicate inside macrophages has been shown to be 
associated with the spread of C. gattii in northwestern North America and may even have 
triggered the outbreak [130]. The strain associated with this outbreak – VGIIa - has a higher 
IPR than other C. gattii genotypes associated with a unique tubular mitochondrial 
morphology. It is postulated that this confers a protective effect  by enabling repair of intra-
phagosomal oxidative damage to mitochondrial DNA [130]. Such VGIIa yeasts with tubular 
mitochondrial morphology were found to be highly resistant to host Reactive Oxygen Species 
(ROS) [138]. In contrast to C. gattii,  with C. neoformans it is yeast uptake by macrophages, 
rather than the IPR, which has been found to correlate with the patient’s cerebrospinal fluid 
(CSF) fungal burden in HIV infected patients [135]. Furthermore, infection with high-laccase-
activity, high-uptake C. neoformans correlates with both higher pre-treatment fungal 
burdens in patients’ CSF and slower rates of CSF fungal clearance with antifungal treatment, 
which may lead to an increased risk of death[135]. Strains with smaller capsules, while more 
readily engulfed by macrophages, may possess mechanisms that confer improved 
intracellular survival and proliferation.  
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Figure 1.9-1. Interactions between infecting Cryptococcus yeasts and phagocytic cells from the host’s innate immune system.
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1.10. Acute infection versus latency in cryptococcosis 
It is commonly held that active cryptococcosis in humans is largely the result of reactivation 
of latent, or dormant infection. Acute infection, following defined exposure incidents, has 
been reported, but seems to be a very rare event [139,140]. The evidence supporting latency 
prior to disease is derived from studies investigating C. neoformans -specific seroprevalence 
in adults [141–143]. Findings from a study in New York found serological evidence of 
previous exposure to C. neoformans infection from children as young as 2 years (over 50%), 
implying exposure is common and occur very early in life, resulting in long term latency [144]. 
The serological reactivity and prevalence in children differed according by geographical 
region, suggesting regional-associated differences in exposure [145].  
Further evidence is derived from a study from France. In this study, AIDS-associated 
cryptococcosis patients, resident in France for a median period of 110 months, and without 
exposure to an African environment for at least 10 years, were found to be  associated with 
infection by C. neoformans strains with African origins [146]. In another report, solid-organ-
transplant patients were seropositive for cryptococcal antigens before the procedure, 
suggesting subsequent cryptococcal disease in these patients was reactivation from 
dormancy following immunosuppressive therapy [147]. Re-infection of the same strain(s) is 
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unlikely in this case because acute and progressive cryptococcal disease is only possible when 
patients are exposed to an unusually high inoculum of yeasts. Together, these data suggest 
that patients acquire and sequester initial infection with C. neoformans early in life. Active 
disease manifestation then occurs when patients acquire immunosuppression, most 
commonly HIV, resulting in loss of immune control and disease activation.  
While in theory it would be possible to confirm the latency theory by comparing the latent 
strain with the disease strain, in practice this is impossible because the point of latent 
infection is (presumed) asymptomatic, and the strain cannot be obtained.  However, most 
cases of recurring cryptococcosis are associated with persistence of the single original isolate, 
even after long periods of antifungal treatment, providing indirect evidence consistent with 
the latency hypothesis [148–150].  
However, it is of course possible that ‘relapse’ in these cases in fact represents re-infection  
by a different isolate of the same genotype, given the ubiquitous distribution of C. 
neoformans in the environment and the largely clonal structure of the global C. neoformans 
population [92,101,151,152]. Conversely, relapse infection by a different genotype could 
represent either new infection or reactivation from a previous mixed infection with multiple 
strains [150]. Mixed infection by strains of different genotypes/serotypes may occur in up to 
20% of all cryptococcosis cases [150].  
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1.11. Cryptococcal virulence factors 
1.11.1. The polysaccharide capsule 
Capsular structure 
The cryptococcal capsule is unique amongst human pathogenic yeasts, and is comprised 
primarily of two polysaccharides, glucuronoxylomannan (GXM) and galactoxylomannan 
(GalXM), with a lesser proportion of mannoproteins (MP)[153]. GXM is a complex 
polysaccharide with a repeating structure of α-1,3-mannose with β-D-xylopyranosyl, β-D-
glucuronosyl and 6-O-acetyl branching and accounts for 90-95% of capsular mass. GalXM is 
an α-(1→6)-galactan containing four short oligosaccharide branch structures and constitutes 
about 8% of the capsular mass. Mannoproteins constitutes less than 1% of capsular mass and 
share several structural features including N-terminal signal sequences, serine/threonine 
(S/T)–rich C-terminal regions, and glycosyl-phosphatidylinositol anchor motifs.  
Heteropolymer branching is a notable conformation of the cryptococcal capsule. This is due 
to the fact that cryptococcal polysaccharides are synthesized intracellularly and transported 
to the extracellular space via vesicle-mediated secretion, with additional biochemical 
modification as they migrate through the cell-compartments to the cell surface [154–157]. 
The degree of branching and/or structural complexity influences the ability of capsular 
polysaccharides to interfere with phagocytosis, stimulate nitric oxide production by 
 28 | P a g e  
 
macrophages, protect against reactive oxygen species (ROS) and antibody reactivity, as well 
as determining the half-life of capsular polysaccharide molecules in serum [158].  
Capsule structure varies substantially depending on the strains and the surrounding 
environment, as well as during the course of infection [159]. Electron microscopy data reveal 
a heterogeneous structure consisting of an electron-dense inner layer and an electron-sparse 
outer layer [160–162]. With this configuration, the outer layer appears more permeable 
while the inner layer is more rigid, able to block larger macromolecules such as antibodies 
and complements proteins from reaching the cell wall [160,162,163].  
Capsule size 
Capsule size is highly variable, not only between different strains but also among individual 
cells from the same strain. Despite its importance in pathogenesis, the relationship between 
capsule size and virulence is not simple. In one study, HIV patients infected with strains 
producing large capsules were more likely to have higher intracranial pressures at 
presentation and lower fungal clearance rates upon treatment with amphotericin B and 
fluconazole [164]. Consistent with this, it has been demonstrated that acapsular C. 
neoformans strains have reduced pathogenicity in mice [165,166].  The fact that acapsular C. 
neoformans strains are only capable of causing prolonged brain infections in nude mice 
(mutants with an absent or deficient thymus resulting in T-cell failure) suggests that these 
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strains would only present virulence in severely immunocompromised hosts [167]. However, 
disease due to strains with small capsules in humans has been reported [167]. 
Role of the capsule in cryptococcal pathogenesis 
The role of the capsule in cryptococcal survival and defense against hosts’ immune response 
is well-established [153,164,168]. In the environment, the capsule protects yeast cells from 
dehydration and desiccation and contributes to survival in low humidity conditions [114]. In 
addition, encapsulated C. neoformans strains are less likely to be phagocytosed and killed by 
the amoeba Acanthaamoeba castellani, [115]. Within mammalian hosts, the capsule protects 
un-opsonized yeasts from ingestion by phagocytes and impedes host immune response in 
vitro [169].  
Capsular shedding may also have a role in pathogenesis in vivo [153]. Shed capsular 
polysaccharides are secreted into vesicles around the phagosome; the accumulation of these 
vesicles in the cytoplasm of the host cell results in macrophage dysfunction and lysis  
[170,171]. Capsular polysaccharide materials have also been found to induce proliferation 
and differentiation of normal CD4+ T cells into a (non-protective) Th2 phenotype, favoring 
intracellular parasitism and dissemination of C. neoformans [172].  
In patients, data suggest that high levels of capsular antigen in CSF are associated with 
increased intracranial pressure, headaches and visual disturbance [173]. In addition, capsular 
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material impedes host neutrophil recruitment [174], interferes with cytokine response [175–
179], induces macrophage apoptosis either via a Fas-ligand mediated pathway or nitric oxide 
production [180], and delays host dendritic cell maturation and activation [181]. 
1.11.2. Thermotolerance 
The ability to grow at mammalian body temperatures (37oC or higher) is an obvious yet 
essential attribute for any would-be invasive fungal human pathogen [182–185]. There are 
several proposed models for the origin and evolution of thermotolerance in C. neoformans. It 
has been hypothesized that a bolide collision 65 million years ago eliminated a vast 
proportion of the Earth’s fauna and triggered a global chain reaction of volcanic and seismic 
activities, giving rise to a massive fungal bloom that fed on decaying vegetation [182]. Under 
these conditions, endothermy was a costly but effective adaptation for surviving mammals 
and birds species to offer protection against such a large fungal inoculum. Fungi would have 
to adapt too to successfully infect, colonize and cause disease in these new endothermic 
hosts [182] – however, since Cryptococcus spp. do not seem to require a mammalian host in 
any stage of its life cycle, adaptations to warmer environments seems a more plausible 
explanation for its thermotolerance.  
While C. neoformans can grow in a wide range of temperatures (30oC to 40oC) [185], there is 
considerable variation in thermo-tolerance between different strains, and some evidence 
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that this is determined by geographic origin [186]. For instance, C. neoformans var. 
neoformans strains, which in general are more susceptible to high temperature than the 
globally distributed C. neoformans var. grubii, are more commonly found in temperate 
Europe [186]. Evidence suggesting that Cryptococcus spp. originated from Africa further 
supports the speculation that growth at higher temperatures, essential for pathogenicity, is a 
survival advantage that resulted from environmental selection pressures in regions with 
higher ambient temperatures [81,116].  
1.11.3. Laccase and melanin production 
Melanin is a brownish black pigment produced through the oxidative polymerization of 
phenolic compounds. C. neoformans produces melanin with an oxidative enzyme called 
laccase which synthesizes melanin from L-DOPA, dopamine, norepinephrine and epinephrine 
[187–189]. Given the fact that environmental isolates of C. neoformans are often melanized, 
melanization may have evolved as a survival strategy to protect cells from UV radiation and 
facilitate growth at extreme temperatures [118,190,191]. Defects in melanin production 
result in improved mouse survival in laboratory models, suggesting a role in virulence [189]. 
Melanin has various roles in cryptococcal viability and pathogenicity including protection 
against enzymatic degradation, antimicrobial peptides, oxidative stress and heavy metal 
toxicity [192–194]. Of note, melanin has been shown to decrease the efficacy of 
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amphotericin B in vitro[194]. Histopathological studies of lung tissue at different time points 
during the course of experimental mouse infection also reveal yeast cell enlargement due to 
melanin accumulation in the cell wall, a characteristic conferring resistance against oxidative 
stress and antimicrobials [195]. C. neoformans var. grubii isolates from HIV-infected patients 
with higher range laccase activity have higher ex-vivo CSF survival and are more resistant to 
antifungal treatment[135]. 
1.11.4. Titan/Giant cell formation 
During the course of cryptococcal infection, yeast cells undergo various morphological 
transformations, depending on conditions. One such morphological change, first described in 
2010, is titan cell formation [196]. These are giant cryptococcal cells, up to 100 μm in 
diameter, and may account for  up to 20% of the lung fungal burden 24 hours after infection 
[197]. These larger cells are often polyploid (but uni-nucleated), suggesting an absence of cell 
fission following DNA replication [113]. 
 In mouse models of infection, the giant cell subpopulation is typically 10% to 80% of the 
total pulmonary fungal population, depending on the duration of infection, degree of 
pulmonary inflammatory response and total fungal burden[121]. Mice infected with a lower 
dose of yeasts, and with less severe pulmonary symptoms, produce a higher proportion of 
giant cells[121]. DNA replication without the subsequent completion of mitosis and/or 
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cytokinesis results in the elevated chromosomal numbers (frequently tetraploidy or 
octaploidy) associated with giant cell formation. However, the daughter cells (produced by 
budding) from giant cells are usually haploid or diploid[121,197].  
Pheromone and cyclic AMP-dependent signaling pathways have been shown to be major 
regulators of cryptococcal cell gigantism[113,121,198–200]. In addition temperature can be 
an important stimulus for giant cell formation. Yeast-cells from one brain tissue isolate were 
found to be of normal size (~5µm) at 25oC in vitro but expanded to a diameter of 25µm when 
cultured at 35oC[201].  
The formation of giant cells may be part of a survival strategy facilitating evasion of host 
immune defenses to allow colonization and establishment of infection: giant cells are 
frequently found in extracellular spaces and are generally more resistant to phagocytosis 
than regular yeast cells, suggesting that the giant cells represent a more viable extracellular 
subpopulation, co-colonizing with the intracellular population of smaller cells which have 
taken advantage of being engulfed, to facilitate dissemination[196,202]. Lower CSF fungal 
burdens in patients with chronic or latent infections are in keeping with the observation that 
lower inoculum seem to induce more gigantism[113], whilst it is the smaller cells which 
hijack macrophages to gain access to the CSF. Morphological heterogeneity during the course 
of infection is an obstacle for the host immune response [195]. Specifically, giant cells appear 
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to be much more resistant to phagocytosis and antifungals, representing an extracellular 
population that are extremely fit; the normal sized cells, on the other hand, could be 
phagocytosed but can still survive, proliferate and readily disseminate [195]. This may explain 
some of the observed difficulties in cryptococcal disease therapy [195].  
1.12. Genome “flexible stability” and survival-driven adaptability 
1.12.1. Cryptococcal genomic stability versus flexibility  
Early characterization of cryptococcal genomes employed electrophoretic karyotyping [203]. 
The size and number of cryptococcal chromosomes was highly variable in both clinical and 
environmental isolates, suggesting extensive chromosomal rearrangement and genomic 
flexibility [204]. Further investigation revealed the extent of variation within the population 
and suggested meiotic-driven karyotypic variation [205,206]. Karyotype changes also occur 
during the course of a single infection; this fact was observed in a series of human clinical 
cases, and confirmed in a mouse model of infection where karyotype was recorded before 
infection, and in organisms retrieved from body tissues [207]. Gross chromosomal 
rearrangement has been observed in closely related strains isolated from the same patient 
77 days apart, further supporting host selective pressures as a driving force behind this 
genome flexibility [208].These results are in accordance with the notion that infecting yeasts 
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adapt to selective pressures within the host and the result may be a virulence-associated 
phenotype [159,209].  
Large scale genomic studies employing comparative genomic hybridization reveal previously 
unobserved insertion and deletion type mutations (indels) within both var. neoformans and 
var. grubii, as well as a predisposition to aneuploidy which may confer resistance to 
fluconazole [66,210,211], a strategy also employed by Candida albicans where chromosomal 
rearrangement and duplication is proposed as a mechanism allowing populations to respond 
to selective pressures[212]. The term heteroresistance is used to refer to this situation, 
where a subpopulation of resistant organisms exists amongst a larger population of 
susceptible siblings, thanks to some degree of genomic plasticity.  
Most reports linking antifungal drug resistance in Cryptococcus spp. with aneuploidy focus on 
azoles, particularly fluconazole[213]. Various studies on azole heteroresistance in C. 
neoformans have demonstrated disomy in chromosomes 1 and 4 occurring in resistant 
subpopulations selected from growth conditions containing high antifungal drug 
levels[66,214]. Resistant clones emerging in media with the highest drug levels were found to 
have disomies in 4 chromosomes : Chr1, 4, 10 and 14[66,214]. Amplification of ATP-
transporter efflux pump genes like Erg11 and Afr1 on Chr1 was shown to correlate with azole 
resistance [66]. Disomy on Chr4 has been associated with genes required for endoplasmic 
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reticulum integrity under azole stress [214]. However it is not known whether increasing uses 
azoles were responsible for the development of cryptococcal heteroresistance or whether 
resistant subpopulations always existed in the global cryptococcal population [213]. 
1.12.2. Genomic features associated with adaptation for survival and in-host 
virulence 
In addition to chromosomal aneuploidy following exposure to antifungals, other forms of 
chromosomal variations that are associated with adaptation to environmental selection were 
also detected. For instance, close examination of the sub-telomeric regions of C. neoformans 
var. grubii strains has identified an enrichment of hexose transporters and tandem repeats of 
an arsenite resistance gene (Arr3) whose copy numbers were proportional to resistance to 
arsenite compounds[124]. Interestingly, this genomic variation was unique to MLST-
ST5[124]. Since the sub-telomeric regions in Saccharomyces cerevisae, Candida glabrata and 
Plasmodium falciparum were known for extensive accumulation of gene families that are 
essential for niche adaptation, the Arr3 repeats, though not important for in pathogenesis or 
antifungal resistance, may be essential for survival in environmental niches contaminated 
with high concentration of arsenite compounds [124]. The highly diverse sub-telomeric 
regions of cryptococcal strains from the VNI, VNIB and VNBII lineages all showed evidence of 
enrichment for transporters, which may have unknown functions related to niche adaptation 
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[215]. In addition, fungal transcription factors including FZC20, FZC41, SIP402, and FZC22, the 
last of which has been shown to affect virulence in mice when deleted [216], have been 
shown to be enriched in the 40kb sub-telomeric regions. 
Functional enrichment analysis of genes under positive selection in VNI and the two VNIB 
lineages revealed sugar transporters from the MFS family (Major facilitator superfamily) 
were highly selected in all 3 lineages [215]. Of note, isolates from the VNI clades seem to 
harbor high number of inositol transporters and catabolism genes that are under selective 
pressure [215].  As inositol is present in high concentration in human brain as well as being 
involved in cryptococcal mating and virulence [96,217–219], selection for inositol 
transporters and utilization could potentially influence lineage-specific host range and 
pathogenicity in human hosts [215].  
1.13. Transcriptomics and stress response pathways of C. neoformans  
In addition to genomics studies, a wealth of information has recently been attained from 
transcriptional profiling of C. neoformans molecular responses to stress conditions mimicking 
conditions in the host. Most studies employed in vitro infection models and well-
characterized laboratory strains of C. neoformans to study the transcriptional response to a 
range of stress conditions including high temperature [220–222], oxidative stress [223] and 
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capsule inducing conditions [224,225], to expression during infection of murine macrophages 
[226,227] and mammalian hosts [228–230]. These findings provided the basis of the current 
understanding of cryptococcal pathogenesis in the host.  
1.13.1. Response to high temperature 
The genes and pathways that are associated with cryptococcal temperature-dependent 
growth are among the most widely studied and characterized. These genes are often 
involved in key regulatory and metabolic pathways, which mean they are essential for 
multiple stress responses beside growth at high temperature, with direct or indirect impact 
on the expression of key virulence factors. For example, the gene VPH1, encoding a vesicular 
proton pump, is a universal regulator of capsule production, urease expression and laccase 
expression, as well as growth at 37oC [231]. The transcriptional activator MGA2, was 
previously found to be associated with growth at high temperature and virulence, was also 
involved in fatty acid synthesis [222]. In addition, temperature-dependent growth tends to 
be linked to genes involved in oxidative stress response, due to the fact that C. neoformans 
cells produce more oxidative waste as ambient temperature increases [185]. An example 
here is the mitochondrial gene SOD2 (manganese superoxide dismutase) which is responsible 
for detoxification of intracellular organelles but also has a role in regulating growth at high 
temperature [232]. Furthermore, temperature-regulated genes also tend to be a part of the 
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cryptococcal virulence composite. For instance, AOX1, SOD1, SKN7 and MGA1 are previously 
identified virulence-associated genes whose transcription is regulated by temperature 
[93,185,233,234].  
However, not all temperature regulated genes are clearly associated with virulence. One 
such example is CBP1 which has temperature regulated expression but is not clearly 
associated with virulence [235]. In contrast, genes can be essential for thermo-tolerance but 
their expression may not be temperature-regulated. An example of this is CNA1 (calcineurin 
A subunit) [234,236,237].  
Notably, there could be species/varietal-specific differences in transcriptional response to 
changes in temperature, as demonstrated for COX1 [237]. High levels of expression of heat 
shock proteins (HSP60, HSP70 and HSP90) at 37oC were detected in the serotype D strain 
B3501A but not in the serotype A H99 strain, suggesting that temperature as high as 37oC is 
not necessary a stress condition for serotype A strains [230]. In fact, induction of HSP60, 
HSP70 and HSP80/90 at 37oC does occur in low-iron environments, suggesting an 
interconnecting relation between iron concentrations in the host and regulation of heat 
shock proteins in vivo [230]. 
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1.13.2. Response to oxidative stress  
Phagocytic cells of the host innate immunity such as macrophages and neutrophils generate 
reactive oxygen (ROS) and nitrogen (RNS) species that are toxic to most invading pathogens, 
including C. neoformans. The oxidative stress defense mechanism of C. neoformans includes 
production of non-enzymatic antioxidants (melanin [238] and mannitol) and enzymatic 
antioxidants (peroxidases[239], catalases[240], superoxide dismutase[241], among others). 
The catalase family of C. neoformans consists of 4 members (CAT1-CAT4), whose deletion 
from the wild-type strain does not result in defects in oxidation resistance or mouse 
virulence[240], implying there is a degree of functional redundancy between this class and 
other components of the cryptococcal antioxidant defense system [240].  
Another constituent of the antioxidant defense system in C. neoformans is the thiol-
peroxidases (TSA1 and TSA2), which are essential for resistance to oxidation as well as 
virulence [223,242]. In addition, the disulfide reduction thioredoxins TRX1 and TRX2; the 
thioredoxin reductase TRR1, are involved in the reduction and recycling of the oxidized, 
inactive form of peroxiredoxin as well as virulence and survival in macrophages[243]. Other 
enzymes that have antioxidative properties in C. neoformans include the glutathione 
peroxidases GPX1 and GPX2[244], the cytosolic copper-zinc superoxide dismutase 
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(SOD1)[93], the mitochondrial manganese superoxide dismutase (SOD2)[232], the 
cytochrome c peroxidase (CCP1)[239] and the alternative oxidase (AOX1)[234]. 
1.13.3. Gene expression during phagocytosis by macrophages 
It is the employment of stress response pathways that enable C. neoformans to survive and 
replicate following phagocytosis by host macrophages [245–249]. To elucidate the 
transcriptional profile under oxidative stress the fungal cell transcriptome is sequenced 
either after phagocytosis by macrophages or grown in nutrient rich YPD medium and treated 
with exogenous H2O2 [227,250]. The extent and pattern of the transcriptional response was 
found to be much weaker in the cells residing inside the macrophages compared to the 
robust transcriptional response observed in the cells treated with exogenous H2O2 in YPD 
medium, suggesting that the environment has a direct effect on the transcriptional response.  
Gene expression profiling of C. neoformans upon phagocytosis by murine macrophages and 
Acanthamoeba castellanii have identified gene sets that are both up or down-regulated in 
both model systems, highlighting the similarities of the two intracellular niches[251]. 
Mitochondria-localized peroxidases, superoxide dismutases and catalases are among the 
most up-regulated genes upon phagocytosis of C. neoformans by murine macrophage[68]. A 
NADH-ubiquinone oxidoreductase, a zinc-binding oxidoreductase, a putative glutathione 
transferase and the flavohemoglobin denitrosylase gene FHB1 are among the most highly-
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upregulated [68]. FHB1 has previously been associated with sensitivity to nitrosative stress 
and virulence in both murine macrophage and murine model of infection [252].  
Phagocytosis also induced the up-regulation of a number of transmembrane transporters, 
believed to indicate increased metabolic activity in response to nutrient starvation in the 
phagosome [68,251]. Carbohydrates transporters are among the most induced, including the 
hexose transporter ITR4 (homolog of JEC21 ITR1), and the glucose transporter GTH1, which is 
important for melanin production and virulence [68]. Other types of highly up-regulated 
transporters include those associated with nitrogen starvation (AMT1 and AMT2), iron 
acquisition (FET3 and FTR1) and peroxisomal protein transport/biogenesis (PEX5 and PEX7).  
Genes identified as essential for cryptococcal virulence were also induced during 
macrophage infection, including laccase (LAC1 and LAC2), capsule production and 
modification genes (CAP10, CAS1, CAS2, CAS31, CAS32), the G protein α-subunit GPA1, the 
cAMP pathway (PKA1) and calcineurin (CNA1) [68]. Another interesting aspect of 
C. neoformans transcriptional response to phagocytosis in the murine macrophage in vitro is 
the repression of genes involved in the translation process (maintenance of the ribosome, 
processing of pre-rRNA, or translation initiation and elongation), which is presumably a result 
of nutrition starvation in the phagosome [69]. 
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1.14. C. neoformans gene expression in humans at the site of infection 
The bulk of our knowledge on the cryptococcal transcriptome is derived from carefully 
controlled in vitro experiments under specific test conditions, which enable sufficient 
biological and technical replication. While this produces reproducible and robust 
transcriptomics data, most experiments were conducted using a few well-characterized 
laboratory strains under specifically-defined in vitro conditions, and remains to be seen how 
these data would relate to complex in vivo conditions and human disease. Cryptococcal gene 
expression in the host is supposed to be both site and time specific [253]. For instance, it has 
been proposed that human cryptococcal meningitis involves at least six stages: (i) 
colonization and establishing infection in the lungs following the inhalation of infectious 
propagules; (ii) pulmonary yeasts survival and proliferation; (iii) dormancy of yeast cells in 
the host tissue; (iv) reactivation of latent infection with renewed yeast growth; (v) in-host 
dissemination of the yeasts; and finally (vi) growth of yeasts in brain tissue and the sub-
arachnoid space. The transcriptional responses of C. neoformans would vary in response to 
the unique host tissue and stages of infection. 
To date there is only one of study of in vivo cryptococcal gene expression in humans in the 
literature, reported by Chen and colleagues from Dr. John Perfect’s research team at Duke 
University, North Carolina, USA [253]. This study involves comparative RNAseq profiling of 
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yeast pellets directly originated from human cerebral spinal fluid (CSF) samples and RNA 
from yeasts of the same isolates growth in either rich medium (Yeast Peptone Dextrose-YPD) 
or ex vivo human CSF. It was revealed that transcriptional profiles of yeasts in human CSF are 
highly similar to those cultured in YPD under in vitro conditions [253]. Gene ontology analysis 
of the differentially expressed genes in the patient’s CSF and in YPD in comparison to cells 
grown in ex vivo human CSF indicated that the expression of genes in the cellular metabolism 
category increased, suggesting that yeast cells are actively growing in patient CSF.  A number 
of up-regulated genes that were specific for the CSF condition were detected, including 
genes previously predicted to be essential for virulence. These included SRX1, which was 
involved in resistance to oxidative stress [254]; ENA1 and RIM101 which were important for 
cryptococcal virulence in animal models [255–257]. Further transcriptional profiling studies 
on a larger number of samples from human specimens at various stages of infection would 
be required to better understand cryptococcal gene networks and pathways involved in in 
vivo human pathogenesis. 
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1.15. Host immune response to cryptococcal infection 
1.15.1. Role of cell-mediated immunity in response to cryptococcal infection 
Understanding the host immune response to cryptococcal infection has the potential to 
improve disease management. Much of the current understanding of host immune response 
to cryptococcal infection came from various in vitro and animal studies.  Cell mediated 
Immunity (CMI) contributes to fungal control and clearance through direct cytotoxic effects 
or immune regulatory effects of natural killer T cells (NKT) and T-lymphocytes. Various 
studies have demonstrated the essential roles of CD4+ and CD8+ T-cells in immune response 
against cryptococcal infection [258–265]. Secreted granulysin and perforin, which are 
expressed by both NKT cells, CD4+ and CD8+ T-cells, are involved in CMI-regulated killing of 
cryptococcal yeasts[258,262,266–268]. An IFN-γ/TNF-α–producing peripheral CD4+ T-cell 
stimulated by cryptocccal mannoprotein response was associated with increased 
concentrations of proinflammatory cytokines at the site of infection ,which was linked to 
better outcome [269].   
The regulatory effect of CMI in cryptococcal infection is complicated and equally essential for 
fungal clearance since effective host immune response is essential for better outcome. 
Various studies in mice have linked the balance between Th1 (regulated by T helper cell type 
1) and Th2 (regulated T helper cell type 2) cytokines and mortality [270–273]. While Th-1 
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cytokines such as TNF-α, IL-12 and Interferon γ  (IFN- γ ) confer better survival and fungal 
clearance in mice[274–278], Th2 cytokines such as  IL-4, IL-5 and IL-10 were not 
protective[279–282].  M1-polarized macrophages associated with a Th1 response have been 
shown to be fungicidal while Th2-associated M2-polarized macrophages were not[283–285]. 
Interaction with host macrophages, which has been previously associated with cryptococcal 
persistence and dissemination in the host, is modulated by host cytokine response[272]. In 
addition, IL-17 and the Th-17 response has recently been associated with better fungal 
clearance in C. neoformans -infected mice[286,287]. ] 
1.15.2. Role of B-cell immunity during cryptococcal infection 
B-cell immunity was demonstrated to be involved in control of cryptococcal infection at 
different stages/site of infection. For example, studies of B-cell response in B-cell-deficient 
SCID mice suggest  B-cell immunity also plays an important role in the brain when T-cell 
immunity is impaired [288]. The fact that B-cells are the most prevalent lymphocytes in the 
lungs of C. neoformans -infected A/JCr mice [289] and that B-cell-deficient C57BL/6J mice 
resulted in higher mortality and increased pulmonary pathology [290] suggest that B-cells 
play an active role in modulating immune response in the lung.  
Another role of B-cells is to produce “natural occurring” IgM antibody that has an intrinsic 
ability to bind conserved fungal cell wall components such as α- and β-glucans [291]. It has 
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previously been shown that peripheral blood IgM memory B cell levels were lower in HIV-
infected individuals who developed cryptococcal disease than in those who did not [292] and 
that HIV-infected patients had lower levels of serum GXM-binding IgM than did HIV-
uninfected individuals [293].  
1.15.3. Cytokine response in human infection 
Data from humans are limited. The fact that individuals with underlying immunosuppressive 
conditions, especially HIV/AIDS, are most susceptible for cryptococcal infection suggests that 
cell-mediated immunity (CMI) plays a central role in host defense against cryptococcosis. 
Disease in HIV infected patients is associated with advanced disease and profound 
immunosuppression. The median CD4 count in HIV infected patients in Vietnam is less than 
20 cells per mm3 (normal range 500 – 1500 cells/mm3 [294,295]. Patients with HIV-associated 
cryptococcal meningitis presenting with high fungal burdens in cerebrospinal fluid (CSF) and 
slow rates of yeast clearance had lower levels of proinflammatory TNF-α , IFN- γ and IL-6 in 
the CSF [296]. Diminished Th1 response in HIV-infected patients [297] and increased levels of 
Th2 cytokines in organ-transplant patients[298] imply that the Th1/Th2 balance plays a role 
in determining the risk of infection and disease outcome. However, while animal studies 
support the Th1/Th2 dichotomy, its association with disease outcome in late stage HIV-
infected patients with cryptococcal meningitis is less apparent[269]. This likely reflects the 
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discrepancy between controlled conditions of experimental animal models and the 
complexity of human disease, especially with regards to late-stage HIV infection.  
1.16. C. neoformans var. grubii infection in immunocompromised hosts 
The vast majority of cryptococcal disease is due to infection with C. neoformans and is 
associated with immunosuppressive conditions including HIV/AIDS, malignancy, organ 
transplantation, chronic organ failure and immunosuppressive therapy. Globally, HIV/AIDS 
remains the primary risk factor for cryptococcal disease despite the available of antiretroviral 
therapy. Global cryptococcal disease burden is most severe where there is high number of 
people with HIV/AIDS infection, especially in Sub-Saharan Africa or Southeast Asia [1]. The 
first estimation of the global annual incidence of cryptococcosis was about 957,900 cases per 
year (range 371,700–1,544,000) resulting in 624,700 deaths by 3 months after infection [1]. 
However this estimation was conducted using data from before the widespread use of ARTs. 
The global introduction of effective antiretroviral therapy (ART) has helped reduce the 
number of newly acquired HIV infection but at the same time increase the number of people 
living with AIDS [9]. This, along with increasing number of solid organ transplantation and 
immunosuppression therapy in recent decades, mostly in developed countries, represent an 
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increasing human population with immunosuppression highly susceptible to cryptococcal 
disease.  
A new study in 2017 that takes into account the vastly changed landscape of the global HIV 
epidemiology and involves more new data estimates that 278,000 people have cryptococcal 
antigenaemia every year, with 73% of meningitis cases occurring in sub-Saharan Africa [2]. 
Global incidence of cryptococcosis is summarized in Figure 1.16-1. Other known underlying 
immunosuppressive conditions include prolonged treatment with corticosteroids, organ 
transplantation, advanced malignancy, diabetes, sarcoidosis and idiopathic CD4 
lymphocytopenia [5,16,78,299,300].  
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Figure 1.16-1. Global estimation of annual incidence of cryptococcosis (the number of people positive with antigenaemia) according to 
country in 2014 (adapted from Rajasingham et al. 2017) [2].
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1.17. C. neoformans var. grubii infection in apparently immunocompetent 
hosts 
1.17.1. Global epidemiology of C. neoformans var. grubii infection in apparently 
immunocompetent hosts 
Cryptococcal disease in immunocompetent hosts is often attributed to C. gattii, which is now 
considered a primary human pathogen [301–305]. This species is well recognized in the 
tropics, has most usually been associated with immunocompetent patients, and is 
infrequently found in HIV infected patients even in highly HIV-endemic regions 
[301,302,306].  
Less frequently, disease in apparently healthy individuals due to C. neoformans is reported. In 
particular, disease in HIV uninfected apparently immunocompetent patients has been 
reported form Vietnam, Australia, China and elsewhere in Asia.  For instance, the incidence 
of cases in immunocompetent patients due to C. neoformans  in Australia from 1994 to 1997 
was higher than C. gattii, except for in the tropical Northern Territories [301]. In 
East/Southeast Asia, the majority of disease in HIV uninfected patients is due to C. 
neoformans  var. grubii, even in tropical areas where C. gattii would be expected to be more 
common [107,109,111,307]. In contrast to Thailand in Southeast Asia where the majority of 
reported cases of cryptococcosis are associated with HIV infection [92,102]; most cases 
 52 | P a g e  
 
reported from China and Japan were from HIV-uninfected patients [103,105–107,109,307–
312]. Though some of these patients may have other underlying immunosuppressive 
diseases, a significant number are from patients with no apparent immune defects. For 
instance, a retrospective epidemiological analysis of cryptococcal meningitis in China from 
1981 to 2013 reported that 40% of cases occurred in otherwise apparently healthy patients 
without any obvious immunosuppressive condition.  21% were HIV-associated and the 
remaining 39% occurred in HIV-uninfected patients with other underlying diseases [310]. This 
contrasts with the US, where cases in apparently immunocompetent hosts account for 17% 
to 22% of the reported total number of cases in patients without HIV infection or organ 
transplantation [313].  
1.17.2. Proposed mechanisms of C. neoformans var. grubii-associated infection in 
apparently immunocompetent individuals  
While mechanisms such as intracellular parasitism and atypical mitochondrial morphology 
have been linked to increased virulence in C. gattii infection in immunocompetent hosts 
[8,138,314–316], it is less clear how C. neoformans var. grubii causes disease in the 
immunocompetent. Several potential mechanisms have been proposed. For example, given 
that C. neoformans var. grubii co-exist in similar environments and can both cause 
mammalian infection, it is possible C. neoformans var. grubii has acquired features 
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associated with infecting immunocompetent hosts from C. gattii, possibly through mating. In 
fact, clinical hybrid isolates of C. neoformans (both serotype A and D) and C. gattii have been 
described and reported [317–319]. However these hybrids are rare -  a large scale screening 
of over 350 international clinical isolates only identified 4 serotype A/B hybrid strains, 
suggesting that mating between species is extremely rare [320]. Furthermore, where 
hybridization with C. gattii has occurred it has not been associated with increased virulence 
of C. neoformans var. grubii [321].  
Previously, regulation of the cAMP signaling system has been associated with changes in 
virulence phenotype of C. neoformans var. grubii. Mutants lacking the downstream repressor 
pkr1 are hypervirulent in mice [200,321–323]. However, no association between pkr1 and in 
the ability to cause disease in apparently healthy patients has been seen. Exactly how C. 
neoformans var. grubii strains can infect and cause disease in immunocompetent patients is 
still unknown.  
 The mechanisms of cryptococcal virulence is highly complex and diverse, as reflected by 
considerable genomic plasticity and phenotypic variations [113,148,324–330]. Variation in 
the expression of known virulent including the capsule, susceptibility to antifungal drugs, 
anti-phagocytosis mechanisms, and others are also well-documented [331–336]. High degree 
of phenotypic variation among closely related strains suggests that some of these strains may 
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also be inherently more virulent than others. The fact that ST5 strains (synonymous to the 
AFLP-defined cluster VNI-γ in Vietnam which is later characterized as ST5 in Chapter 2 of this 
thesis) from China and Vietnam infect both HIV-infected and HIV-uninfected patients as well 
as being the most prevalent genotype isolated from HIV-uninfected patients implies that the 
virulence composition of an infecting strain may play equally essential roles as the host's 
defenses. The genetic makeup of a strain i.e. a genotype or lineage may be associated with 
higher prevalence or mortality in a host group. For example, MLST typing of HIV-associated 
pediatric isolates C. neoformans var. grubii (VNI) from South Africa revealed that boys are 
more likely to be infected with ST8 than girls while other STs were equally distributed 
between both sexes [337]. MLST genotyping also suggested  an association between ST93 
and its closely related variants with higher mortality in Ugandan HIV-associated patients with 
cryptococcal meningitis, compared to ST4 or ST5 isolates [338]. However, genotype as a 
standalone factor cannot explain for the complexity of cryptococcal virulence. For instance, 
clinical C. neoformans var. grubii isolates were more virulent in mice than environmental 
isolates while having the same MLST genotypes [339]. On the other hand, it is important to 
keep in mind that disease in human hosts is more complicated and dynamic than in well-
controlled animal models. While HIV-associated CM patients appear uniformly 
immunosuppressed, non HIV-associated CM patients represent a more immunologically 
heterogeneous population with or without subclinical innate or acquired immunodeficiency. 
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Therefore, phenotypic variation among strains with the same genotype, especially with 
regard to infection in apparently immunocompetent patients, may indicate a role for 
microevolution within the host. Alternatively, phenotypic variations among a single 
cryptococcal lineage could have been a result of adaptation to diverse selection forces in the 
environment.  
1.17.3. Epidemiology of C. neoformans var. grubii-associated infection in apparently 
immunocompetent patients in Vietnam 
In the tropical setting of Vietnam, C. neoformans var. grubii accounts for the vast majority of 
cases, regardless of HIV status [307]. Over 70% of cases in HIV-uninfected patients (total 
n=57), most of whom had no obvious underlying immunosuppressive conditions,  were 
attributed to C. neoformans var. grubii while the remaining cases were caused by C. gattii 
[307]. Mortality rate among this patient group at discharge is 19% with 20% of survivors 
affected by blindness [307]. All C. neoformans var. grubii isolates from HIV-uninfected and 
HIV-infected patients in Vietnam were URA5 molecular type VNI [103]. Subsequent AFLP-
genotyping of 144 representative isolates from both HIV-infected and HIV-uninfected defined 
two major clades of C. neoformans var. grubii (termed VNI-γ and VNI-δ) [103]. 84% of 
infections in HIV uninfected patients were due to VNI-γ strains; this compared with HIV 
infected patients, where only 38% of strains were from this cluster (odds ratio 8.30; 95% 
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confidence interval (CI): 3.04 to 26.6;  p<0.0001) [103]. Moreover, in HIV-uninfected patients 
with VNI-γ infection, underlying disease was less common than in patients with VNI-δ 
infection, occurring in 23% versus 67% (odds ratio 6.43; 95% CI: 0.75 to 85.1; p = 0.05) [103]. 
No association was found between HIV risk group, age, gender or temporal/geographic 
distribution and AFLP cluster [103].  
The fact that a clonal group of C. neoformans var. grubii isolates were found in apparently 
healthy hosts with no underlying immunosuppressive conditions suggests that these isolates 
derived from a lineage with increased pathogenicity. The fact that a smaller number of 
organisms were able to induce the same degree of mortality, as reflected by lower baseline 
VNI-γ fungal burden in CSF and similar patients survival rate [325], would also suggest higher 
pathogenicity of the VNI-γ organisms. The lower prevalence of VNI-γ isolates in HIV-infected 
patients could be explained by their potentially lower environmental prevalence due to their 
association with a rare and unique environmental niche, compared to VNI-δ. This hypothesis 
is highly plausible since cryptococcal virulence in mammals and human hosts has been 
considered an effect of survival adaptation to environmental stresses [94,112,340,341]. 
Alternatively, since higher number of CM cases in apparently healthy hosts due to C. 
neoformans var. grubii were reported in China, Japan, Korea and Vietnam than any other 
locations, it is possible that there are as yet unidentified host factors specific to 
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East/Southeast Asians that contribute to higher susceptibility to cryptococcal disease among 
these populations.  
1.18.  Aims of the thesis 
Cryptococcosis has long been associated with HIV/AIDS and other immunosuppressive 
conditions. In Asia and Vietnam C. neoformans var. grubii is the main variety accounted for 
the majority of cryptococcosis cases. However in Vietnam we also observe high number of 
cases in apparently immunocompetent, HIV-uninfected patients caused by C. neoformans 
var. grubii, which is highly unusual. Given that the strains that cause disease in 
immunocompetent patients are largely derived from a single AFLP defined cluster, we 
hypothesize that strains of this cluster have increased virulence potential. The research 
questions resolved in this thesis was developed from this main hypothesis. The specific 
questions and aims of this study, with corresponding hypotheses when available, are as 
follow. (Data chapter 2 and data chapter 4 were purely exploratory thus no hypotheses were 
stated)  
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1. What is the genetic structure of clinical C. neoformans var. grubii isolates in Vietnam 
and Laos? How do they relate to the global population? 
This is an exploratory chapter aiming to describe the population structure of clinical C. 
neoformans var. grubii isolates from HIV-infected and HIV-uninfected patients from Vietnam 
and the neighboring country Laos using Multilocus Sequence Typing (MLST). The emphasis 
would be to integrate the Vietnamese/Laos C. neoformans var. grubii population structure 
into the global context.  
2. What phenotypic differences distinguish the lineage that causes disease in 
immunocompetent hosts (VNI-γ) from other Vietnamese lineages?  
Hypothesis: VNI-γ strains are more virulent than VNI-δ strains  
I aim to compare in vitro phenotypes previously associated with virulence between strains of 
the lineages that can and cannot cause disease in immunocompetent patients. I will use a 
mouse model of infection to compare strains of different lineage in vivo including tissue 
dissemination, host survival, immune responses, and pathological patterns.  
3. Does a macrophage model of infection distinguish lineages that can and cannot cause 
disease in immunocompetent patients?  
Hypothesis: in vitro macrophage parasitism could predict and indicate lineage-specific 
virulence potential. 
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While animal models are a useful tool to study pathogenesis and virulence, they are 
expensive, time-consuming, and ethically complex. This limits the number of strains that can 
be tested, and therefore effects that are significant at the population level can be missed if 
there is significant within lineage variability. Previous studies with outbreak C. gattii strains 
have shown that in vitro intracellular proliferation rate (IPR) in macrophages is associated 
with increased mortality in mice. Therefore, in the thesis I adapt the established in vitro 
macrophage model for higher throughput to compare IPR and yeast uptake of macrophages 
for C. neoformans var. grubii isolates from HIV-infected and HIV-uninfected patients in 
Vietnam. 
4. What are the differences in transcription that distinguish lineages that affect 
immunocompetent patients from those that only affect the immunosuppressed? 
C. neoformans var. grubii isolates from HIV-infected and HIV-uninfected patients in Vietnam 
are mostly identical i.e. strains from both groups possess all known cryptococcal virulence 
factors and are both pathogenic to human hosts. While comparative genomics has revealed a 
homology as well as unique genetic features between C. neoformans var. grubii isolates from 
HIV-infected and HIV-uninfected patients, little is known about how strains from each 
genotype regulate their genes. We aim to study genotype-specific patterns of gene 
expression at baseline by investigating gene expression profiles of representative strains 
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from each genotype during normal in vitro growth conditions. These results would help 
generate more hypotheses for further investigation of cryptococcal virulence.   
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Chapter 2 
POPULATION STRUCTURE OF CRYPTOCOCCUS NEOFORMANS  
VAR. GRUBII FROM VIETNAM IN A REGIONAL AND GLOBAL CONTEXT 
2.1. Chapter 2 Introduction 
The clinical and environmental Cryptococcus neoformans var. grubii isolates from South, East 
and Southeast Asia exhibit a clonal population structure[101,103]. Multilocus Sequence 
Typing (MLST) epidemiological studies from East Asia have shown limited genetic diversity 
among the majority of environmental and clinical isolates [104,106,111]. Different 
geographical areas have distinct population structures, particularly in relation to the 
predominant sequence types [101]. Previous studies suggested that though in relatively close 
geographical proximity, the population structure of Cryptococcus neoformans var. grubii 
from Thailand and China are significantly different [92,342]. We recently reported the 
population structure of Cryptococcus neoformans var. grubii from Vietnam [325], but 
analyses were focused on associations between clinical features and population structure. 
My specific goals were (i) to describe the genetic structure of the Laotian Cryptococcus 
neoformans var. grubii population using MLST, and (ii) to set the Vietnamese and Laotian 
populations within the global context.  
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2.2. Chapter 2 Materials and Methods 
2.2.1. Ethics statement 
All studies from which samples were derived were approved by the relevant institutional 
review board: the Hospital for Tropical Diseases Ethical Review Board, Ho Chi Minh City, the 
National Ethics Committee for Health Research Viet Nam, the Ministry of Health, Lao PDR, 
and either the Oxford Tropical Ethics Committee, University of Oxford, or the Ethics 
Committee of the Liverpool School of Tropical Medicine. All patients were adults and gave 
written informed consent to enter the clinical studies. Where the patient lacked capacity to 
consent through illness, the written consent of the responsible next of kin was obtained. All 
clinical data and samples were anonymized. 
2.2.2. Patients and isolates  
The Vietnamese isolates (total n=136) included in this work were clinical isolates from the 
cerebrospinal fluid (CSF) of patients enrolled in a randomized controlled trial of antifungal 
therapy in HIV-infected patients (n=98) between 2004 and 2011, and a prospective, 
descriptive study of HIV-uninfected patients with central nervous system (CNS) infections 
(n=38) enrolled between 1998 and 2009 [103,307]. The Laotian isolates were from 81 
patients with cryptococcal meningitis (67 HIV-infected, 8 HIV-uninfected and 6 with unknown 
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HIV status) consecutively admitted to Mahosot Hospital, Vientiane, between 2003 and 2015.   
2.2.3. DNA extraction and Restriction Fragment Length (RFLP) 
Total genomic DNA was extracted from all organisms using the Masterpure Yeast DNA kit 
(Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer’s instructions. 
Restriction fragment length polymorphism analysis (RFLP) of the orotidine monophosphate 
pyrophosphorylase (URA5) gene was used to confirm species/varietal status of all C. 
neoformans var. grubii isolates [343]. PCR of the URA5 gene was conducted in a final volume 
of 50 µL. Each reaction contained 50 ng of DNA, 1X HotStart PCR buffer (NEB, USA), 0.2 mM 
each of dATP, dCTP, dGTP, and dTTP (Roche Diagnostics GmbH), 2 mM magnesium acetate, 
0.5 U HotStart Taq DNA polymerase (NEB, USA), and 0.15 μM of each primer URA5 (5'- ATG 
TCC TCC CAA GCC CTC GAC TCC G - 3') and S01 (5'- TTA AGA CCT CTG AAC ACC GTA CTC - 3'). 
PCR was performed in an Nexus SX1 thermal cycler (Eppendorf, USA) at 95°C for 15-min, 
followed by 35 cycles of 20s denaturation at 94°C, 40s annealing at 61°C, and 1 min extension 
at 72°C, followed by a final extension cycle for 3 min at 72°C. 10 µL of PCR products were 
double digested with Sau96I (0.2 U/µL) and HhaI (0.8 U/µL) for 3 h at 37oC, followed by a 
final 10min incubation at 60oC. Restriction products are separated by 3% agarose gel 
electrophoresis at 100 V for 5 h. RFLP patterns were assigned visually by comparing them 
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with the patterns obtained from the control strains (VNI-VNIV and VGI-VGIV) kindly provided 
by Prof. Wieland Meyer, University of Sydney. 
2.2.4. Multilocus Sequence Typing (MLST) 
Seven MLST loci (CAP59, GPD1, IGS1, LAC1, PLB1, SOD1, and URA5) were amplified and 
sequenced following the procedures of the International Society for Human and Animal 
Mycology (ISHAM) MLST consensus typing scheme for C. neoformans 
(http://mlst.mycologylab.org) [30]. Sequencing was performed using BigDye v3.1 Chemistry 
(Applied Biosystems, CA, USA) on an ABI 3130 Genetic Analyzer (Applied Biosystems, CA, 
USA). Both forward and reverse amplicons of each locus were sequenced. Consensus 
sequences were manually edited using ContigExpress and aligned in AlignX , implemented in 
VectorNTI Suite 7.0 [344]. A single Allele Type (AT) number was assigned to each of the seven 
loci by comparing consensus DNA sequences with the ISHAM database, resulting in a seven-
number allelic profile for each isolate. The allelic profiles defined the corresponding STs. 
MLST profiles and DNA sequences at each MLST loci for isolates from regions other than Laos 
and Vietnam were obtained from NCBI. For the global analysis, we used data reported by 
Simwami et al. [92], Mihara et al. [107] and Cogliati et al. [152] included in Khayhan et al. 
[101], and from Chen et al. [82], Ferreira-Paim et al. [151], Beale et al. [345]and Dou et al. 
[105]. 
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2.2.5. Phylogenetic analyses 
For global comparison, information on MLST genotypes, patient HIV status, and source of 
isolation for 1047 isolates from other countries  across Asia and Southern Africa were 
obtained from NCBI [82,92,101,107,152]. These consisted of clinical and environmental C. 
neoformans var. grubii isolates from Southeast Asia (Indonesia, Thailand, Vietnam); East Asia 
(Japan, China, South Korea); South Asia (India), Middle East (Qatar, Kuwait); North America 
(USA); South America (Brazil, Argentina); Europe (Germany, Italy, France, Belgium); 
Australasia (Australia) and Africa (Botswana, Malawi, Tanzania, Uganda, Zaire, South Africa). 
Further details of the isolates information are presented in Appendix 1 . 
First, we determined the best DNA substitution model for the concatenated dataset using 
MEGA v6.0.6 [346]. The Kimura 2-parameters model with gamma distribution was selected 
as the best fit model using the Bayesian information criteria (BIC) calculated with MEGA 
v6.0.6 [346]. To evaluate patterns of evolutionary descent among genotypes according to 
their source and geographic region, the allelic profile of the Vietnamese, Laos and global 
dataset were applied to the goeBURST  algorithm in PHYLOVIZ 2.0 software available at 
http://www.phyloviz.net [347,348]. A group founder was defined as the sequence type with 
the most number of linked single locus variants (SLV). The concept of a clonal complex (CC) 
was adopted when a SLV linkage with the founder ST was observed.  
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2.2.6. Multidimensional (MDS) clustering 
Genetic distance (Fst) and geographical distance were visualized by the non-metric 
multidimensional scaling method. Fst were calculated from concatenated sequences of the 7 
MLST housekeeping genes using DnaSP v5 [349]. MDS calculation was performed using 
RStudio Version 0.98.1103 built with R-3.4.0 (https://www.rstudio.com and https://www.r-
project.org). Network analysis and visualization was conducted using the R package igraph 
(version 1.1.2, http://igraph.org/r/). 
2.3. Chapter 2 Results 
2.3.1. MLST reveals dominance of ST4 and ST6 sequence types in Laos 
All isolates from Vietnam were previously determined as molecular type VNI by RFLP, mating 
type α [350]. The 136 Vietnamese isolates consisted of 13 different sequence types (ST) of 
which ST5 (n=66; 48%) and ST4 (n=32; 23%) were the most prevalent, followed by ST6 (n=12; 
9%), ST93 (n=8; 6%), ST32 (n=7; 5%), ST39 (n=3; 2%) and 7 less common STs with less than 3 
isolates each. Of 13 STs detected in Vietnam, were previously undefined in the MLST 
database: ST306, ST338, ST339 and ST340. These 4 STs were singletons, each accounting for 
<1% of the total number of isolates. Isolates from the AFLP-defined VNI-γ cluster were ST5 
while those from the VNI-δ were attributed to all other STs in the Vietnamese population.  
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All 81 Laotian isolates belonged to the RFLP-defined VNI group. Among them, ST4 and ST6 
accounted for over 40% each of the total number of isolates, and were 4-fold more prevalent 
than ST5; (ST4, n=35 (43%); ST6, n=33 (41%); ST5, n=9 (11%), Figure 2.3-1 and Table 2.3-1). 
Less than 3% of isolates from Laos (n=2) were ST93. This contrasted with its adjacent 
neighbor, Vietnam, where ST5 predominated (48%), followed by ST4 (24%), ST94 (9%) and 
ST6 (9%).  
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Table 2.3-1. Distribution of major Sequence Types (ST) in the Asia/Middle East regions   
Country/ 
HIV status 
Sequence Type (ST)* 
4 5 6 31 32 39 53 69 93 174 177 187 188 194 195 306 
China 
 
104 
 
1 
  
5 
 
1 
    
2 1 
 
HIV(-) 
 
80 
 
1 
  
4 
 
1 
    
1 
  
HIV(+) 
 
24 
    
1 
      
1 1 
 
India 1 
 
2 7 
    
28 3 1 1 
    
HIV(-) 1 
  
4 
    
6 2 1 1 
    
HIV(+) 
  
2 3 
    
22 1 
      
Indonesia 8 
 
10 
    
2 16 
 
3 
     
HIV(-) 
          
1 
     
HIV(+) 8 
 
10 
    
2 16 
 
2 
     
Japan 
 
20 
              
HIV(-) 
 
20 
              
HIV(+) 
                
Kuwait 1 2 
     
1 1 1 
      
HIV(-) 
 
2 
     
1 
 
1 
      
HIV(+) 1 
       
1 
       
Laos 32 8 32 
     
1 
  
1 
   
1 
HIV(-) 3 2 2 
     
1 
       
HIV(+) 29 6 30 
        
1 
   
1 
Qatar 1 2 
 
2 
            
HIV(-) 
 
1 
 
2 
            
HIV(+) 1 1 
              
Thailand 64 20 57 
     
3 
       
HIV(-) 2 
       
1 
       
HIV(+) 62 20 57 
     
2 
       
Vietnam 32 66 12 
 
7 3 
  
8 
   
2 
 
1 1 
HIV(-) 3 31 1 
 
2 
          
1 
HIV(+) 29 35 11 
 
5 3 
  
8 
   
2 
 
1 
 
Total 139 222 113 10 7 3 5 3 58 4 4 2 2 2 2 2 
(*): any minor sequence type with only one isolate was excluded from this 
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Figure 2.3-1. goeBURST  analysis integrating the Laotian and Vietnamese C. neoformans var. grubii isolates into the major Asian clonal 
complex. Minimum spanning tree showing the major Asian clonal complex. (A): Laos and Vietnam as part of the global population. The main subgroups of 
the major clonal complex are indicated by circles. (B): the major clonal complex broken down into geographical regions: East Asia (China and Japan), 
Southeast Asia (Vietnam, Laos, Thailand and Indonesia), South Asia (India), plus the reference groups Middle East (Qatar and Kuwait), Europe, North/South 
America and Africa. 
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2.3.2. Correlation between infection with ST5 and HIV status 
Isolates of ST5 have previously been reported to be associated with HIV uninfected patients 
in East Asia and Vietnam [103,106,107,307,312]. Most cases of cryptococcal meningitis in 
Laos were associated with HIV infection. The ST5 lineage accounted for just 9% (6 of 67) of 
infections in HIV infected patients, suggesting a relatively low prevalence in the environment. 
Of 8 cases of meningitis in Laos in HIV uninfected patients, 2 were due to ST5 isolates (Odds 
Ratio 3.39 [95%CI: 0.56 to 20.64], p=0.18, Fisher’s exact test). HIV serostatus was not known 
for the remaining 6 patients. 
To increase the power to test an association between ST5 isolates and HIV infection, I 
gathered previously described data from Asia, Europe, South America and Africa on lineage 
and patient HIV serostatus [82,101,325,345].  Clinical isolates with unknown HIV status were 
excluded from the analysis. Of 194 HIV uninfected patients, 136 (70%) were infected with ST5 
isolates; of 791 HIV infected patients, 117 (15%) were infected with ST5 isolates (Odds Ratio 
13.51 [95%CI: 9.38 to 19.45], p<0.0001, Fisher’s exact test). There were 296 clinical or 
environmental ST5 isolates in the dataset; East and Southeast Asia accounted for the 
majority of these (n=153 (51%) and n=104 (35%), respectively). Here, the relative proportion 
of ST5 isolates from each country decreased along a clockwise arc from Northeast to 
Southwest: Japan (n=36; 86%, 95%CI: [72 - 94]), China (n=116; 86%, 95%CI: [80 - 92]), 
Vietnam (n=66; 48%, 95%CI: [40 - 57]), Thailand (n=29; 13%, 95%CI: [9 - 18]) and Laos (n=9; 
11%, 95%CI: [5 - 20]). ST5 accounted for 20% (n=2) and 40% (n=2) of the total number of 
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isolates from Kuwait and Qatar in the Middle East, respectively. The majority of cases of 
disease in apparently immunocompetent, HIV-uninfected patients were from East and 
Southeast Asia.  ST5 has been reported from elsewhere, including Brazil (n=3; 2%, 95%CI: [5 – 
7]), South Africa (n=27; 15%, 95%CI: [10 - 22]), Uganda (n=1; 6%, 95%CI: [0 - 30]) and 
Botswana (n=1; 0.7%, 95%CI: [0.0 – 3.7]), but in these regions disease in HIV uninfected 
patients due to the type has rarely been reported [82,151,345].  
2.3.3. goeBURST analysis and geographical distribution 
I used the previously published data to elucidate how the Laotian and Vietnamese 
populations fit in the wider global context [82,101,104,151,345]. GoeBURST analysis placed 
C. neoformans var. grubii isolates from Vietnam and Laos, along with those from all other 
Asian, North/South American, Middle Eastern and African countries in a clonal complex 
(Figure 3.2-1). The main clonal complex included 3 main goeBURST sub-groups derived from 
ST174; sub-group 63 (ST63), sub-group 4 (ST4/ST6), sub-group 5 (ST5) and sub-group 31 
(ST31/ST32/ST93) (Fig 1A). Sub-group 63 was a Double Locus Variant (DLV) from ST174 and 
was more distant to the other 3 sub-groups. While most South African and Ugandan isolates 
were included in the main clonal complex, the bulk of isolates from Botswana were 
separated from the major clonal complex by at least 5 SLVs. ST174 was placed at the center 
of the clonal complex and was identified as a potential group founder of the clonal complex 
when analyzed by both parsimony (Figure 2.3-1) and maximum likelihood analyses  
(Figure 2.3-2). 
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Figure 2.3-2. Molecular Phylogenetic analysis by Maximum Likelihood method.  
The evolutionary history was inferred by using the Maximum Likelihood method based on the Kimura 
2-parameter model. The tree with the highest log likelihood (-6364.7916) is shown. The percentage of 
trees in which the associated taxa clustered together is shown above the branches. Bootstrap values 
over 50% were shown. ST174 was indicated by red arrow and ST4/ST5/ST6 by dark blue arrow. ST174 
is suggested to be the most recent ancestor observable for ST4, ST5 and ST6 lineages. 
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I observed an association between geographical location and STs (Figure 2.3-1). Most Asian 
isolates were included in sub-group 4 and sub-group 5 while isolates from other regions were 
widely distributed across the clonal complex. Sub-group 63 included European, North/South 
American, African, as well as a few East Asian isolates, but none from Southeast Asia. While 
sub-group 4 was reported from other continents, it was highly prevalent in Southeast Asia 
(n=317, 66% of all Southeast Asian isolates (total N=479)). Isolates from sub-group 5 had a 
wide distribution but in different proportions depending on the geographical regions: the 
Middle East (n=4; 33% (regional total N=15)), Africa (n=33; 10% (regional total N=346)), 
Europe (n=5; 13% (regional total N=39)), North America (n=1; 11% (regional total N=9)), 
South America (n=3; 2% (regional total N=133)), Southeast Asia (n=105; 22% (regional total 
N=479)) and most notably from East Asia (n=158; 88% (regional total N=180)). Similarly, sub-
group 31 was also widely distributed but was most prevalent in South America (n=110; 83% 
(regional total N=133)) and South Asia (n=53; 85% (regional total N=62)). Other regions with 
sub-group 31 populations included Africa (n=86; 25% (regional total N=346)), the Middle East 
(n=4; 27% (regional total N=15)), North America (n=3; 33% (regional total N=9)), Europe (n=6; 
15% (regional total N=39)). Sub-group 31 was much less common in East Asia (n=6; 3% 
(regional total N=180)) and Southeast Asia (n=52; 11% (regional total N=479)). 
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2.3.4. Genetic distance between C. neoformans populations from different 
geographical regions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3-3. Mutidimensional scaling plot of genetic distances (Fst) of global C. neoformans var. 
grubii isolates from HIV-infected patients.  
Vietnam appeared to represent an intermediate population between that from Laos/Thailand and 
that from China. Among Southeast Asian populations, that of Indonesia is most similar with the Indian 
population, possibly due to the uniquely high proportion of ST93, a feature also shared by  
C. neoformans var. grubii from India and Brazil. 
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Table 2.3-2– Genetic distance matrix (Fst) between different C. neoformans var. grubii populations 
 
Laos Indonesia Thailand India S. Africa Vietnam Brazil China 
Laos 0 0.263 0.002 0.676 0.158 0.09 0.62 0.424 
Indonesia 
 
0 0.245 0.155 0.029 0.077 0.146 0.285 
Thailand 
  
0 0.605 0.205 0.095 0.632 0.28 
India 
   
0 0.112 0.304 0.016 0.635 
S. Africa 
    
0 0.068 0.156 0.086 
Vietnam 
     
0 0.362 0.075 
Brazil 
      
0 0.495 
China 
       
0 
I used the fixation index (Fst) to evaluate pairwise genetic differentiation between different 
geographical regions. Multidimensional scaling (MDS) was carried out to provide a 2-D 
visualization of the Fst distance matrix (Figure 2.3-3 and Table 2.3-2). Botswana, being 
structurally highly diverse, is in stark contrast to other countries and therefore was removed 
from the analysis. On the other hand, due to the apparent propensity of ST5 towards HIV-
uninfected patients, the Fst analysis only included isolates from HIV-infected patients from 
Laos, Thailand, Vietnam, Indonesia, China, India, South Africa and Brazil. Very few isolates 
from Japan, Korea, Kuwait or Qatar were known to be from HIV-infected patients and thus 
isolates from these countries were also excluded from the analysis. In addition, isolates from 
any countries with fewer than 20 isolates were also excluded on the grounds that it was 
difficult to be sure they were representative of the country’s wider C. neoformans var. grubii 
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population.  
The MDS plot revealed that the Indian C. neoformans var. grubii population was most closely 
related to the Brazilian population (Fst=0.016), followed by the Indonesian population 
(Fst=0.155), and was more distant to other Southeast Asian countries (Vietnam, Thailand and 
Laos, Fst ranging from 0.304 to 0.676). Of the Southeast Asian populations, those from Laos 
and Thailand were most genetically close (Fst=0.002); the Indonesian population was most 
closely related to the Vietnamese population (Fst=0.077). The population from Vietnam, 
while being placed closer to Indonesia in the MDS analysis, appeared to be intermediate 
between China in East Asia (Fst=0.075) and Laos/Thailand in Southeast Asia (Fst=0.090 and 
Fst=0.095, respectively). This is in spite of the fact that both Vietnam and Laos share northern 
borders with China (Fst=0.424 between Laos and China). In fact, the Thai and Chinese 
populations appeared genetically closer than the Laos-China populations (Fst = 0.280).  
2.4. Chapter 2 Discussion  
The population structure of C. neoformans var. grubii has been described for a number of 
Asian countries [101], including Vietnam[325], Thailand [92,102], India[100], China 
[308,312,351,352], Japan[107] and Korea[111]. However, data from Laos have been lacking, 
and Vietnamese data have not previously been placed into the global context. To address 
this, we typed 81 isolates from Laos and re-analyzed 136 previously published isolates from 
Vietnam using MLST. An advantage of our dataset is that it contains significant numbers of 
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strains from both HIV infected and uninfected patients. In contrast, reports from China and 
East Asian countries are dominated by clinical isolates from HIV-uninfected patients, while 
studies from Thailand and other Southeast Asian countries including Singapore[353], 
Malaysia[354] and Indonesia[355], present isolates predominantly from HIV-infected 
patients. The differences between the immune statuses of patients sampled in different 
countries complicate interpretation of the data, but also mean that Vietnam is in a unique 
position to demonstrate the association between Cryptococcus neoformans var. grubii ST5 
and host immune phenotype.  
In China, ST5 is the dominant sequence type, accounting for over 90% of infections 
[105,106,110]. While it is present in both immunocompetent and immunocompromised 
patients, relatively few cases of HIV-associated disease have been reported [105]. The 
reasons for this are unclear. While China has a relatively low prevalence of HIV (estimated at 
<0.1% of the adult population in 2015 [356]), given the size of its population the few cases of 
HIV-associated disease reported may represent bias in study design, HIV testing or research 
interests. However, a recent report of cryptococcosis cases from Jiangxi, China included 35 
cases of cryptococcosis in HIV-infected patients, of which 33 were ST5. Overall, 73 out of 86 
patients in this study infected with ST5 isolates (85% of all cases) [357]. 
In contrast to China, the C. neoformans var. grubii population from Thailand appears more 
diverse according to MLST, with 14 STs reported, among which ST4 and ST6 are most 
common, outnumbering ST5 infections 6 to 1 [92,101,102]. We found the population 
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structure of isolates from Laos to be similar to that in Thailand, with ST4 and ST6 (both 
belonging to sub-group 4) accounting for the majority of disease. This dominance of a single 
sub-group in both Thailand/Laos and China contrasts with Vietnam, where ST5, ST6 and ST4, 
belonging to two separate sub-groups, are similarly prevalent.  The Thai data are notable for 
the lack of CM cases reported from HIV-uninfected patients. It seems unlikely that this 
represents under-reporting of non-HIV associated disease which is generally considered 
remarkable; rather, we hypothesize that this reflects a low prevalence of ST5 isolates in the 
environment, which is clearly associated with apparently immunocompetent patients 
elsewhere in Asia [103,105,106,110,325]. If the ST5 lineage was common in Thailand and 
Laos, we would expect to detect this from reporting of disease in HIV infected patients - in 
Vietnam it is responsible for >35% of cases of cryptococcal meningitis in HIV infected 
patients. Thus in Vietnam the Cryptococcus population seems to represents an intermediate 
population between Laos/Thailand to the West, and China to the Northeast, consistent with 
its geographical location.  
Of note, Indonesia also appears to have two equally dominant burst groups among clinical 
isolates. ST4/6 isolates account for 44%, of human infections, with ST93, common in East 
Africa and also frequently reported from India, accounting for a further 44%[101].   
The differences in population structure we see moving from west to east are likely driven by 
ecological and/or human factors. Ecological differences between the regions could select for 
enrichment of particular STs if there are differences in the relative fitness of the STs in those 
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niches. Southeast Asia is a geographically and ecologically diverse area known for its high 
species density [358,359]. The south of the region has a hot tropical climate with dry and wet 
seasons; the north is temperate with hot summers and cold winters. The Annamite mountain 
range, covered in dense rain forests, rises to over 3000 meters and runs the length of 
Vietnam, forming a barrier separating Thailand, Laos and Cambodia from Vietnam and 
southern China. There are also significant differences in elevation (for example, Chiang Mai, 
in Northern Thailand and the source of most published Thai data, and Vientiane in 
Northwestern Laos are at significantly higher elevation than Ho Chi Minh City and much of 
Southeastern China (170-300 meters versus 10-20 meters above sea level). Other than 
elevation and temperature, localized differences in soil biogeochemistry, environmental 
predators such as amoebae [115],  and tree species may also be relevant.  For example, Laos, 
Cambodia, Vietnam and China are among Asian countries where there is significant 
contamination of groundwater with high levels of arsenite [360,361]. Recently it has been 
shown that ST5 C. neoformans var. grubii isolates possess tandem repeats of the arsenite 
efflux transporter (Arr3) [124]. The greater the number of these repeat elements the higher 
the resistance to toxic arsenic containing compounds [124]. Differences in the distribution of 
this pollutant could correlate with the distribution of ST5. Other human activities that could 
influence ecology or human exposure to infection include irrigation, urbanization and mining, 
and human migration and international trade links could influence dispersal of C. neoformans 
var. grubii lineages in Asia and elsewhere.  
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In addition to ecological factors, the varying prevalence of lineages in particular human 
populations could be a result of differential host susceptibility to particular lineages. Such 
human genetic factors have previously been associated with susceptibility to tuberculosis 
[362]. However, the dominant ethnic group in Vietnam (Kinh, >80%) is genetically closer to 
ethnic groups in Northern Thailand than to the Han Chinese from Beijing or Southern China 
[363]. In fact, the differences between the Thai and Vietnamese C. neoformans populations 
we demonstrated here suggest that the diversity of the pathogen population is not driven by 
host susceptibility. Nevertheless, it remains possible that subtle human genetic 
polymorphisms exist that result in differential susceptibility to different cryptococcal 
species/lineages. 
Our observations augment the findings of Ferreira-Paim and co-workers who suggest that the 
populations of C. neoformans var. grubii found in many geographical regions across Asia and 
the Middle East arose from ST174, [151]. The ST174 expansion model is supported by 
goeBURST and maximum likelihood phylogeny analyses which show it is the most 
parsimonious candidate as the group founder of sub-groups 4, 5 and 31, which account for 
over 90% of the Southeast Asian isolates. We did not observe ST174 in either Vietnam or 
Laos but it has been present in previously published datasets from South Asia and the Middle 
East, with 3 isolates from India and 1 isolate from Kuwait[101], and has also been from 
Germany in a patient of Asian origin[364]. The prevailing hypothesis with respect to the 
evolution of CN, suggests that the current circulating Asia population emerged “Out-of-
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Africa”[81]. Our data neither confirms nor support this hypothesis but rather is showing that 
the extant population of CN associated with human disease in Asia has descended from a 
single common ancestor. Given the age of C. neoformans as a species, and the fact that it is 
not primarily a human pathogen, nor is it spread from person to person, it seems somewhat 
unlikely that its global distribution is driven by migration of (latently or actively) infected 
humans. However, as described earlier, other human factors may be relevant. The 
emergence of the preponderance in most countries of strains of a single burst group on a 
background of greater diversity, suggests different fitness of different STs to particular 
ecological types. 
2.5. Chapter 2 Conclusion 
This chapter addresses the lack of knowledge of the molecular epidemiology of C. 
neoformans var. grubii from Vietnam and Laos and places these populations into a broader 
context. I detected a change in predominant STs as one moves from western to eastern 
longitudes and that the Vietnamese C. neoformans var. grubii population appears 
intermediate between Thai/Laotian and Chinese populations. My data also suggest that 
ST174 is a putative most recent common ancestor for the majority of Cryptococcus 
neoformans var. grubii sequence types in Asia. The C. neoformans var. grubii population in 
Asia present in this study appeared mostly clonal, which is similar to previous reports. Most 
studies focusing on VNI, including mine, are weakened in that while cryptococcosis results 
from the inhalation of infectious propagules from the environment, few environmentally 
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sourced isolates have been characterized and thus the true diversity of the species in any 
country may be underestimated. More efficient environmental isolation techniques and 
systematic sampling would facilitate further understanding of the true species diversity by 
regions and could potentially reveal bottleneck events leading to the rise of pathogenic 
lineages. 
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CHAPTER 3  
IN VITRO AND IN VIVO VIRULENCE OF CLINICAL C. NEOFORMANS VAR. GRUBII 
ISOLATES FROM HIV-INFECTED AND HIV-UNINFECTED PATIENTS IN VIETNAM 
3.1. Chapter 3 Introduction 
The burden of cryptococcal meningitis is highest in sub-Saharan Africa and South/Southeast 
Asia where there are more people living with HIV/AIDS. In these tropical and subtropical 
regions, C. gattii CM is relatively uncommon in HIV-infected patients, usually accounting for 
only 1-2% of cryptococcosis in HIV-infected individuals, although higher rates have been 
reported from Botswana and Malawi (up to 30% of all CM cases) [365,366]. It is widely 
acknowledged that C. gattii primarily causes disease in immunocompetent patients while C. 
neoformans is associated with disease in immunocompromised patients [80,304].  
Where cryptococcal meningitis due to C. neoformans var. grubii  occurs in HIV-uninfected 
individuals, reports most often describe patients with an increased disease susceptibility due 
to some other underlying immunosuppressive conditions [302,367,368]. However, in 
Australasia and the USA no clear underlying immune deficit is identified in approximately 
20% of CM cases in HIV-uninfected individuals [369,370]. In Vietnam, disease in HIV-
uninfected patients accounts for approximately 10% of all CM cases admitted to our referral 
hospital in Ho Chi Minh City (HCMC) [307]. We have previously reported that the majority of 
HIV-uninfected patients had no identified cause of immunosuppression, and that >80% of 
HIV-uninfected CM patients were infected by yeasts belonging to a single  amplified fragment 
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length polymorphism (AFLP)-defined cluster of C. neoformans, which we had  named VNI-γ  
[103].  Our clinical observation has been replicated in China where over 70% of CM cases 
from apparently immunocompetent individuals were infected with C. neoformans [109]. The 
yeasts isolated from immunocompetent patients in China were closely related to each other, 
and belonged to a single multi-locus sequence type (MLST), sequence type (ST)5 [106]. 
Similarly, this ST accounted for more than 80% of non-HIV-associated cases of CM in South 
Korea, although some patients from this group had other underlying, potentially 
immunosuppressive conditions [111]. The association between a particular ST/genotype and 
host immune phenotype could be explained by a lineage-specific increase in pathogenic 
potential or microbial fitness, a currently unidentified host immune deficit, or a combination 
of these factors.  
This chapter aims to explore the hypothesis of whether VNIγ/ST5 isolates are more virulent 
than VNI-δ/non-ST5 isolates: 
 Compare virulence-associated phenotypes in a range of in vitro experiments between 
ST5 and non-ST5 C. neoformans var. grubii strains from HIV-infected and HIV-
uninfected patients from Vietnam.  
 Compare the relative in vivo virulence and immune responses of ST5 and non-ST5  
C. neoformans var. grubii strains using a mouse model of cryptococcosis. 
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3.2. Chapter 3 Material and Methods 
3.2.1. C. neoformans isolates and culture conditions 
This study included clinical isolates from the cerebrospinal fluid (CSF) of patients enrolled in a 
randomized controlled trial of antifungal therapy in HIV-infected patients, and a 
prospectively descriptive study of HIV-uninfected patients with central nervous system (CNS) 
infections  [103,307]. All studies were approved by the Institutional Review Board of the 
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam and the Oxford Tropical Ethics 
Committee or Liverpool School of Tropical Medicine (UK). Bulk isolate from each patient was 
kept at -80oC using Microbank beads (Pro-Lab Diagnostics, UK). Isolates were single-colony-
purified for all subsequent experiments. I randomly selected 15 isolates from each HIV group 
(15 from HIV-infected patients and 15 from HIV-uninfected patients) for characterization. 
Mating type, AFLP fingerprints and 7-digits consensus MLST profiles (CAP59, GPD1, IGS1, 
LAC1, PLB1, SOD1, URA5)  for all isolates were previously determined [30,325,371]. C. 
neoformans yeasts were propagated using Yeast Peptone Dextrose (YPD) broth and 
incubated overnight at 30oC with agitation. Cells were harvested and washed 3 times in 
phosphate-buffered saline (PBS). Inoculum was quantified using the Cellometer X2 cell-
counter (Nexelom Biosciences, USA). Isolates and clinical information from corresponding 
patients were summarized in Table 3.2-1.  
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3.2.2. Growth at high temperature/ex vivo human CSF and melanin production  
Growth at high temperature and in ex vivo human CSF were tested as previously described 
[372] with modifications for quantitative assessment. Unless otherwise specified, all reagents 
and media for phenotyping were purchased from Sigma-Aldrich, USA (now Merck, USA). To 
assess fungal growth at different temperatures, inoculum was adjusted to 108 cells/ml, 
serially diluted, spot-inoculated in duplicate on YPD agar in 5µl and incubated at 30oC or 37oC 
for 48 hours. After 48 hours, colony forming units (CFU) were counted and recorded in 
CFU/ml. For the ex vivo CSF growth assay, baseline pre-antifungal treatment CSF supernatant 
from random de-identified HIV-infected patients enrolled into an antifungal therapy trial was 
pooled, filtered, and stored at -80oC until use. 10µl of 108 cells/ml yeast suspension was 
inoculated into 90µl of pooled CSF and incubated at 37oC with 5%CO2. Inoculated CSF was 
serially diluted and spotted on YPD agar at days 1 and 3 post-inoculation. All experiments 
were repeated in triplicate. The H99-derived mutant Δena1, lacking a cation-ATPase-
transporter which resulted in decreased viability in human CSF and within macrophages, was 
used as a negative control for the ex vivo CSF assay [373]. H99 was included as a reference in 
all experiments. Data were standardized by expressing the results as a ratio of the CFU/ml of 
the test isolate to the CFU/ml of H99. Melanin production was assessed by plating 5μl of 
106cells/mL cell suspension on L-DOPA agar containing 1g/L L-asparagine, 1g/L glucose, 3g/L 
KH2PO4, 250mg/L MgSO4.7H2O, 1mg/L Thiamine HCl, 5μg/L Biotin, 100mg/L L-DOPA, 20g/L 
Bacto Agar (Becton Dickinson, USA) ([374,375]. Plates were incubated in the dark at 30oC or 
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37oC for 3 days. Difference in colony melanization was compared visually with reference to 
H99 and a mutant with diminished melanin pigmentation. 
3.2.3. Extracellular urease and phospholipase activity 
Time to complete pigmentation on Christensen’s urea agar medium was used as a marker for 
extracellular urease activity. 10μl of 108 cells/ml yeast suspension was spotted on 
Christensen‘s urea agar and incubated at room temperature. Time to complete pigmentation 
was recorded using timelapse imaging in 1 minute interval using a Gopro Hero 6 camera 
(Gopro, USA). Extracellular phospholipase activity was screened on egg yolk medium as 
previously described, with minor modifications [376]. The egg yolk medium contained 
Sabouraud agar with 1M sodium chloride, 0.005M calcium chloride and 8% sterile egg yolk 
enrichment (Merck, USA). 5 µl of C. neoformans yeast suspension (108 cells/ml) was spotted 
on egg yolk agar and incubated at 30oC for 72 hours. Diameter of the precipitation zone (D) 
formed around the colonies and diameter of the respective colonies (d) after 72 hours were 
recorded. A D/d ratio for each isolates was calculated. H99 was included in each experiment 
batch. Final data were expressed as a ratio between the test isolate’s D/d ratio and that of 
H99.  Each isolate was tested in 3 technical triplicates.  
3.2.4. In vitro capsule enlargement and cell size measurement 
To measure in vitro cryptococcal capsule thickness, all isolates were streaked onto capsule-
inducing agar containing powdered Dulbecco Modified Eagle Medium (DMEM) 
 88 | P a g e  
 
[supplemented with 4.5g/L glucose, L-glutamine, sodium pyruvate], NaHCO3 250mM, 
NaMOPS 1M,  Neomycin 200mg/ml, Cefotaxime 100 mg/ml. Plates were incubated at 37oC in 
5% CO2 until single colonies were visible [377]. Unless otherwise specified, all reagents were 
purchased from Sigma-Aldrich. India ink smears were prepared on a glass slide and visualized 
at 100X magnification using a CX41 microscope (Olympus, Japan). Images were captured 
using a DP71 Camera system with DP Controller software (Olympus, Japan) and processed 
using ImageJ (rsb.info.nih.gov/ij/). Capsular thickness was calculated by subtracting the cell 
body diameter (DCD, no capsule) from whole cell diameter (DWC, including capsule). At least 
30 individual microscopic yeast cells were assessed for each isolate.  
3.2.5. Mouse inhalation infection model of cryptococcosis 
All mouse infection experiments were conducted as previously described according to Duke 
University's Institutional Animal Care and Use Committee guidelines and approvals [228].  
6-weeks old female A/J mice were sedated with isoflurane and inoculated intranasally with 
the selected C. neoformans var. grubii isolate by dropping 25µl of yeast suspension 
containing 5x104 cells into the nares. Five ST5 strains (BK147, BK44, BMD700, BMD1338 and 
BMD1646) and three non-ST5 strains (BMD1415, BK80 (both ST4) and BMD1367 (ST306)) 
were chosen for animal experimenting. Animals were monitored daily and euthanized by CO2 
inhalation at indicated time points (fungal burden and in vivo responses) or until loss more 
than 15% body weight was observed (virulence assay).  
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3.2.6. Determining in vivo fungal burden  
5 mice were infected with each isolate on two independent experiments for assessment of 
virulence at 7 and 14 days post-infection. All animals in each experiment set were euthanized 
by CO2 inhalation either on day 7 or day 14 post-infection. Fungal burden at each time point 
was assessed by excising the left superior lobe of the lung and homogenizing the tissue by 
bead beating. Tissue homogenate was serially diluted and plated onto YPD agar 
supplemented with 100mg/ml ampicillin. The plates were incubated at 30oC for 48 hours and 
the number of C. neoformans colony forming units (CFU) recorded. Fungal burdens were 
expressed as CFU per gram of tissue (CFU/g).  At each time point, additional lung lobes were 
also collected for determining in vivo histopathology and cytokine response, as described 
below. 
3.2.7. Determining in vivo histopathology 
At specific time points (7 or 14 days post-infection), the right superior lung lobe from each 
mouse was excised and immersed in 10% formalin (replaced with 70% Ethanol after 24 
hours) for fixation. Fixed, uninflated lung specimens were stored at 4oC until further 
processing. After paraffin embedding, sliced sections were stained using the period acid-
Schiff (PAS) or mucicarmine. Histopathological examination was performed by an 
independent pathologist blinded to the infecting strain. The resulting tissue damage was 
scored from 0 (no changes) to 10 (severe changes), corresponding to the severity of 
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pathology in 4 different categories: necrosis, hemorrhage, edema and inflammation as per 
the Duke Veterinary Diagnostic Laboratory (Division of Laboratory Animal Resources). 
3.2.8. Determining in vivo cytokine response  
To assess the severity of the inflammatory responses at specific time points (day 7 and day 
14 post-infection), the middle lobe from the right lung of each infected mouse was excised 
and homogenized by bead beating in 1ml sterile PBS/Protease inhibitor. 500µl of lung 
homogenate was used for cytokine profiling. Cytokines representing T-helper type 1 (Th1) (IL-
12p70, TNF-α, IFN-γ), T-helper type 17 (IL-17) and T-helper type 2 (Th2) (IL-4, IL-5, IL-10) 
responses were measured using a customized Bio-Plex Pro™ Mouse Cytokine Th1/Th2 Assay 
kit (Biorad, USA) with the BioPlex 200 platform according to the manufacturer’s guidelines. 
Data were retrieved using BioPlex Manager Software. The upper and lower limits of 
quantification (ULOQ and LLOQ) were based on a standard curve. All values falling below the 
LLOQ were replaced with the midpoint between zero and the LLOQ. Data were standardized 
by lung weight and presented as picogram of cytokines per gram lung tissue (pg/g). 
3.2.9. In vivo virulence assay  
The virulence assay was conducted independently from the day 7/day 14 experiment. Each of 
the 8 selected isolates was intranasally inoculated in 10 A/J mice. Mice were monitored daily 
until loss of more than 15% body weight, which is a sign of distress, was observed.  Mice 
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were then euthanized by CO2 inhalation at point of impending death. In vivo fungal burden at 
the point of impending death was also recorded as previously described. 
3.2.10. Statistical analysis 
GraphPad Prism version 5.04 for Windows (GraphPad Software, San Diego California USA; 
www.graphpad.com) was used for data visualization and statistical analyses of fungal loads, 
cytokine profiling, capsular/cell size, and survival proportions. Mann-Whitney U-test was 
used for comparing fungal load and cytokine concentrations. Kaplan-Meier survival curves, 
and the log-rank test were used for survival analysis. Capsule/cell size was analyzed in 
GraphPad Prism 5.04 for Windows and compared using Welch’s t-test. The Fligner-Killeen 
test of variance homogeneity for analyzing variation in capsule/cell size and Fisher’s exact 
test were performed using R software, version 3.2.4 (http://www.r-project.org). One way 
ANOVA with a post hoc multiple comparison test (Dunnett or Bonferroni) integrated in 
Graphpad was used to compare cytokine concentrations between individual isolates.  
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Table 3.2-1. Typing and corresponding patients information for C. neoformans var. grubii 
isolates selected for phenotyping (n=30) 
 
 
  
NO. ISOLATE DATA PATIENT DATA 
Strain name AFLP  MLST  Underlying Disease Sex 
1 BK14 VNI-δ 4 HIV M 
2 BK163 VNI-δ 4 HIV M 
4 BK225 VNI-δ 4 HIV M 
6 BK48 VNI-δ 4 HIV M 
7 BK59 VNI-δ 4 HIV F 
8 BK69 VNI-δ 4 HIV M 
9 BK74 VNI-δ 4 HIV M 
10 BK80* VNI-δ 4 HIV M 
11 BK87 VNI-δ 4 HIV M 
12 BK88 VNI-δ 4 HIV M 
13 BK89 VNI-δ 4 HIV M 
15 BMD1415* VNI-δ 4 Lupus M 
3 BK218 VNI-δ 6 HIV M 
5 BK234 VNI-δ 6 HIV F 
14 BMD1367* VNI-δ 306 Gastric cancer F 
16 BK147* VNI-γ 5 HIV M 
17 BK44* VNI-γ 5 HIV M 
18 BMD101 VNI-γ 5 None known M 
19 BMD1228 VNI-γ 5 None known F 
20 BMD1291 VNI-γ 5 None known F 
21 BMD1338* VNI-γ 5 None known M 
22 BMD1353 VNI-γ 5 None known M 
23 BMD1452 VNI-γ 5 None known F 
24 BMD1646* VNI-γ 5 None known M 
25 BMD1716 VNI-γ 5 None known F 
26 BMD367 VNI-γ 5 None known M 
27 BMD673 VNI-γ 5 None known F 
28 BMD700* VNI-γ 5 None known M 
29 BMD854 VNI-γ 5 None known F 
30 BMD899 VNI-γ 5 None known F 
AFLP = AMPLIFIED FRAGMENT LENGTH POLYMORPHISM 
MLST = MULTI LOCUS SEQUENCE TYPING 
M = MALE, F = FEMALE 
* INDICATES ISOLATES SELECTED FOR MOUSE EXPERIMENT 
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3.3. Chapter 3 results 
3.3.1. ST5 C. neoformans isolates from Vietnam expressed higher in vitro capsular 
enlargement than non-ST5 isolates. 
We assessed and compared common in vitro virulence-related phenotypes between selected 
ST5 and non-ST5 isolates from HIV-uninfected and HIV-infected patients, respectively. 
Phenotypes tested included extracellular urease and phospholipase production, melanin 
production, in vitro capsular enlargement, growth at high temperature and in pooled human 
CSF. Upon microscopic examination we observed that the ST5 C. neoformans yeast cells 
developed significantly thicker capsule during in vitro culture than non-ST5 isolates 
( p<0.0001, Welch’s t-test; also see Table 3.2-1).  
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Table 3.3-1. Variability in in vitro capsule thickness and cell diameter between ST5 and non-
ST5 Cryptococcus neoformans strains from Vietnam 
 
 
  
 MLST Group 
Variable ST5  Non-ST5  
Capsule Thickness (μm)   
Mean* 2.64 2.01 
Median 2.25 1.94 
95% CI  2.49 - 2.79 1.94 - 2.07 
Range 0.01 - 9.56 0.02 - 6.16 
Coefficient of Variation
$
 (%) 0.63 0.37 
   
Cell diameter (μm)   
Mean* 11.38 9.69 
Median  10.00 9.56 
95% CI of Mean 10.96 - 11.79 9.52 - 9.87 
Range 4.74 - 27.22 5.25 - 19.89 
Coefficient of Variation
$
 (%) 0.41 0.20 
* P<0.0001, t-test with Welch’s correction.  
$
 P< 0.0001, Fligner-Killeen test of homogeneity of variance. 
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Individual ST5 C. neoformans cells were also significantly larger in size than cells from the 
non-ST5 strains (p<0.0001, Welch’s t-test; also see Table 3.3-1). A high degree of variation in 
both capsule size and cell diameter was detected between individual ST5 isolates (Figure 
3.3-1 and Table 3.3-1 ). A Fligner-Killeen test for homogeneity of variance confirmed this 
variation to be significantly greater for ST5 than non-ST5 isolates (p<0.0001) for both capsule 
size and cell diameter. BMD1646, a ST5 strain, appeared markedly bigger and highly 
encapsulated than any other isolates. The differences in capsule thickness and cell diameter, 
as well as intra-genotype variation among ST5 isolates was significant and was not an effect 
driven by the outlier BMD1646.  
In contrast, there were no genotype-specific differences in all other in vitro phenotypes 
tested: growth at 30oC (p=0.10, Welch’s t-test) and 37oC (p=0.23, Welch’s t-test); ex vivo 
survival in CSF after 1-day exposure (p=0.72, Welch’s t-test) and 3-days exposure  (p=0.77, 
Welch’s t-test) (see Figure 3.3-2 and Figure 3.3-3), extracellular urease activity and 
phospholipase activity (Figure 3.3-4 and Figure 3.3-5).  
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Figure 3.3-1. In vitro induced capsule thickness and cell diameter of individual Cryptococcus 
neoformans strains from Vietnam. 
AFLP-VNI-γ/MLST-ST5 strains expressed higher degree of variation in both capsule size and cell 
diameter in vitro, which remains significant even when the outlier BMD1646 was removed from the 
analysis (p<0.0001 for both capsule and cell size, Fligner-Killeen test).  Scattered plot represents single 
cells from an individual strain. Data for individual strains are presented as mean with error bars 
denoting standard deviation. Strains selected for experiment in mice were indicated by asterisks. 
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Figure 3.3-2. Growth of ST5 (n=15) and non-ST5 (n=15) C. neoformans var. grubii isolates from 
Vietnam at 30oC and 37oC.  
Data were obtained from 30 isolates (15 ST5 and 15 non-ST5) in 3 different experiment batches. 
Identical cell inoculum for each isolates was serial diluted on YPD agar and grown at 30oC or 37oC until 
visible colonies could be seen and counted. H99 was included in each experiment batch as internal 
control. Data were expressed as Colony Forming Unit (CFU) per ml ratio between a test isolate and 
that of H99 in the same experiment batch. Boxplots (Tukey method) describe the median and 
interquartile range with whiskers indicating the lower and upper quartiles. Values lower or higher 
than 1.5 times the lower or upper quartile, respectively, are indicated by clear circles. No statistically 
significant differences could be detected in growth at both 30oC (p=0.10) and 37oC (p=0.23) (Mann-
Whitney test).  
  
 98 | P a g e  
 
 
Figure 3.3-3. Ex vivo growth in human CSF of ST5 (n=15) and non-ST5 (n=15) C. neoformans isolates 
from Vietnam. 
Data were obtained from 30 isolates (15 ST5 and 15 non-ST5) in 3 different experiment batches. 107 
cells from each isolates was inoculated in pooled human CSF and incubated at 37oC/5% CO2. At day 1 
and day 3 post-inoculation, cell suspension is serial diluted on YPD agar and grown at 30oC until 
visible colonies could be seen and counted. H99 was included in each experiment batch as internal 
control. Data are expressed as Colony Forming Unit (CFU) per ml ratio between a test isolate and that 
of H99 in the same experiment batch. Boxplots describe the median and interquartile range with 
whiskers indicating the lower and upper quartiles. Values lower or higher than 1.5 times the lower or 
upper quartile, respectively, are indicated by open dots. No statistically significant differences could 
be detected in ex vivo CSF growth at both day 1 and day 3 post-inoculation (p=0.72 and p=0.77, 
Mann-Whitney test). 
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Figure 3.3-4. Extracellular phospholipase activity of C. neoformans var. grubii isolates from Vietnam 
(ST5: n=15 and non-ST5: n=15).  
10 µl of 108 cells/ml yeast suspension were spotted on Sabouraud agar with egg yolk supplement for 
assessment of phospholipase activity after 72 hours as previously described. Data are expressed as a 
ratio between measurements of the test isolates and that of H99. Boxplots (Tukey method) describe 
the median and interquartile range with whiskers indicating the lower and upper quartiles. Values 
lower or higher than 1.5 times the lower or upper quartile, respectively, are indicated by open dots. 
No statistically significant differences in phospholipase activity between the two test groups were 
observed.  
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Figure 3.3-5. Extracellular urease activity of C. neoformans var. grubii isolates from Vietnam (ST5: 
n=15 and non-ST5: n=15), according to time to complete color change on Christensen agar.  
10μl of 108cells/ml yeast suspension was spotted on individual Christensen’s urea agar. Medium color 
would change from yellow to pink due to pH changes when urea in the medium was broken down by 
extracellular urease. Since all C. neoformans var. grubii isolates tested positive for urease activity, 
time to complete color change on Christensen agar was used as an indirect measure of extracellular 
urease activity. Each isolates were tested in triplicates. No significant difference in urease activity was 
observed (p=0.77, log-rank test). 
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Phenotyping data for the 8 isolates selected for mice experiment are shown in the following 
Figure 3.3-6, Figure 3.3-7 and Figure 3.3-8. The reference C. neoformans var. grubii H99 
strain and H99-derived mutants as controls were also included in each respective experiment 
(see below).   
 
Figure 3.3-6. Growth at different temperature of 8 C. neoformans isolates from Vietnamese 
patients that were tested for virulence in mice, representing both ST5 (n = 5) and non-ST5 (n = 3).  
A similar inoculum of yeasts from each isolates were spotted onto YPD agar and incubated at either 
30oC or 37oC. All strains expressed similar growth at 30oC. Two ST5 strains (BMD1646 and BK147) 
appeared less viable than other strains at 37oC. H99 was included as a reference.  
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Figure 3.3-7. Ex vivo growth in human cerebrospinal fluid (CSF) of 8 clinical C. neoformans isolates 
from Vietnamese patients that were tested for virulence in mice, representing both ST5 (n = 5) and 
non-ST5 (n = 3) genotypes.  
The same inoculum of yeasts were inoculated in pooled human CSF and incubated at 37oC. Inoculum 
was diluted and plated on YPD agar at day 1 and day 3 post-inoculation. One ST5 strains (BMD700) 
appeared less viable than all other strains at day 1. At day 3 post-inoculation four out of the 5 ST5 
strains displayed markedly reduced viability than the 3 non-ST5 strains.  The H99-derived mutant 
Δena1, lacking a cation ATPase transporter which resulted in decreased viability in human CSF and 
within macrophages, was used as a negative control for the ex vivo CSF assay.  
H99
ena1Δ
BMD1415 
BMD1367
BK80
BMD1646
BMD700
BMD1338
BK147
BK44
Neat 10-1 10-2 10-3 Neat 10-1 10
-2 10-3
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(VNI-γ)
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Figure 3.3-8. Melanin production on L-DOPA medium of eight clinical C. neoformans isolates from 
Vietnamese patients representing both S5 (n =5) and non-ST5 (n = 3) genotypes that were tested 
for virulence in mice.  
For each isolates, 10 μl of 106 cell suspension was inoculated on L-DOPA agar and incubated in the 
dark at 30oC and 37oC. No clear genotype-specific patterns of melanization were observed at either 
30oC or 37oC. The five ST5 strains displayed marked variation in the degree of pigment production, 
from mildly melanized (BK147) to highly melanized (BK44 and BMD1646). Strain order: 1:BK44 (ST5); 
2:BK80 (ST4); 3:BK147 (ST5); 4:BMD700 (ST5); 5:BMD1338 (ST5); 6:BMD1367 (ST306); 7:BMD1415 
(ST4); 8:BMD1646 (ST5); 9:H99; 10: an insertion mutant with diminished melanin production used as 
negative control. 
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3.3.2. ST5 isolates from were less virulent than non-ST5 isolates in experimental 
mice infection 
We tested the hypothesis of whether higher prevalence of ST5 infection in apparently 
healthy hosts was associated with higher virulence potentials of these strains using a murine 
model of infection. Infections with the ST5 strains were associated with significantly longer 
survival time than infection with the non-ST5 strains (p<0.0001, log-rank test, also see  
Figure 3.3-9).  
 
 
 
 
 
 
 
 
 
Figure 3.3-9. Kaplan-Meier survival curves for mice infected with either VNI-γ or VNI-δ Cryptococcus 
neoformans strains. 10 mice were infected per strain (ST5: n=5, non-ST5: n=3).  
Mice were monitored daily until the point of more than 15% weight loss or visible suffering and were 
then sacrificed by CO2
 inhalation. Mice infected with ST5 strains had statistically significantly longer 
survival times than those infected with non-ST5 strains (P<0.0001, Mantel-Cox log rank test). 
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Figure 3.3-10. Survival proportions for mice infected with 8 individual Cryptococcus neoformans 
strains representing 2 main cryptococcal genotypes in Vietnam.  
A/J mice were infected with 8 representative Cryptococcus neoformans strains (5 VNI-γ/ST5 strains, 
denoted by black symbols, and 3 VNI-δ/non-ST5 strains, denoted by open symbols). 10 mice were 
included for each strain from each genotype. Mice were monitored daily until over 15% weight loss 
and were sacrificed by CO2
 inhalation.BMD1415 and BMD1338 represent the most virulent VNI-δ and 
VNI-γ strain, respectively. Mice infected with BK147 and BMD1646 (indicated by straight Kaplan-
Meier lines at 100% survival rate) survived for as long as 42 days post-infection, at which point the 
experiment was terminated and all infected mice euthanized.  
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There was significant variability in the effect of individual yeast strains of the same lineage on 
survival time (Figure 3.3-10). Notably, two ST5 strains (BK147 and BMD1646) appeared to be 
substantially attenuated in comparison to the other ST5 strains with mice infected with these 
strains surviving up to day 40 post infection. Due to the time constraint all mice infected with 
these two attenuated strains were euthanized at day 40 post-infection. The differences in 
survival times between mice infected with ST5 and non-ST5 strains remained significant 
when data from these two isolates were removed from the comparative analysis (p=0.003, 
log-rank test, data not shown). Of the eight strains selected for infecting mice, the two most 
virulent were BMD1415 (ST4), and BMD1338 (ST5); infection with these isolates resulted in 
100% mortality by days 17 and 18, respectively (median survival 15 and 17 days, 
respectively). BMD1338 was significantly less virulent than BMD1415 (p=0.0015, log-rank 
test). No significant difference in virulence was detected between BMD1338 and BMD1367, 
the second most virulent non-ST5 strain.  
All strains successfully established lung infection and disseminated to the brain of the mice as 
early as day 7. Consistent with the survival data, the non-ST5 strains established a higher 
fungal burden in the lung than the ST5 organisms at all time-points (p=0.0002, p<0.0001, and 
p<0.0001 at day 7, day 14, and at the point of 15% weight loss, respectively, Mann-Whitney 
U-test) (Figure 3.3-11 and Table 3.3-2). Moreover, these data were not driven by the two 
severely attenuated isolates (BK147 and BMD1646) as the fungal loads associated with ST5 
infections remained low even when these two isolates were excluded from the analysis. Lung 
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fungal burdens from mice infected with BMD1646 (ST5) and BK147 (ST5) were mostly low for 
as long as day 14 (Figure 3.3-12). On the other hand, despite these differences in fungal 
burden in the lung, there were no genotype-specific differences in fungal burden in the brain 
up to day 14. However, brain fungal burdens in non-ST5 infections were significantly higher 
than the brain fungal burdens in ST5 infections at the point of 15% weight loss (mean 
logCFU.g-1 (95%CI); 4.5 (3.9-4.7) and 2.9 (2.2-3.6) for non-ST5 and ST5 respectively, p=0.01, 
Mann-Whitney U-test).    
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Table 3.3-2. Tissue fungal burden in mice at days 7, 14 and death by infecting MLST Sequence Type 
  
Fungal burden  
(Mean log10 colony forming units per gram tissue)  
[95%CI] 
 
Tissue ST5 Non-ST5 P-value 
Lung (Day 7) 
4.96 
[3.86 - 6.05] 
7.07 
[6.85 - 7.29]* 
<0.01 
 
Brain (Day 7) 
0.81 
[0.38 - 1.24] 
1.59 
[0.87 - 2.30] 
0.05 
 
Lung (Day 14) 
5.48 
[4.34 - 6.62] 
8.00 
[7.77 - 8.23]* 
<0.0001 
 
Brain (Day 14) 
1.56 
[0.81 - 2.31] 
1.91 
[1.12 - 2.69] 
0.36 
Lung (Death) 
3.81 
[3.05 - 4.57] 
6.53 
[6.30 - 6.76]* 
<0.0001 
 
Brain (Death) 
2.90 
[2.23 - 3.56] 
4.29 
[3.90 - 4.68]* 
0.01 
 
*Statistical significance by Mann-Whitney test.   
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Figure 3.3-11. Fungal burden in lung tissue at day 14 (A), lung fungal burden at point of impending 
death (B) and brain fungal burden at point of impending death (C) according to infecting genotype. 
5 mice were infected per strain (ST5 N = 5, non-ST5 N = 3).  
Mice were monitored daily until there was > 15% weight loss or visible suffering and were then 
sacrificed by CO2
 inhalation. Non-ST5 fungal burden appeared higher than that of ST5 in both lung and 
brain tissue at all time-points (Mann-Whitney test, **: P<0.0001, *: P<0.05). The horizontal line within 
the box indicates the median; boundaries of the box indicate the 25th and 75th percentile and the 
whiskers indicate the highest and lowest values of the results; outliers are denoted as black dots.
 110 | P a g e  
 
lo
g
1
0
(C
F
U
/g
)
B
K
44
B
K
14
7
B
M
D
70
0
B
M
D
13
38
B
M
D
16
46
B
K
80
B
M
D
13
67
B
M
D
14
15
0
1
2
3
4
5
6
7
8
9
10
lo
g
1
0
(C
F
U
/g
)
B
K
44
B
K
14
7
B
M
D
70
0
B
M
D
13
38
B
M
D
16
46
B
K
80
B
M
D
13
67
B
M
D
14
15
0
1
2
3
4
5
6
7
8
9
10
L
o
g
1
0
(C
F
U
/g
)
B
K
44
B
K
14
7
B
M
D
70
0
B
M
D
13
38
B
M
D
16
46
B
K
80
B
M
D
13
67
B
M
D
14
15
0
1
2
3
4
5
6
7
8
9
10 VNI- (ST5)
VNI- (non-ST5)
lo
g
1
0
(C
F
U
/g
)
B
K
44
B
K
14
7
B
M
D
70
0
B
M
D
13
38
B
M
D
16
46
B
K
80
B
M
D
13
67
B
M
D
14
15
0
1
2
3
4
5
6
7
8
9
10
lo
g
1
0
(C
F
U
/g
)
B
K
44
B
K
14
7
B
M
D
70
0
B
M
D
13
38
B
M
D
16
46
B
K
80
B
M
D
13
67
B
M
D
14
15
0
1
2
3
4
5
6
7
8
9
10
L
o
g
1
0
(C
F
U
/g
)
B
K
44
B
K
14
7
B
M
D
70
0
B
M
D
13
38
B
M
D
16
46
B
K
80
B
M
D
13
67
B
M
D
14
15
0
1
2
3
4
5
6
7
8
9
10
Lung fungal burden at day 7
post-infection
Brain fungal burden at day 7
post-infection
Lung fungal burden at day 14
post-infection
Brain fungal burden at day 14
post-infection
Lung fungal burden at death
Brain fungal burden at death
 
 
 
 
 
 
 
 
 
 
Figure 3.3-12. Fungal burden in mice tissue at specific time points during the course of experimental mice infection (day 7 and day 14 post-infection, 
point of impending death). 
Chosen ST5 (n=5) and non-ST5 (n=3) isolates were inoculated into five A/J mice on different experimental batches to assess in vivo virulence. Fungal load 
were standardized into CFU per gram tissue (CFU/g). Data for each isolates were presented as averaged CFU/g from five mice in the same group with error 
bars denoting standard deviation.   
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3.3.3. C. neoformans isolates from HIV-uninfected patients induced higher levels of pro-
inflammatory TNF-α production in the lungs of infected mice 
We next measured the concentration of cytokines from lung homogenates of A/J mice 
infected with the various strains at days 7 and day 14 post-infection. Cytokine concentrations 
at these time points are shown in  
Figure 3.3-13, according to the genotype of the infecting organism. At day 7, ST5 infections 
were associated with significantly higher concentrations of TNF-α in the lung than non-ST5 
strain infections (p=0.01, Mann-Whitney U-test; also see Table 3.3-3). Furthermore, among 
ST5 strain infections at day 7, TNF-α concentrations were highest for the two specific strains 
that appeared to be most attenuated in the mouse survival model (BK147 and BMD1646), 
and lowest in BMD1338, the most virulent ST5 isolate in the mouse model. By day 14, mean 
TNF-α concentration associated with the ST5 strains had declined from 3933.71 pg/g to 
2802.36 pg/g. Other Th-1 cytokines including IL-12, IL-17 and IFN-γ also decreased in ST5-
infected mice between day 7 and day 14 (p<0.001, p<0.01 and p=0.02, Mann-Whitney U-test, 
respectively). 
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Figure 3.3-13. Genotype-specific cytokines concentrations from lung homogenate of A/J mice at 7 and 14 days post infection with 5x104 C. neoformans 
cells/mouse.  
Five mice were infected with each strain from each genotype at each time points. Box and whisker plots comparing levels of each cytokine between each 
genotype at day 7 and day 14 post-infection. ST5 strains induced significantly higher level of TNF-α at day 7 but by day 14 mice infected with non-ST5 
strains appeared to have much higher proinflammatory cytokines. The horizontal line within the box indicates the median; boundaries of the box indicate 
the 25th and 75th percentile and the whiskers indicate the highest and lowest values of the results; outliers are denoted as black dots. Data are 
standardized as picogram of cytokine per gram lung tissue. Asterisks show statistical significance by Mann-Whitney test. 
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Table 3.3-3. Cytokine concentrations from lung homogenate of infected mice at day 7 and 
day 14 post-infection according to infecting Cryptococcus neoformans AFLP group 
 
Mean cytokine concentration  
(pg per gram of lung tissue)  
[95%CI] 
 
Cytokine ST5 Non-ST5 
*P Value 
(ST5 vs non-ST5) 
Day 7    
Th-1 
 
 
IL-12 853.12 822.87 0.30 
 [750.50 - 955.80] [608.90 - 1037.00]  
IFN-γ 136.02 150.59 0.97 
 [115.00 - 157.00] [105.80 - 195.30]  
TNF-α 3933.71 3256.25 0.01 
  [3486.00 - 4381.00] [2630.00 – 3882.00]  
Th-2 
 
 
IL-4 230.79 253.24 0.92 
 [162.80 - 298.80] [11.60 - 349.90]  
IL-5 561.05 459.85 0.91 
 [369.00 - 753.10] [344.40 - 575.40]  
IL-10 145.01 139.99 0.68 
  [128.20 - 161.80] [119.30 - 160.70]  
     
Th-17 IL-17 268.48 243.41 0.24 
  [155.90 – 381.00] [165.60 - 321.20]  
TNF-α/IL-10 ratio 27.13 23.26 N/A 
Day 14    
Th-1 
IL-12 547.84 213.72 <0.01 
 [412.40 - 683.30] [120.50 - 306.90]  
IFN-γ 91.2 1760.67 0.09 
 [57.25 - 125.20] [166.50 - 3355.00]  
TNF-α 2802.36 6378.76 <0.01 
  [2385.00 - 3220.00] [3374.00 - 9384.00]  
Th-2 
IL-4 1154.72 800.35 0.60 
 [673.50 – 636.00] [604.70 – 996.00]  
IL-5 294.6 347.55 0.15 
 [170.40 - 418.80] [279.20 - 415.90]  
IL-10 
132.76 
[102.10 - 163.40] 
220.15 
[172.40 - 267.90] 
0.01 
Th-17 IL-17 175.75 1012.49 0.01 
  [65.54 – 286.00] [459.20 – 1566.00]  
TNF-α/IL-10 ratio 21.11 28.97 N/A 
* Mann-Whitney test.  
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In contrast, non-ST5 strain infections resulted in increased mean TNF-α levels from  
3256.25 pg/g to 6378.76 pg/g (p=0.0003 and p=0.0235, Mann-Whitney U-test, respectively; 
also see Table 3.3-3) between days 7 and 14. However, the high concentration of TNF-α seen 
in non-ST5 strain infections at day 14 was driven by a single isolate - BMD1415;  TNF-α 
concentrations in the lung in mice infected with this isolate were significantly higher than for 
infections with any other ST5 or non-ST5 isolate (p<0.05, Mann-Whitney U-test). There were 
no statistically significant differences in TNF-α concentration at day 14 when data from 
infections due to this isolate were excluded from the analysis. The same BMD1415-driven 
pattern also occurred when comparing IFN-γ and IL-17 concentrations at day 14. The 
concentrations of these two cytokines in BMD1415-infected mice appeared significantly 
higher than in mice infected with any other isolates (p<0.05, Mann-Whitney U-test; see 
Figure 3.3-14). However, IL-12 concentrations fell in non-ST5 strain infected mice, including 
BMD1415, between day 7 and 14 (4 fold decrease, p<0.0001, Mann-Whitney U-test)  
(Figure 3.3-15).  
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Figure 3.3-14. TNF-α, IFN-γ and IL-17 levels associated with individual isolates at day 14. 
TNF-α, IFN-γ and IL-17 at day 14 were significantly higher in mice infected with non-ST5 strains. 
BMD1415 induced significantly higher levels TNF-α, IFN-γ and IL-17 than any other isolates (p<0.05, 
ANOVA with Dunnett’s multiple comparison test). Bar plot presents picogram of cytokine per gram 
lung tissue. Error bars denote standard deviations. 
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Figure 3.3-15. Genotype-specific changes of cytokine concentration from lung homogenate of A/J mice infected with 5x104 C. neoformans cells/mouse 
between day 7 and day 14 post-infection. 
 Box and whisker plots compare levels of each cytokine between day 7 and day 14 for each genotype. The horizontal line within the box indicates the 
median, boundaries of the box indicate the 25th and 75th percentile and the whiskers indicate the highest and lowest values of the results; outliers are 
denoted as black dots. Data are standardized as picogram of cytokine per gram lung tissue. Asterisks show statistical significance by Mann-Whitney test. 
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1 
I also measured the TNF-α/IL-10 ratio as a proxy marker of the relationship between a Th-1 
and a Th-2  response [378]. From day 7 to day 14 post-infection, the TNF-α: IL-10 ratio 
decreased almost 1.28 fold in mice infected with ST5 isolates while those infected with non-
ST5 strains exhibited a TNF-α: IL-10 ratio increase of 1.25 fold. However, when BMD1415 
(ST4) was excluded from the analysis the TNF-α/IL-10 ratio in mice infected with non-ST5 
strains decreased by a factor of 0.67. By day 14 we detected elevated concentrations of IL-17 
and IFN-γ in non-ST5 infected mice (5-fold and 17-fold increments, respectively (Table 3.3-3), 
but not in ST5 infected mice. Again, this effect was largely associated with BMD1415, since 
the concentrations of IL-17 and IFN-γ induced by this isolate at day 14 were significantly 
higher than for all others (p<0.05, one way ANOVA test; also see  
 
 
 
Figure 3.3-14). 
3.3.4. Histopathological examination 
Histological examination of infected lung tissue revealed evidence of inflammation, 
hemorrhage, edema and necrosis in most cases. These changes were generally greater by 
day 14 in comparison to day 7. There were no clear differences in histological scores between 
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sequence types, other than strain BMB1646 (ST5) which had only mild inflammation with no 
necrosis or hemorrhage seen (Figure 3.3-16). PAS staining revealed extensive perivascular 
infiltration of leukocytes in mice tissue associated with both infecting genotypes (BMD1338-
ST5 and BMD1415-ST4, Figure 3.3-17). The extrapulmonary space of BMD1338-infected mice 
was markedly packed with localized infiltrating leukocytes (Figure 3.3-17). Though we could 
not quantitatively assess and compare genotype-specific capsule size in vivo, ST5 yeasts 
appeared extensively encapsulated in the lung sections, especially at day 14 (Figure 3.3-17). 
Diffuse capsular localization could be observed in the mucicarmine staining images (Figure 
3.3-18).
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Figure 3.3-16. Histopathological scores in 4 categories of tissue damage (Inflammation, necrosis, hemorrhage and edema). 
Thin sections of parafin-embedded lung specimens from infected mice were stained using the Periodic Acid Schiff (PAS) method. Specimens were 
randomized, blinded and assessed by an independent pathologist. Histopathological scores ranged from 0 (no changes) to 10 (severe changes), 
corresponding to the severity of pathology in 4 different categories: necrosis, hemorrhage, edema and inflammation as per the Duke Veterinary Diagnostic 
Laboratory protocol (Division of Laboratory Animal Resources). 
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Figure 3.3-17. Periodic acid Schiff (PAS) staining of pulmonary tissue from mice infected with BMD1338 and BMD1415 on days 7 ad 14.  
The two strains represent ST5 and non-ST5, respectively. A/J mice were inoculated intranasally with 5x104 yeast cells. Lung specimens were harvested at 
days 7 and 14 for histopathological examination. Photomicrographs were obtained at 200X magnification; the scale bar represents 215 μm). (A-B): lung 
sections from mice infected with BMD1338 (VNI-γ/ST5) at day 7 and day 14, respectively. (C-D): lung sections from mice infected with BMD1415 (VNI-
δ/ST4) at day 7 and day 14, respectively. Perivascular infiltration (red arrows) and necrosis are more marked by day 14 for both strains. Encapsulated 
yeasts (yellow arrows), notable for the larger cell size and capsule thickness of BMD 1338 compared with BMD1415. Sections with leukocytes localization 
are enlarged on the outer right panels. 
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Figure 3.3-18. Mucicarmine staining from paraffin-embedded mice pulmonary tissue. 
Polysaccharide components from the capsule of Cryptococcus neoformans yeasts are visualized in pink stain. Photomicrographs were obtained at 400X 
magnification. The scale bar indicates 50 μm. Red and blue arrows indicate where the inner and outer layers of the capsule are stained, respectively. These 
indicate the white spaces in and around the alveolar tissue are evident of the capsules presence.
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3.4. Chapter 3 Discussion 
Previous work from my group described two distinct AFLP-defined clusters of C. neoformans 
var. grubii in Vietnam: VNI-γ, which accounted for the majority of cases in HIV-uninfected 
patients and were all MLST-ST5, and VNI-δ which mostly consisted of isolates from HIV-
infected patients and included all other MLST sequence types in the population [103,325]. 
The high prevalence of ST5 infection in HIV-uninfected patients could be explained either by 
these strains being intrinsically more virulent or due to unidentified lineage–specific host 
immune defects or exposures. In this study we investigated the first hypothesis by comparing 
previously identified virulence-associated phenotypes and in vivo virulence and immune 
responses in the mouse model by lineage. The strains were grouped on the basis of their 
genetic relatedness using AFLP and MLST genotyping. There could have been genomic 
variations within and between the lineages that MLST did not have enough resolution to 
distinguish. However since all ST5 strains fitted well within the AFLP-defined cluster of VNI-γ 
in our study, we believe our random sampling was well-justified in that it well-represented 
the two major clades of the C. neoformans var. grubii population from Vietnam. 
 Strains from all STs were able to grow in ex vivo human CSF and at 37oC as well as having 
extracellular urease and phospholipase activity - essential characteristics for establishing 
human infection. However, we could not identify any apparent ST-specific difference of 
growth under these conditions, suggesting that the ability to establish disease in HIV-
uninfected/immunocompetent patients is not driven by simple adaptations to high 
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temperature or growth in human CSF. However, we found ST5 cells to be both significantly 
larger than non-ST5 cells and to have thicker capsules in vitro. The capsule of C. neoformans 
plays important roles in pathogenesis, from interfering with phagocytosis by host 
macrophages to modulating the host immune response [164,379–381]. Previously, it has 
been shown that variation in capsule size correlates with pathogenic potential of C. 
neoformans [382]. Ex vivo capsule size has also been associated with higher intracranial 
pressure, slower clearance of yeasts and paucity of inflammation in humans [164].  Our study 
demonstrates that while ST5 isolates have significantly higher capacity for in vitro capsule 
enlargement, this phenotype did not translate into increased virulence in the mouse model.  
Mice infected with ST5 isolates not only had better survival but also lower tissue fungal 
burdens than those infected with non-ST5 strains, contrary to recent human data which 
supports morphological changes being associated with more severe pathology in the human 
host (e.g ex vivo capsule size and capsular shedding has been associated with increased 
intracranial pressure in CM patients with HIV[164]).  
There are several possible explanations for the lower virulence of ST5 in mice we observed. 
First, virulence in mice is variable depending on mouse breed and may not accurately reflect 
the immunological heterogeneity of the human population [383]. Second, yeasts with 
different pathogenic potentials, associated with their isolation from different sources (i.e. 
clinical versus environmental, immunocompromised vs immunocompetent patients) may 
have the same or paradoxical pathogenic potential in experimental animal models. For 
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instance, C. gattii is often associated with infection in immunocompetent patients and 
therefore is considered more virulent (or fit) in the human host than C. neoformans. 
However, it has been shown that the hypervirulent C. gattii strain R265, responsible for the 
on-going Vancouver outbreak, has similar virulence in both C57BL/6 and A/J mice to the C. 
neoformans H99 strain, which is derived from a patient on chemotherapy with Hodgkin’s 
disease [384]. Similarly, R272, a Vancouver outbreak C. gattii VGIIb strain also displayed 
identical degree of virulence as WM276, an environmental isolate from Australia, in murine 
models [384]. Third, the A/J mouse strain is not immunologically intact and thus may be an 
imperfect model of infection for immunocompetent hosts [385]. Rather, A/J mice may be a 
better model of disease in immunosuppressed patients, as they are highly susceptible to 
cryptococcal disease, and the patterns of cytokine expression in mice with disseminated 
cryptococcosis are similar to those seen in HIV-infected patients with CM [386]. Our results 
suggest that additional models that better mimic infection in apparently immunocompetent 
hosts may be needed to explain the complex interaction between C. neoformans and the 
human host.  
In cryptococcal infection in mice, a Th1 type immune response, defined by the TNF-α/IL-10 
ratio, is considered to be protective, while a Th2 response is associated with poor outcomes 
[271,282]. We did not detect genotypic-driven changes in TNF-α/IL-10 ratios over time, 
although higher TNF-α concentrations were induced by ST5 strains at day 7 suggesting this 
genotype elicited a more intense initial inflammatory response. This finding could be 
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explained by the increased capsular size of ST5 organisms - previous studies have suggested 
that capsule components, or cryptococcal cells themselves, have a dose-dependent ability to 
stimulate TNF-α production by various immune effector cells [387,388]. ST5 organisms, 
though present in mice in fewer number than non-ST5,  induced stronger inflammatory 
response in mice 7 days post-infection, suggesting that TNF-α production may be driven by 
capsular components rather than cell number. Previously, it has been suggested that C. gattii 
is able to cause disease in apparently immunocompetent patients because it induces a less 
severe inflammatory response than other cryptococci [384]. However data generated from 
our murine infection experiments do not support a less severe inflammatory response being 
the mechanism underlying the ability of ST5 C. neoformans var. grubii organisms to cause 
disease in the immunocompetent.   
In vivo controlled infection studies in mice commonly define pathogenicity as the microbe’s 
capability to cause disease in a susceptible host, whereas virulence corresponds to the 
severity of the ensuing pathology [68]. Using the same infective dose for all strains we failed 
to demonstrate that ST5 strains had greater virulence than non-ST5 organisms. The 
difference we observe in prevalence of different lineages in immunocompetent and 
immunosuppressed human patients may alternatively represent a specific difference in the 
ability of the organisms to colonize the host and establish infection, which we were unable to 
assess with our experimental system.  
 126 | P a g e  
 
Spores are presumed to be the main infectious propagule for Cryptococcus spp [69]. Capsule 
biosynthesis genes are required for both efficient sexual development and spore formation 
and dispersal [70]. Given the higher rate of capsular enlargement and higher variation in 
capsule size in ST5 strains, it is possible that capsule biosynthesis genes are more active in 
ST5 yeasts, resulting in qualitative differences in their spores that confer higher infectivity 
when interacting with immunocompetent hosts. Moreover, the higher rates of variability 
that we see in this and other virulence phenotypes (for example, growth at 37oC) within ST5 
strains in this study hint that higher phenotypic variability in ST5 may be an adopted strategy 
that facilitates the exploitation of novel niches. This strategy could have resulted in a 
phenotype which allowed the successful colonization of one or more novel environmental 
nich(es), and as a bystander-effect, allowed the exploitation of infrequent specific human 
immune deficits. This hypothesis should be investigated further to better understand any 
links between in vitro capsular enlargement and cryptococcal disease in apparently healthy 
hosts.  
Thus, our cohort of ST5 yeast isolates displayed two notable phenotypes.  First, in general 
they appeared to be less virulent in a murine model than the other sequence types, as 
demonstrated by reduced fungal burdens in tissue, induction of greater early immunological 
responses and prolonged mouse survival.  Second, ST5 strains induced larger in vitro capsule 
and cell sizes than the other genotypes, and notably greater variability between individual 
strains for this phenotype. Our data lead us to three main conclusions. First, clinical isolates, 
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which have by their nature already undergone selection within the human host, can possess 
wide variability in the expression of virulence phenotypes within a single lineage.  Secondly, 
the use of host risk factors and immune phenotype to derive an understanding of the factors 
that drive the pathogenicity of Cryptococcus neoformans may be more complex than 
anticipated. Associations may be difficult to make due to the relevance of the particular in 
vitro phenotypes, animal models used, within strain heterogeneity, and population 
substructure.  Moreover, there may be significant heterogeneity in the immune response of 
apparently immunocompetent patients which selects particular sub-cohorts of isolates of the 
same lineage. Thirdly, the categorization of strains into specific clades with limited genetic 
information such as MLST may lack precision to understand the relative fitness of specific 
strains in the human host.  It is likely that whole genome sequencing will provide better 
mapping of the relationships between strains and virulence. Lastly, we tested a relatively 
small number of strains, and may have lacked power to detect relevant differences that are 
present at the wider population level.  
3.5. Chapter 3 Conclusion 
In this study, I demonstrated genotype-specific differences in in vitro and in vivo virulence 
phenotypes between C. neoformans var. grubii strains isolated from hosts with different 
immune status. There was also significant variation among strains isolated from apparently 
immunocompetent patients in specific in vitro and in vivo phenotypes tested. This higher rate 
of phenotypic variation may represent an evolutionary strategy for C. neoformans var. grubii 
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to take advantage of novel niches and contribute to their ability to infect apparently 
immunocompetent hosts, despite generally being less virulent in a mammalian animal 
model. Furthering the understanding of the pathogenesis of cryptococcal meningitis will 
require investigation of large numbers of strains with associated robust clinical information, 
and the development of high throughput laboratory phenotypic studies that have clinical 
relevance in humans.  
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Chapter 4 
 
ASSESSING INTRACELLULAR PARASITISM OF  
C. NEOFORMANS VAR. GRUBII ISOLATES FROM VIETNAM USING A HIGH-
THROUGHPUT IN VITRO MACROPHAGE MODEL OF INFECTION 
4.1. Chapter 4 Introduction 
Phagocytic cells of the innate immune system (e.g. dendritic cells, macrophages and 
polymorphonuclear leukocytes) are the first line of host defense against cryptococcal 
infection [389–391]. These phagocytic cells are also important in modulating the nature and 
outcome of adaptive immune responses. However, cryptococcal yeasts have also acquired 
the ability to avoid intracellular killing, proliferate inside host macrophages, transfer laterally 
between adjacent macrophages and escape from macrophages using lytic or non-lytic 
(vomocytosis) mechanisms [131,392,393].  This intracellular parasitism capacity is thought to 
have evolved through interactions with predating amoebas in the environment, which in turn 
delivers a survival advantage in the mammalian host [94]. Intracellular parasitism of 
macrophages has important implications. First, it directly affects fungal burden in the host, 
which has been shown to be correlated with outcome in human disease [135]. In fact, it has 
been shown that intracellular C. neoformans yeasts proliferate faster inside human 
macrophages than extracellular yeasts [394]. Second, an intracellular niche potentially 
provides an alternative mode of dissemination within the host and facilitates immune 
evasion [392]. Hijacking host monocytes in a ‘Trojan-horse’ mode of action has been 
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identified as one of the many routes employed by C. neoformans to cross the Blood-Brain 
Barrier[132].  
Macrophage parasitism may also be important in both the establishment and maintenance of 
latent infection, active disease being believed to be the result of reactivation from latency 
[395]. Repeated lateral transfer of intracellular yeasts between adjacent macrophages has 
been suggested as a frequent event occurring during latent infection,  aiding both immune 
avoidance and dissemination [393].  
Generally, previous in vitro studies of cryptococcal pathogenesis employed a few well-
characterized strains (e.g. C. neoformans var. grubii H99, C. gattii R265 etc.). It is unclear how 
results from the use of these repeatedly passaged single examples of particular varieties 
generalize to the wider clinical context. For example, isolates from the same molecular 
genotypes or isolation source (both clinical and environmental) may possess different in 
vitro/in vivo phenotypes and virulence potential [333,396]. Further understanding of 
cryptococcal pathogenesis may depend upon studying large numbers of strains with detailed 
associated clinical information. There is a need to develop high throughput in vitro models to 
test phenotypes with clinical relevance to humans. 
Using an in vitro murine macrophage model of infection, Ma Hansong and colleagues 
demonstrated that high intracellular proliferation capacity, both in murine macrophages and 
human peripheral blood mononuclear cells, was predictive of experimental murine virulence 
and presumably contributed to virulence in humans [130]. This correlation is independent of 
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cryptococcal species (C. neoformans or C. gattii) or mouse breed used [130]. Alanio et al. 
[136] demonstrated that disease outcome in humans involved a complex interplay between 
host response and specific cryptococcal virulence properties by employing a high-throughput 
flow-cytometry based macrophage model that allowed simultaneous and rapid quantification 
of C. neoformans intracellular proliferation and yeast uptake by macrophages. In this study, 
patients infected with isolates that with high yeasts uptake rate and high intracellular 
proliferation rate (26%; n=14)  had a 5-fold-increased risk of death [136]. On the other hand, 
patients infected with isolates exhibiting both a low yeasts uptake rate and low intracellular 
proliferation rate (19%; n=10) had a 15-fold-increased risk of having positive CSF cultures 
after 2 weeks of antifungal therapy [136]. Therefore, intracellular proliferation and 
macrophage yeast uptake could potentially be used as a parameter to indicate cryptococcal 
virulence. 
In this chapter I employ and develop the in vitro macrophage models of infection developed 
by Ma Hansong et al., [130]and Alanio et al.,[136] in order to determine how it relates to the 
clinical  virulence of C. neoformans var. grubii isolates defined by their ability to infect HIV-
uninfected and HIV-infected patients in Vietnam.  
Specific Chapter aims are: 
1. Develop and refine a high throughput in vitro macrophage model of infection to 
compare the pathogenicity of Vietnamese C. neoformans var. grubii isolates at the 
lineage level. 
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2. Compare and identify possible differences in macrophage parasitism capacity 
between the VNI-γ/ST5 lineage and the VNI-δ/non-ST5 lineage of C. neoformans var. 
grubii in Vietnam. I hypothesize that the VNI-γ/ST5 lineage would have higher 
virulence potential than other lineages, consistent with its ability to exclusively infect 
immunocompetent patients. 
3. Identify any association between macrophage parasitism characteristics and patient 
outcomes. 
4.2. Chapter 4 Materials and Methods 
4.2.1. Clinical C. neoformans var. grubii isolates and culture conditions 
The C. neoformans var. grubii isolates used in this study were clinical isolates from the 
cerebrospinal fluid (CSF) of patients enrolled in a randomized controlled trial of antifungal 
therapy in HIV-infected patients between 2004 and 2011, and a prospective, descriptive 
study of HIV-uninfected patients with central nervous system (CNS) infections enrolled 
between 1998 and 2009 [294,307]. All studies were approved by the Institutional Review 
Board of the Hospital for Tropical Diseases, Ho Chi Minh City, and the Oxford Tropical Ethics 
Committee or Liverpool School of Tropical Medicine UK.  
On positive growth from CSF, a sweep was taken through colonies for archiving. Yeasts were 
archived at -80oC in Microbank beads (Pro-Lab Diagnostics, UK). Unless otherwise specified, 
all isolates were single-colony purified prior to experiments and were propagated in Yeast 
Peptone Dextrose (YPD) broth at 30oC overnight with agitation. Data for mating type and 
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Amplified Fragment Length Polymorphism (AFLP) genotyping were previously determined 
and published [103]. MLST genotyping was done and presented in Chapter 2 of this thesis. 
A total of 47 C. neoformans var. grubii isolates were randomly chosen from a list of 136 
clinical isolates and included in the screening experiment using method 1. These included 24 
AFLP/VNI-γ isolates and 23 AFLP/VNI-δ isolates, randomly chosen from each respective AFLP 
group. Among the 24 AFLP/VNI-γ isolates, 14 were isolated from HIV-infected patients while 
the remaining 10 were isolated from HIV-uninfected patients. All 23 AFLP/VNI-δ isolates were 
isolated from HIV-infected patients. As reported in Chapter 1, while AFLP/VNI-γ isolates 
infect both HIV-uninfected and HIV-infected patients, all AFLP/VNI-γ isolates isolated from 
HIV-uninfected patients were MLST-ST5. Isolates other than ST5 were collectively called 
“non-ST5”. 
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4.2.2. Cell line and cell culture techniques 
The J774.A2 cell line (hereafter J774) was purchased from the American Type Culture 
Collection (ATCC) to study the interaction of C. neoformans clinical isolates with 
macrophages. J774 is a murine macrophage-like cell line derived from a reticulum sarcoma. 
Cells were maintained at 37°C in the presence of 5% CO2 in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% 
penicillin–streptomycin (fresh medium) (all from Invitrogen). The cell monolayer was 
inspected for viability and density daily and passaged when cells reached 70-80% confluence. 
Cells were used between 10 and 35 passages. 
4.2.3. Phagocytosis assay 
J774 cells (2.5x105 cells/ml) were seeded in 24-well plates one day before the assay. On the 
day of experiment, cells were incubated for one hour in Serum Free Medium (SFM) 
containing 100 ng/ml phorbol myristate acetate (PMA). Meanwhile, overnight YPD-grown 
cryptococcal cells were washed three times with PBS and inoculum quantified using a 
Cellometer cell counter (Nexcelcom, USA). For experiments with opsonized cryptococci, yeast 
cells were incubated with 20% pooled human sera (healthy volunteer derived in accordance 
with OUCRU policy) at 37°C for one hour. Non-opsonised yeasts were used as negative 
control by replacing opsonins with PBS. To commence the assay, SFM medium containing 
PMA was removed from the 24-well plates and the cells washed once with PBS; then 1ml 
SFM medium containing 2.5 x106 yeast cells were added (Infection Ratio 10 Yeast to 1 
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Macrophage).  The phagocytosis assay was allowed to proceed for two hours in a humidified 
incubator at 37°C with 5% CO2. Non-internalized yeasts were then removed by successive 
washes with pre-warmed SFM or PBS, at which point the experiment is stopped for 
Phagocytic index scoring or extended for determining intracellular proliferation rate. The 
experiment design is summarized in Figure 4.2-1. 
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Figure 4.2-1. In vitro Intracellular proliferation experiment design (adapted from Ma Hansong’s method) [130]. 
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1 
4.2.4. Assessing macrophage parasitism parameters using an in vitro macrophage 
model of infection 
Four main parameters are assessed in the current model: 
Phagocytic Index (PI) is the proportion of macrophages that have ingested any cryptococcal 
cell, i.e. the number of macrophages with internalized yeasts divided by the total number of 
macrophages assessed at 2-hours post-infection. PI is an indicator of phagocytosis efficacy. It 
is influenced by phagocytosis routes (opsonin-dependent or opsonin-independent) and any 
intrinsic anti-phagocytic capabilities of the C. neoformans isolate. The PI does not take into 
account the actual number of yeasts phagocytosed by each individual macrophage.  
PI = No. Macrophages with internalized yeasts/ No. Total Macrophages assessed 
Intracellular Cryptococcus Load at 2-hours (ICL2 in cells/ml) measures how readily and in 
what quantity yeast cells are phagocytosed by macrophages and is directly related to IPR. 
ICL2 is positively correlated with PI. ICL2 is determined by counting the number of 
internalized yeasts after lysing macrophages, assuming clean removal of uninternalized, 
extracellular yeasts, using a hemocytometer. 
Intracellular Cryptococci Load at 18-hours (ICL18 in cells/ml): similar to ICL2, ICL18 is the 
number of intracellular yeasts after 18 hours. A high intracellular cryptococci load post-
internalization by macrophages at later time points indicates either a high rate of 
intracellular replication (if initial yeast uptake was low) or high initial yeast uptake. ICL18 is 
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determined by counting the number of intracellular yeasts after lysing macrophages 18 hours 
post-infection using a hemocytometer. 
Intracellular Proliferation Rate (IPR) is an index of how rapidly ingested yeasts replicate inside 
macrophages. IPR is the ratio between ICL18 and ICL2, thus having no quantification unit. 
IPR>1 indicates active intracellular replication, IPR<1 suggest that intracellular replication is 
exceeded by intracellular killing.  
IPR = ICL18 / ICL2 
Each isolate was assessed using the same inoculum repeated in 3 wells (technical replicates) 
in each experiment batch and the experiment was repeated on 3 different occasions 
(biological replicates) to account for intra and inter-experimental variations, respectively. A 
final value for each variable (IPR, PI, ICL2 and ICL18) was calculated as a mean of 3 biological 
replicates. 
4.2.5. Determining Intracellular proliferation rate (IPR) and Phagocytic Index (PI) (Ma’s 
method) 
The phagocytosis assay was left to progress for 2 hours (37oC, 5%CO2) in 2 separate 24-well 
plates in order to determine the PI at T = 0 (2 hours post inoculation and T = 18 (18 hours 
after the initial phagocytosis assay). At each time point (T = 0 and T = 18) un-internalized 
yeast cells in each plate were removed by repeated gentle washing with PBS. 1ml of SFM 
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medium was added to each well of the T18 plate, which was then incubated at 37oC with 5% 
CO2 for another 18 hours.  
Initial yeast uptake in the T0 plate was determined by adding 200µl of sterile water in each 
well to lyse macrophages. After 15-30 minutes, macrophages lysate containing released yeast 
cells were aspirated and transferred to a clean tube. Another 200 µl of sterile water was 
added to collect remaining yeast cells at the bottom of the plates. Yeast cells were stained 
and diluted 1:3 in Trypan Blue and count under the 20X objective of a CX41 upright 
microscope (Olympus) using disposable glasstic hemocytometers (KOVA, Fisher Scientific, 
USA).  
Intracellular proliferation rate (IPR) was calculated by dividing total internalized yeast cell at 
T18 by the initial yeast uptake at T0. Intracellular cryptococci load (ICL) at 2 hours and 18 
hours post-infection were total yeast count at T0 and T18, respectively. The T18 time point 
was chosen because maximum IPRs are reached maximum between 16 hours and  24 hours 
post-infection[130].  
Each strain was tested in triplicate (technical replicates) and in 3 different batches of 
macrophage culture (biological replicates). Cell images in 24-well plates at 2 hours post-
phagocytosis were observed and captured using a Nikon Eclipse TS100F inverted bright-field 
microscope with phase-contrast capability and a Nikon D5200 digital camera for subsequent 
phagocytic index scoring. Captured images were manually scored for phagocytic index using 
ImageJ software (rsb.info.nih.gov/ij/). Phagocytic index (PI) was defined as the percentage of 
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macrophages with internalized yeast cells divided by the total number of macrophages 
counted (at least 400 cells).  
4.2.6. Data analysis 
Analyses were performed using mean values from 3 biological replicates obtained for all 
strains. Additional analyses were done following removal of outliers for each isolate. Outlier 
values among 3 biological replicates were detected and removed using the Median Absolute 
Deviation (MAD) method. As a measure of dispersal, the MAD uses the median for the 
deviation scores and is less susceptible to the influence of outliers compared to the standard 
deviation [397]. The absolute deviation from the median is the difference of the value and 
median after the positive or negative sign is removed: |X-Median|. The median absolute 
deviation is calculated by taking the median of the absolute deviations from the median: 
MAD = median (|X1 - Median|, |X2-Median|, ... , |Xn-Median|) 
Data values (xi) are selected such that: 
Median – MAD*2.5 ≤ xi ≤ Median + MAD*2.5 
The final value of each variable (IPR, PI, ICL2 and ICL18) for each isolate was the mean from 
the 3 biological replicates with outliers removed. The Mann-Whitney test was used for 
between-groups statistical comparisons. All analyses were performed using R version 3.4.0 
(https://www.r-project.org). 
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4.2.7. Assessing yeast-macrophage interaction using flow cytometry (method 2) 
4.2.7.1. Reagents and C. neoformans labeling 
Solophenyl flavine 7GFE 500 specifically stains chitin contained in the cell wall of fungi and 
was used to label C. neoformans. Solophenyl flavine exhibits maximum emission at a 
wavelength of 490 nm when excited at 365 nm; this is similar to Pacific Blue stain (maximum 
emission at 452nm when excited at 401nm) and is detectable using the Pacific Blue channel 
on the FACSCanto II flow cytometer (BD, USA). Yeast cells were collected from standard YPD 
culture, washed twice, and re-suspended in phosphate-buffered saline (PBS). The cells were 
then incubated with Solophenyl flavine at 10 μg/ml in PBS for 10 min in the dark at room 
temperature, followed by washing twice in PBS. Following monoclonal antibody 
opsonization-based J774 phagocytosis assay (Figure 4.2-3 and Section 4.2.7.2, described 
below), AF546-conjugated anti-mouse IgG monoclonal antibodies from goat were used to 
differentiate selectively stain extracellular yeasts population (Alexa Fluor-546 with Ex-max 
562nm/Em-max 570). After cell lysis, AF647-conjugated anti-mouse IgG monoclonal 
antibodies from goat were then used to differentiate cell debris and all yeasts (Alexa Fluor-
647 with Ex-max 650nm/Em-max 668nm). Since fluorescence spectrum of Alexa Fluor-546 
and Alexa Fluor-647 were almost identical to R-phycoerythrin (PE) and Allophycocyanin 
(APC) in the respective yellow and red channel of FACSCanto II, we used the PE and APC 
channels for flow-cytometry experiments involving Alexa Fluor-546 and Alexa Fluor-647, 
respectively (Figure 4.2-2). The overall experiment design is summarized in Figure 4.2-3.  
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Figure 4.2-2. Fluorescence excitation and emission spectra of fluorophores used in the flow 
cytometry modification of Ma’s method.  
Solophenyl flavine (SF; Max Ex: 410nm/Max Em: 455nm), Alexa Fluor-546(AF546; Max Ex: 
556nm/Max Em: 573nm) and Alexa Fluor-647 (F647; Max Ex: 650nm/Max Em: 665nm), which have 
similar excitation and emission spectra to Pacfic Blue, R-phycoerythrin (PE) and Allophycocyanin (APC) 
were used to stain yeast cell wall, extracellular yeasts and all yeast cells after macrophage lysis, 
respectively. Flow cytometry analyses were performed using the FACSCanto II cell sorter and FACS 
Diva software (BD).  
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Figure 4.2-3. Flow cytometry experiment design for in vitro intracellular parasitism screening
Solophenyl Flavine
(cell wall staining)
Phagocytosis assay
with F12D2 mAb
(2 hours)
Wash away 
extracellular yeasts
Dislodge
Macrophages
Using Accutase
FACS Canto II
Phagocytosis assay
Stain extracellular yeasts
with F12D2 + anti-IgG-AF546
Lyse macrophages by 
adding sterile water
Stain all released yeast cells with 
F12D2 + anti-IgG-AF647
Phagocytic index
scoring
IPR, ICL 
scoring
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1 
4.2.7.2. Phagocytosis assay for flow cytometry 
J774 macrophages were cultured and seeded in 3 separate 24-well plates at 2.5x105 cells per 
well as previously described. The first plate was used for phagocytic index measurement; 
intracellular proliferation rates were assessed using the remaining 2 plates. H99 is included in 
every batch as a control for inter-experiment variation. On the day of the experiment, 250μl 
of 10 μg/ml working stock of F12D2 anti-cryptococcal capsular polysaccharide IgG1 
monoclonal antibody from mouse (a kind gift from Prof. Thomas Kozel, University of Nevada, 
Reno, USA) and 250μl of SF- stained C. neoformans cell suspension were added to the J774 
cell-monolayer and incubated at 37°C in 5% CO2 for 2 hours (C. neoformans/J774 ratio, 2.5:1). 
Non-adherent extracellular yeast cells were then removed by PBS washing, and incubation 
was stopped to assess phagocytosis or extended to determine intracellular proliferation. 
Phagocytic Index (PI) was determined after dislodging adherent macrophages from the 
bottom of plate 1 by adding 400μl of Accutase enzyme solution (Invitrogen).  
To determine the intracellular cryptococci load at 2 hours (ICL2) and 18 hours (ICL18), 
residual extracellular yeast cells were stained by addition of F12D2 monoclonal antibodies 
(0.5 μg/ml) and antimouse IgG1 pre-conjugated with Alexa Fluor-546 for 30 minutes and 
washed in PBS, after which J774 cells were lysed by adding 400μl sterile water. In order to 
differentiate potentially unstained C. neoformans cells from cell debris, an additional step 
was performed using F12D2 and antimouse IgG1 pre-conjugated with Alexa Fluor-647. All 
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yeast cells were APC(+), while only extracellular yeast cells were APC(+) PE(+). Intracellular 
yeasts would be those gated with APC(+)/PE(-)/Pacific Blue(+). Intracellular proliferation was 
determined for each clinical C. neoformans var. grubii isolate at 18 hours post-infection (IPR). 
Phagocytosis and proliferation were analyzed in two independent experiments. Refer to 
Figure 4.2-3 for experiment design. 
4.2.7.3. Flow cytometry data analysis 
Flow cytometry analyses were performed using FACSCanto II and FACSDiva software 2.0 
(Miltenyi BioTeC, USA) to provide absolute quantification. Samples were analyzed using 
FlowJo 10.0 software (Tree Star, Inc.). Aggregates were excluded by gating relevant events in 
the forward scatter/side scatter (FSC/SSC) contour plot. Four parameters were calculated: 
(i) The phagocytic index (PI) as the number of gated macrophage events in the 
Pacific Blue(+) gate (plate 1) 
(ii) Intracellular proliferation (IPR) as the ratio between daughter cells (Pacific Blue+) 
at 18 hours post-infection and mother cells (Pacific Blue+) at 2 hours post-
infection. 
(iii) Intracellular cryptococci load at 2 hours post-infection (ICL2) as the number of 
events at the APC(+)/PE(-)/Pacific Blue(+) at the relevant time point. 
(iv) Intracellular cryptococci load at 18 hours post-infection (ICL18) and as the number 
of events at the APC(+)/PE(-)/Pacific Blue(+)at the relevant time point. 
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Results were expressed as the ratio of the given parameter for the test strains compared 
to the H99 parameter determined in the same run. Details of fluorescence staining and 
flow-cytometry gating are summarized in Table 4.2-1. 
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Table 4.2-1. Flow cytometry staining strategy for selection of different yeast populations 
 
 
PBpos
PBposAPCpos
PBposPEposAPCpos
(after lysis)
PBposPEpos (before lysis)
Intracellular yeasts Extracellular yeasts
Unstained
Inoculum
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4.3. Chapter 4 Results 
4.3.1. Macrophage parasitism parameters using Ma’s method 
4.3.1.1. General assessment of macrophage parasitism parameters among 
the Vietnamese C. neoformans var. grubii isolates  
All isolates information and macrophage data are presented in Table 4.3-1. Scoring of 
Phagocytic Index of infected and non-infected macrophages is illustrated in Figure 4.3-1. 
Using pooled human serum for opsonization, most isolates had PIs in the range of 30% to 
50% (median [IQR]: 35.7% [29.6-47.4+). Only 23% of the test isolates (11 out of 47) had PIs ≥ 
50%. The majority of isolates underwent active replication within macrophages, i.e. had IPR 
values being greater than 1 Table 4.3-1. There was a moderate positive correlation between 
IPR and PI (r=0.44, p=0.002, Spearman test), as well as PI and ICL18 (r=0.40, p=0.006, 
Spearman test) across the whole population (Figure 4.3-2). An association between ICL2 and 
ICL18 (r=0.25) was observed, though this just failed to reach conventional levels of statistical 
significance (p=0.08, Spearman test, see Figure 4.3-3). 
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Table 4.3-1. Isolates information and result summary for method 1  
No. ID AFLP MLST 
goeBURST  
cluster 
HIV 
ICL2  
(log10 cells/ml) 
ICL18 
(log10 cells/ml) 
IPR PI 
1 BMD700 VNI-γ 5 5 Negative 6.19 6.39 1.15 0.12 
2 BMD1646 VNI-γ 5 5 Negative 6.68 6.45 1.06 0.16 
3 BMD1338 VNI-γ 5 5 Negative 6.15 6.43 1.99 0.41 
4 BMD1232 VNI-γ 5 5 Negative 6.39 6.23 1.65 0.31 
5 BMD1353 VNI-γ 5 5 Negative 5.99 6.13 1.16 0.49 
6 BMD1452 VNI-γ 5 5 Negative 6.12 6.29 1.48 0.54 
7 BMD1198 VNI-γ 5 5 Negative 6.06 6.16 1.10 0.24 
8 BMD1228 VNI-γ 5 5 Negative 6.23 6.12 2.17 0.36 
9 BMD1291 VNI-γ 5 5 Negative 5.96 6.60 1.72 0.70 
10 BMD1465 VNI-γ 5 5 Negative 5.58 6.33 1.69 0.62 
11 BMD101 VNI-γ 5 5 Negative 6.33 6.52 1.86 0.68 
12 BK48 VNI-δ 4 4 Positive 6.60 6.39 0.77 0.30 
13 BK23 VNI-δ 4 4 Positive 6.49 6.69 1.07 0.35 
14 BK73 VNI-δ 4 4 Positive 5.94 6.19 0.84 0.31 
15 BMD1415 VNI-δ 4 4 Positive 6.56 6.42 1.06 0.24 
16 BK61 VNI-δ 4 4 Positive 6.03 6.46 2.48 0.39 
17 BK80 VNI-δ 4 4 Positive 5.94 6.09 1.46 0.25 
18 BK111 VNI-δ 4 4 Positive 5.96 6.52 1.43 0.55 
19 BK69 VNI-δ 4 4 Positive 6.18 6.48 1.18 0.54 
20 BMD394 VNI-δ 4 4 Positive 6.23 6.42 1.30 0.56 
21 BK139 VNI-γ 4 4 Positive 5.98 6.37 1.30 0.46 
22 BK76 VNI-γ 5 5 Positive 6.18 5.92 0.71 0.12 
23 BK169 VNI-γ 5 5 Positive 6.43 6.66 1.04 0.59 
24 BK190 VNI-γ 5 5 Positive 6.27 6.44 1.28 0.31 
25 BK47 VNI-γ 5 5 Positive 6.58 6.72 1.18 0.35 
26 BK78 VNI-γ 5 5 Positive 6.40 6.57 1.22 0.37 
27 BK39 VNI-δ 5 5 Positive 6.24 6.56 1.47 0.64 
28 BK60 VNI-γ 5 5 Positive 6.19 6.37 1.04 0.50 
29 BK147 VNI-γ 5 5 Positive 6.38 6.37 1.63 0.41 
30 BK38 VNI-γ 5 5 Positive 6.37 6.38 1.37 0.38 
31 BK4 VNI-γ 5 5 Positive 5.96 6.18 1.05 0.37 
32 BK116 VNI-γ 5 5 Positive 6.07 6.24 1.05 0.36 
33 BK175 VNI-γ 5 5 Positive 5.85 5.98 0.75 0.15 
34 BK182 VNI-δ 5 5 Positive 5.64 6.66 1.39 0.66 
35 BK45 VNI-γ 5 5 Positive 6.33 6.13 1.18 0.29 
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No. ID AFLP MLST 
goeBURST  
cluster 
HIV 
ICL2  
(log10 cells/ml) 
ICL18 
(log10 cells/ml) 
IPR PI 
36 BK33 VNI-δ 5 5 Positive 6.06 6.00 1.08 0.04 
37 BK189 VNI-δ 6 4 Positive 6.32 5.90 0.89 0.19 
38 BK46 VNI-δ 32 93 Positive 5.97 6.41 1.37 0.30 
39 BK167 VNI-δ 39 93 Positive 5.53 6.19 1.00 0.41 
40 BK24 VNI-δ 93 93 Positive 6.11 6.55 1.34 0.24 
41 BK157 VNI-δ 93 93 Positive 6.48 6.48 0.83 0.32 
42 BK213 VNI-δ 93 93 Positive 5.94 6.25 1.31 0.32 
43 BK12 VNI-δ 93 93 Positive 6.15 6.09 1.33 0.43 
44 BK85 VNI-δ 93 93 Positive 6.04 5.96 0.89 0.26 
45 BK241 VNI-γ 93 93 Positive 6.38 6.12 1.08 0.38 
46 BMD1367 VNI-δ 306 4 Positive 6.51 6.61 0.86 0.33 
47 BK150 VNI-δ 338 93 Positive 6.50 6.39 0.71 0.41 
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Figure 4.3-1. In silico Phagocytic Index (PI) scoring using ImageJ software.  
Cell images were captured at 200X magnification after 2 hour of phagocytosis assay and PBS washing 
to remove residual non-internalized extracellular yeasts. Red arrows indicate macrophages with 
internalized yeasts (N1). Blue arrows indicate uninfected macrophages (N2).  PI was calculated using 
the formula: PI = N1/(N1+N2) 
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Figure 4.3-2. Correlation between IPR, ICL18 and Phagocytic Index. 
Test of correlation was performed using the Spearman rank test. Resulting P-value and Rho value 
from the Spearman test of correlation are shown on the graphs. Red lines indicate the linear 
regression model (R2=0.15, p=0.001 and R2=0.19, p=0.001 for IPR vs PI and PI vs ICL18, respectively) 
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Figure 4.3-3. Correlation between ICL2 /ICL18 and IPR 
Spearman test of correlation between population-wise ICL2, ICL18 and IPR was performed. Though all 
correlation failed to reach statistical significance at α=0.05, there seemed to be a positive correlation 
between ICL2 and IPR (r=0.25, p=0.08), as well as an inverse correlation between ICL19 and IPR 
 (r=-0.24, p=0.11). 
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4.3.1.2. No difference in any macrophage parasitism parameters was observed based 
on AFLP and MLST clustering 
Macrophage interaction parameters according to AFLP genotypes are summarized in Table 
4.3-2. No statistically significant differences based on AFLP grouping (VNI-γ, n=25 and VNI-δ, 
n=22) were observed. Next, in vitro macrophage parasitism parameters were tested for any 
correlation with goeBURST clusters. As previously described in Chapter 1, the clinical C. 
neoformans var. grubii population in Vietnam consists of 3 main goeBURST subgroups 
formed by ST5 (subgroup 5, n=26), ST4 (subgroup 4, n=12) and ST93 (subgroup 93, n=9), 
respectively. Data for each MLST sub-group according to goeBURST are summarized in Table 
4.3-3. There were no correlations between any goeBURST lineages and macrophage 
parasitism parameters. Isolates from lineage 93 seemed to be less efficient at intracellular 
proliferation than lineage 4 or lineage 5, though this observation again did not quite reach 
statistical significance (p=0.07, Kruskal-Wallis rank test). 
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Table 4.3-2. Macrophage parasitism parameters according to AFLP genotype 
 
 
 
 
 
 
 
 
IPR: Intracellular Proliferation Rate 
PI: Phagocytic Index 
ICL2, ICL18: Intracellular Cryptococci Load at 2 hours or 18 hours post-infection. 
ND
$
: PI data from 1 or more biological replicates were missing for the respective isolates due to technical errors, therefore MAD adjustment could not be done. 
*Data are presented as mean ± standard deviation. Pairwise statistical comparison was performed using Mann-Whitney test.
 
Original  
(Mean ± SD) 
Outliers removed by MAD 
(Mean ± SD) 
Parameter 
VNI-γ  
(n=25) 
VNI-δ 
(n=22) 
*p-values
 
VNI-γ  
(n=25) 
VNI-δ 
(n=22) 
*p-values 
IPR 1.366 ±  0.35 1.223 ± 0.356 0.12 1.316 ± 0.369 1.185 ± 0.379 0.24 
PI% 38.6 ± 16.3 36.5 ± 15.1 0.62 ND
$
 ND
$
  ND
$
 
ICL2 
log10(cells/ml) 
6.20 ± 0.21 6.27 ± 0.23 0.22 6.20 ± 0.24 6.16 ± 0.29 0.49 
ICL18 
log10(cells/ml) 
6.35 ± 0.20 6.35 ± 0.23 0.46 6.29 ± 0.20 6.31 ± 0.30 0.28 
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Table 4.3-3. Macrophage parasitism parameters according to MLST goeBURST sub-groups 
 
Original  
(Mean ± SD) 
 Outliers removed by MAD 
(Mean ± SD) 
 
Parameter 
Sub-group 4 
(n=12) 
Sub-group 5 
(n=26) 
Sub-group 93 
(n=9) 
p-values* Sub-group 4 
(n=12) 
Sub-group 5 
(n=26) 
Sub-group 93 
(n=9) 
p-values* 
IPR 1.320 ± 0.434 1.370 ± 0.345 1.067 ± 0.157 0.06 1.228 ± 0.462 1.322 ± 0.363 1.095 ± 0.250 0.28 
PI% 39.0 ±15.0 39.6 ±16.7 30.3 ± 11.9 0.41 ND
$
 ND
$
 ND
$
 ND
$
 
ICL2 
log10(cells/ml) 
6.31 ± 0.24 6.20 ± 0.21 6.20 ± 0.21 0.37 6.20 ± 0.30 6.20 ± 0.24 6.09 ± 0.29 0.49 
ICL18 
log10(cells/ml) 
6.40 ± 0.23 6.33 ± 0.20 6.26 ± 0.21 0.26 6.41 ± 0.23 6.30 ± 0.21 6.15 ± 0.35 0.08 
IPR: Intracellular Proliferation Rate 
PI: Phagocytic Index 
ICL2, ICL18: Intracellular Cryptococci Load at 2 hours or 18 hours post-infection. 
ND
$
: PI data from 1 or more biological replicates were missing for the respective isolates due to technical errors, therefore MAD adjustment could not be done. 
*Data are presented as mean ± standard deviation. Groupwise statistical comparison was performed using Kruskal-Wallis test.
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4.3.1.3. Isolates from HIV-uninfected patients, especially ST5s, tend to have higher 
IPR 
I performed an exploratory analysis of clustering by the HIV infection status of the isolate 
source, in order to determine whether there was any association between this and the in 
vitro macrophage variables. As previously described, VNI-γ isolates are found in both HIV 
infected and HIV uninfected patients, but account for almost all disease in HIV-uninfected 
patients, particularly when there is no other underlying disease. VNI-δ isolates, on the other 
hand, are mostly associated with disease in HIV-infected patients. Among 25 AFLP-defined 
VNI-γ isolates included in the current study population (n = 47) there were 14 isolates from 
HIV-uninfected patients. The remaining 33 isolates from HIV-infected patients included 11 
VNI-γ and 22 VNI-δ isolates. Isolates from HIV-uninfected patients tended to have higher IPRs 
than isolates from HIV-infected patients (quote a ratio of the difference in the IPRs plus the 
confidence intervals), although this did not reach conventional levels of statistical 
significance (p=0.08, Mann-Whitney test). There were no differences in PI, ICL2 or ICL18. 
However, on removal of outlier results defined by the MAD method, the difference in IPR 
reached statistical significance (p=0.03, Mann-Whitney t-test, also see Table 4.3-4 and 
Figure 4.3-4). 
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Table 4.3-4. Macrophages parasitism parameters according to HIV group 
 
IPR: Intracellular Proliferation Rate 
PI: Phagocytic Index 
ICL2, ICL18: Intracellular Cryptococci Load at 2 hours or 18 hours post-infection. 
ND
$
: PI data from 1 or more biological replicates were missing for the respective isolates due to technical errors, therefore 
MAD adjustment could not be done.. 
*: Data are presented as mean ± standard deviation. Pairwise statistical comparison was performed using Mann-Whitney 
test. 
 
Original 
(Mean ± SD) 
 Outliers removed by MAD 
(Mean ± SD) 
 
 
HIV-uninfected  
(n=14) 
HIV-infected 
(n=33) 
p-values* HIV-uninfected  
(n=14) 
HIV-infected 
(n=33) 
p-values* 
IPR 1.475 ± 0.416 1.224 ± 0.306 0.08 1.446 ± 0.404 1.174 ± 0.338 0.03 
PI (%) 41.0 ± 19.1 36.2 ± 13.9 0.55 ND
$ 
ND
$
 ND
$
 
ICL2 
log10(cells/ml) 
6.22 ± 0.21 6.23 ± 0.22 0.79 6.21 ± 0.28 6.17 ± 0.26 0.44 
ICL18 
log10(cells/ml) 
6.36 ± 0.16 6.33 ± 0.23 0.63 6.33 ± 0.19 6.28 ± 0.28 0.90 
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Figure 4.3-4. Pairwise comparison between isolates from HIV-uninfected (n=14) and HIV-infected patients (n=33). 
Boxplot showing the median and interquartile range with whiskers indicating the lower and upper quartiles. Values lower or higher than 1.5 times the 
lower or upper quartiles were indicated as clear dots. A borderline difference in IPR according to HIV groups was previously observed (Mann-Whitney 
test). Only MAD-adjusted IPR values between HIV groups showed statistical significance.
 160 | P a g e  
 
While ST5 C. neoformans var. grubii isolates are found in both HIV-uninfected and HIV-
infected patients, they are more highly associated with infection in HIV-uninfected 
patients with no apparent immunodeficiency. In fact, where non-ST5 infection occurs in 
HIV-uninfected patients it is usually accompanied by other serious underlying disease 
[103]. I next investigated if the observed difference in IPR between isolates from HIV-
uninfected and HIV-infected patients could be attributed to ST5 isolates. This subset of 
ST5 isolates involved 11 ST5 isolates from HIV-uninfected and 15 ST5 isolates from HIV-
infected. Data are summarized in Table 4.3-5 and Figure 4.3-5. ST5 isolates from HIV-
uninfected patients had statistically significantly higher IPRs compared with ST5 isolates 
from HIV-infected patients (p=0.05, Mann-Whitney test). Correcting for outliers again 
strengthened this finding (p=0.01, Mann-Whitney test).  
Figure 4.3-5 and Figure 4.3-6 suggest that there was a greater degree of variation in IPR 
among isolates from HIV-uninfected patients compared to that from HIV-infected 
patients. This observation was assessed using the Fligner-Killeen test which showed 
statistical significance for both group comparisons (p=0.04 for HIV-uninfected vs HIV-
infected and p=0.05 for the ST5 subset of HIV-uninfected vs HIV-infected). MAD-adjusted 
IPR values for individual isolates are presented in Figure 4.3-7. 
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Table 4.3-5. Macrophage parasitism parameters of ST5 isolates according to HIV 
serostatus of isolate source (uninfected and infected) 
IPR: Intracellular Proliferation Rate 
PI: Phagocytic Index 
ICL2, ICL18: Intracellular Cryptococci Load at 2 hours or 18 hours post-infection. 
ND
$
: PI data from 1 or more biological replicates were missing for the respective isolates due to technical errors, 
therefore MAD adjustment could not be done. 
*: Data are presented as mean ± standard deviation. Pairwise statistical comparison was performed using Mann-
Whitney test 
  
 
Original  
(Mean ± SD) 
Outliers removed by MAD 
(Mean ± SD) 
 
ST5  
HIV-uninfected  
(n=11) 
ST5 
HIV-infected 
(n=15) 
*p-values 
ST5 
HIV-uninfected  
(n=11) 
ST5 
HIV-infected 
(n=15) 
*p-values 
IPR 1.574 ± 0.399 1.220 ± 0.206 0.05 1.548 ± 0.387 1.157 ± 0.243 0.01 
PI (%) 41.9 ± 20.4 37.8 ± 13.9 0.66 ND
$ 
ND
$
 ND
$
 
ICL2 
log10(cells/ml) 
6.15 ± 0.17 6.24 ± 0.24 0.57 6.15 ± 0.28 6.24 ± 0.20 0.29 
ICL18 
log10(cells/ml) 
6.33 ± 0.16 6.34 ± 0.24 0.99 6.30 ± 0.20 6.30 ± 0.22 0.92 
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Figure 4.3-5. Intracellular Proliferation Rate (IPR) comparison between only ST5 isolates. 
Boxplot showing the median the interquartile range with whiskers indicating the lower and upper. 
Values lower or higher than 1.5 times the lower or upper quartiles are indicated as open dots. 
Among ST5 isolates, those isolated from HIV-uninfected patients replicated 34% faster than those 
from HIV-infected patients (p=0.01, Mann-Whitney test). 
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Figure 4.3-6. Intracellular Proliferation Rate (IPR) comparison between ST5 isolates from HIV-
uninfected and non-ST5 isolates from HIV-infected patients.  
Boxplot showing the median the interquartile range with whiskers indicating the lower and upper 
quartiles. Values lower or higher than 1.5 times the lower or upper quartiles are indicated as open 
dots. ST5 isolates from HIV-uninfected patients have significantly higher IPR than non-ST5 isolates 
from HIV-infected patients (p=0.01, Mann-Whitney test). 
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Figure 4.3-7. MAD-adjusted IPR for individual isolates. 
Isolates are grouped according to MLST genotypes (ST5 and non-ST5) and host HIV immune types 
(HIV-infected and HIV-uninfected). Current data suggest that ST5 isolates from HIV-uninfected 
patients had significantly higher IPRs than either ST5 or non-ST5 isolates from HIV-infected 
patients. Scatter plot represents mean of all available biological replicates after removing outliers. 
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4.3.1.4. Association between in vitro macrophage interaction parameters and 
clinical outcomes 
I examined to see whether intrinsic macrophage parasitism characteristics of isolates 
were associated with clinical outcome. From the test population (n=47), patients with 
known mortality-at-10-weeks (n=38; 25 survived and 13 died) and baseline fungal load in 
CSF (n=38) were selected for exploratory analysis of correlation between clinical 
outcomes and macrophage parasitism parameters (Table 4.3-6). No significant 
association between patient’s baseline fungal burden in CSF and any macrophages 
parasitism parameters could be found (p=0.07, p=0.67, p=0.82 and p=0.24 for IPR, PI, ICL2 
and ICL18, respectively, Spearman test of correlation Figure 4.3-8. There seemed to be an 
inverse correlation between IPR and CSF fungal burden, though this correlation was 
insignificant, possibly due to a lack of power (p=0.07, Spearman r=0.29, Figure 4.3-8). 
Likewise, there were no apparent differences between 10-weeks mortality (Alive/Dead) 
and any macrophage parasitism parameters tested (p=0.74, p=0.51, p=0.17 and p=0.70 
for IPR, PI, ICL2 and ICL18, respectively ( Figure 4.3-9).  
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Table 4.3-6. Mortality at 10-weeks of antifungal treatment  
and patients’ fungal burden in CSF before treatment  
No. ID AFLP cluster 
MLST 
Sequence Type 
HIV serostatus *Log.Base.CSF 
10-weeks 
 mortality 
1 BMD700 VNI-γ 5 Negative NA Alive 
2 BMD394 VNI-δ 4 Negative NA Alive 
3 BMD1228 VNI-γ 5 Negative NA Alive 
4 BK4 VNI-γ 5 Positive 2.176 Alive 
5 BK23 VNI-δ 4 Positive 2.550 Alive 
6 BK39 VNI-δ 5 Positive 3.000 Alive 
7 BK24 VNI-δ 93 Positive 3.244 Alive 
8 BK78 VNI-γ 5 Positive 3.415 Alive 
9 BK241 VNI-γ 5 Positive 3.477 Alive 
10 BK80 VNI-δ 4 Positive 4.011 Alive 
11 BK76 VNI-γ 5 Positive 4.439 Alive 
12 BK150 VNI-δ 338 Positive 4.703 Alive 
13 BK12 VNI-δ 93 Positive 4.947 Alive 
14 BK33 VNI-δ 93 Positive 5.121 Alive 
15 BK111 VNI-δ 4 Positive 5.130 Alive 
16 BK147 VNI-γ 5 Positive 5.505 Alive 
17 BK48 VNI-δ 4 Positive 5.708 Alive 
18 BK69 VNI-δ 4 Positive 5.756 Alive 
19 BK169 VNI-γ 5 Positive 5.851 Alive 
20 BK190 VNI-γ 5 Positive 5.903 Alive 
21 BK213 VNI-δ 93 Positive 5.908 Alive 
22 BK46 VNI-δ 32 Positive 6.002 Alive 
23 BK157 VNI-δ 93 Positive 6.057 Alive 
24 BK116 VNI-γ 5 Positive 6.099 Alive 
25 BK45 VNI-γ 5 Positive 6.190 Alive 
26 BK47 VNI-γ 5 Positive NA Dead 
27 BMD1232 VNI-γ 5 Negative NA Dead 
28 BMD101 VNI-γ 5 Negative NA Dead 
29 BK61 VNI-δ 4 Positive 2.823 Dead 
30 BK73 VNI-δ 4 Positive 3.023 Dead 
31 BK38 VNI-γ 5 Positive 4.477 Dead 
32 BK175 VNI-γ 5 Positive 5.017 Dead 
33 BK167 VNI-δ 39 Positive 5.484 Dead 
34 BK60 VNI-γ 5 Positive 6.127 Dead 
35 BK189 VNI-δ 6 Positive 6.732 Dead 
36 BMD1338 VNI-γ 5 Negative 6.908 Dead 
37 BK182 VNI-δ 4 Positive 7.149 Dead 
38 BK85 VNI-δ 93 Positive 7.265 Dead 
39 BK139 VNI-γ 5 Positive 7.302 Dead 
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No. ID AFLP cluster 
MLST 
Sequence Type 
HIV serostatus *Log.Base.CSF 
10-weeks 
 mortality 
40 BMD1367 VNI-δ 306 Negative NA NA 
41 BMD1353 VNI-γ 5 Negative NA NA 
42 BMD1465 VNI-γ 5 Negative NA NA 
43 BMD1415 VNI-δ 4 Negative 3.505 NA 
44 BMD1291 VNI-γ 5 Negative 3.906 NA 
45 BMD1452 VNI-γ 5 Negative 4.243 NA 
46 BMD1646 VNI-γ 5 Negative 4.455 NA 
47 BMD1198 VNI-γ 5 Negative 6.267 NA 
*CSF fungal burden for patients at diagnosis (log10 cells/ml CSF). Clinical information was mostly 
fully available for “BK” patients who enrolled in an intervention RCT for treatment of HIV-
associated cryptococcal meningitis. 
 168 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3-8. Correlation between IPR, PI, ICL2, ICL18 and corresponding patients’ fungal load in the CSF at diagnosis. 
Data represent mean of MAD-adjusted values for each parameter of each isolate. P-value and Rho coefficient of correlation were obtained from the 
Spearman test of correlation. Red lines indicate most probable fitted linear correlation.   
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1 
 Figure 4.3-9. Association between macrophage parameters and patient mortality after 10-weeks of 
antifungal therapy.  
Mortality information at 10 weeks was availble for 38/47 patients (25 survived and 13 died). P-values 
were obtained from pairwise comparison using the Mann-Whitney test. 
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4.3.2. Assessing macrophage parasitism using flow cytometry 
Unwashed extracellular yeasts and time-consuming hemocytometer counting were among 
the major technical difficulties of Ma’s original method that limited the model’s throughput. 
Further modification of the original model was needed to improve accuracy and robustness. 
Here I report the optimization and adaptation of a flow-cytometry based modification of 
Ma’s original model according to protocols reported by Voelz et al. (May lab, University of 
Birmingham, UK) [398] and Alanio et al. (Dromer lab, Institute Pasteur, France) [136]. 
4.3.2.1. Effects of Solophenyl flavine staining on yeast growth 
Fluorescent fungal cell wall stain such as Calcofluor and 7GFF are known to be cell-wall stress 
inducers. In order to determine whether Solophenyl flavine (7GFF) staining affects growth of 
C. neoformans var. grubii, serial-diluted yeast cells were stained with different concentration 
of Solophenyl flavine and grown on YPD agar. There was no apparent growth defect detected 
even when cells from both test strains were exposed to the highest test concentration of 
Solophenyl flavine (1 mg/ml) (Figure 4.3-10). For subsequent FACS experiments yeast cells 
were stained with Solophenyl flavine at the lowest working concentration (10 µg/ml) for 10 
minutes at room temperature in PBS buffer. 
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Figure 4.3-10. Effects of Solophenyl Flavine staining at various concentrations to growth of  
C. neoformans yeasts. 
The reference strain H99 and one test isolate from Vietnam, BK247, were serially diluted and stained 
by incubating with various concentrations of Solophenyl Flavine in PBS buffer for 10 minutes at room 
temperature. Yeast suspension in 10 fold dilution were inoculated on Sabouraud agar and incubated 
at 30oC for 2 days. Solophenyl Flavine has no obvious effect on growth of C. neoformans yeasts. 
 
4.3.2.2. Optimizing the concentration of opsonizing antibody for phagocytosis assay 
and assessment of the Phagocytic Index using flow cytometry 
After dislodging adherent J774 macrophages from 24-well culture plates (with or without 
ingested yeasts) using enzymatic Accutase treatment, the macrophage population were 
separated from extracellular, uningested yeasts (pre-stained with 7GFF) by size selection via 
FSC-SSC gating. The subset macrophage population was further separated into “Unaffected 
macrophages” and “Yeasts-associated macrophages” by gating at the Pacific Blue channel 
(corresponding to the excitation/emission spectrum of 7GFF, also see Figure 4.2-2). The 
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“Yeasts-associated macrophages” population would include both macrophages with ingested 
intracellular yeasts and membrane-bound extracellular yeasts. Phagocytic Index could then 
be determined by calculating the percentage of infected macrophages from the macrophage 
subset (Figure 4.3-11). A 10-fold increase in opsonizing F12D2 concentration (1µg/500µ/well 
to 10 µg/500µl/well) resulted in only a 10% increase of phagocytosis efficacy (Figure 4.3-12). 
As expected, antibody-opsonization resulted in more efficient phagocytosis. Specifically, 
antibody-mediated phagocytosis was 50% more efficient compared to complement-
mediated phagocytosis in the previous experiment using Ma’s method. Therefore for 
subsequent experiments I used 1µg/500µl/well as the standard F12D2 concentration for 
opsonization. 
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Figure 4.3-11. Gating strategy to determine Phagocytic index by flow cytometry. 
The phagocytosis assay was carried out using J774 macrophages and F12D2-opsonized, Solophenyl Flavine-stained yeasts as described in the 
Methods section. After washing off extracellular non-internalized yeasts adherent J774 cells at the bottom were detached enzymatically using 
Accutase. Macrophages and extracellular yeasts populations are selected using SSC vs FSC scattering. Gated macrophages would subsequently 
be separated by plotting SSC and Pacific Blue. CN-infected macrophages would emit purple fluorescence and are gated accordingly. 
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Figure 4.3-12. Optimizing F12D2 mouse IgG1 monoclonal antibody concentration for opsonizing of 
H99 yeasts.  
Phagocytic Index corresponding to different concentrations of opsonizing monoclonal antibody was 
assessed. Barplot represents mean of 3 technical replicates at each concentration with error bars 
indicating standard deviations.  
 
4.3.2.3. Optimizing multiple conjugated antibody staining 
As seen in Figure 4.3-13, increasing primary antibody F12D2 concentrations did not result in 
any notable increase in fluorescence intensity. Any combination of concentrations of primary 
F12D2 and secondary AF647-conjugated anti-mouse IgG1 resulted in a clear separation from 
the unstained yeast population, indicating effective sandwiched antibody staining for flow 
cytometry. Since the differences in fluorescence intensity at different AF647-conjugated anti-
mouse IgG1 concentrations were not significant, the F12D2 (1µg/ml)-AF647 antimouse IgG1 
(1µg/ml) combination was chosen for subsequent experiments. Subsequent staining of 
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AF546-conjugated antibody was performed similarly using the same concentration 
combination. 
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Figure 4.3-13. Optimizing antibody concentration combinations for staining yeast cells. 
F12D2, a mouse monoclonal IgG1 specific for cryptococcal capsular polysaccharide was used as 
primary stain antibody for cryptococci. Antimouse IgG1 from mice pre-conjugated with Alexa Fluor 
647 (AF746, having the same fluorescence spectrum as Allophycocyanin (APC)) was used as a 
secondary stain to detect and separate all cryptococci from macrophage cell debris after hypotonic 
lysis. Graphs display histograms of counted events for different F12D2 and AF647 combinations at the 
APC+ channel. 
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Figure 4.3-14. Optimizing gating strategy. 
Relevant single-cell yeast populations for the test isolate were gated according to a reference sample 
containing only AF647-stained, freshly-grown H99 yeasts. Duplets were excluded by gating at SSC-
H/SSC-W. AF647(+) cryptococci (both intra- and extra- cellular) were further subseted at the APC(+) 
channel. Intracellular yeasts were selected from the total cryptococci subset at the AF647(+)PE(-) 
gate. All 7GFF-stained intracellular yeasts were subsequent selected at the corresponding Pacific Blue 
channel. 
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4.3.2.4. Pilot application of flow cytometry for assessing macrophage parasitism 
I screened randomly selected ST4 (n=21) and ST5 (n=18) isolates from each of the HIV groups 
for testing using the flow cytometry method (total n=39). Phagocytic Index data were 
available for all 39 isolates (Table 4.3-7). Due to technical problems and time constraints, the 
intracellular cryptococci load (ICL2 and ICL18) and intracellular proliferation rate (IPR) could 
only be obtained for 31 isolates (including 13 ST4 and 18 ST5 isolates) (Table 4.3-7). Again, 
outliers were removed using the MAD method as previously described, resulting in 13 ST4 
isolates and 17 ST5 isolates.  
The results are summarized in Table 4.3-8 and Figure 4.3-15. Flow-cytometry and the use of 
H99 as an internal control provided remarkable precision for calculation of Phagocytic Index 
as no outliers were detected by MAD (n=38). Excluding 9 isolates without ICL and IPR data (8 
ST4 and 1 ST5) and subsequent outlier filtering by MAD, 20 isolates (9 ST4 and 11 ST5) were 
suitable for further IPR analysis. Across the whole study population, I observed 2-fold, 7-fold, 
23-fold and 21-fold variation in PI, ICL2, ICL18 and IPR, respectively. There were no 
differences in macrophage parasitism parameters, as assessed by flow-cytometry, according 
to MLST clustering (ST4 vs ST5) (Figure 4.3-16 and Figure 4.3-17).  
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Table 4.3-7. Summary of results and isolates information for method 2 
No. ID HIV ST PI ICL2 ICL18 IPR Log.base.CSF* 
10-weeks 
mortality* 
1 BK151 pos 4 1.04 0.39 1.28 3.27 5.61 Alive 
2 BK156 pos 4 1.17 1.35 1.10 0.81 6.82 Alive 
3 BK163 pos 4 0.90 0.49 1.35 2.77 5.54 Dead 
4 BK188 pos 4 1.01 0.62 2.54 4.12 7.15 Alive 
5 BK189 pos 4 1.25 0.60 2.04 3.40 5.90 Dead 
6 BK205 pos 4 1.15 0.73 2.50 3.44 4.30 Dead 
7 BK48 pos 4 1.42 2.07 6.31 3.04 5.71 Alive 
8 BK87 pos 4 1.30 2.35 0.33 0.14 5.24 Alive 
9 BK14 pos 4 1.42 NA NA NA 6.23 Alive 
10 BK59 pos 4 1.29 NA NA NA 7.00 Dead 
11 BK88 pos 4 1.32 NA NA NA 3.78 Alive 
12 BK89 pos 4 1.46 NA NA NA 6.26 Alive 
13 BK91 pos 4 1.17 NA NA NA 5.24 Alive 
14 BK126 pos 4 1.17 NA NA NA 5.01 Alive 
15 BK225 pos 4 1.26 NA NA NA 0.70 NA 
16 BK74 pos 4 1.51 NA NA NA 6.38 Dead 
17 BK11 pos 4 1.06 1.43 2.99 2.09 5.98 Dead 
18 BK46 pos 4 1.31 1.41 13.86 9.82 6.00 Alive 
19 BK68 pos 4 1.07 0.43 10.63 24.47 6.07 Alive 
20 BK149 pos 4 1.06 0.59 9.05 15.44 0.00 Alive 
21 BK150 pos 4 1.33 1.08 2.45 2.27 4.70 Alive 
22 BMD101 neg 5 1.21 0.56 3.67 6.54 NA Dead 
23 BMD367 neg 5 1.07 0.38 1.61 4.25 NA NA 
24 BMD700 neg 5 1.17 0.36 1.44 4.00 NA Alive 
25 BMD1228 neg 5 0.86 0.54 1.32 2.45 NA Alive 
26 BMD1646 neg 5 1.06 0.64 1.41 2.22 4.46 NA 
27 BMD367 neg 5 1.23 2.68 2.82 1.05 NA NA 
28 BMD854 neg 5 1.23 2.11 0.60 0.28 NA NA 
29 BMD973 neg 5 1.20 1.30 0.88 0.68 NA NA 
30 BMD1228 neg 5 1.22 1.37 5.78 4.22 NA Alive 
31 BMD1338 neg 5 1.11 1.22 8.62 7.08 6.91 Dead 
32 BMD1353 neg 5 1.17 1.19 0.84 0.71 NA NA 
33 BMD1452 neg 5 1.39 NA NA NA 4.24 NA 
34 BMD1198 neg 5 1.22 1.15 1.19 1.04 6.27 NA 
35 BMD1232 neg 5 1.26 0.98 6.95 7.07 NA Dead 
36 BMD1465 neg 5 1.39 1.61 3.91 2.42 NA NA 
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37 BMD1534 neg 5 1.39 5.40 1.10 0.20 NA NA 
38 BMD1592 neg 5 1.23 1.97 4.46 2.27 NA NA 
39 BMD1713 neg 5 1.44 1.52 7.36 4.83 NA NA 
*CSF fungal burden for patients at diagnosis (log10 cells/ml CSF). Clinical information was mostly fully available 
for “BK” patients who enrolled in an intervention RCT for treatment of HIV-associated cryptococcal meningitis.  
NA: ICL2, ICL18 and IPR data were unavailable for these isolates due to technical errors. These isolates were 
excluded in the subsequent analyses where ICL2, ICL18 or IPR were involved. 
 
 
 
Table 4.3-8. Summary of macrophage parasitism using flow-cytometry 
 
Original 
(Mean ± SD) 
 
Outliers removed by MAD 
(Mean ± SD) 
 
H99 ratio ST4 ST5 p-values ST4 ST5 p-values 
PI 1.22 ± 0.16 1.21 ± 0.14 0.89 1.22 ± 0.16 1.21 ± 0.14 0.89 
ICL2 1.04 ± 2.64 1.47 ± 1.20 0.40 1.04 ± 0.64 1.21 ± 0.68 0.61 
ICL18 4.34 ± 4.27  3.17 ± 2.60 0.53 4.67 ± 4.28 3.01 ± 2.60 0.24 
IPR 9.39 ± 22.22 2.84 ± 2.77 0.92 1.43 ± 0.77 1.45 ± 0.78 0.98 
IPR: Intracellular Proliferation Rate 
PI: Phagocytic Index 
ICL2, ICL18: Intracellular Cryptococci Load at 2 hours or 18 hours post-infection. 
Data are presented as ratio between measured values of test isolate and that of H99 in the same experiment batch. Values 
presented in table as mean from 2 biological replicates with standard deviation. Pairwise statistical comparison was 
performed using Mann-Whitney test. 
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Figure 4.3-15. Variation of cytometry-based macrophage parasitism parameters in the test dataset. 
Data are presented in scatterplots with standard deviations. Data for each category were pooled from all isolates in the dataset irrespective of 
AFLP/MLST genotypes or HIV status. 
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Figure 4.3-16. Comparison of macrophage parasitism parameters between ST4 from HIV-infected 
patients and ST5 from HIV-uninfected patients using flow-cytometry (uncorrected for outliers). 
 Statistical comparison of groups was performed using the Mann-Whitney test. Boxplot presents the 
median with interquartile range. Data points outside the interquartile range are presented as clear 
dots.  
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Figure 4.3-17. Comparison of macrophage parasitism parameters between ST4 from HIV-infected 
patients and ST5 from HIV-uninfected patients using flow-cytometry (corrected for outliers).  
Statistical comparison of groups was performed using the Mann-Whitney test. Boxplot presents the 
median with interquartile range. Data points outside the interquartile range are presented as clear 
dots.  
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4.3.2.5. Associating FACS-based macrophage parasitism parameters and clinical 
outcomes 
Comparison of flow cytometry-based Phagocytic Index (PI), Intracellular Cryptococci Load at 
2 hours and 18 hours (ICL2 and ICL18) and Intracellular Proliferation Rate were conducted 
according to patient’s available treatment outcome at 10 weeks (Alive, n=17 or Dead, n=9). 
Results are summarized in Figure 4.3-18. Overall there were no significant associations 
between any macrophage parasitism parameters and either patient mortality after 10 weeks 
of antifungal treatment or CSF fungal burden at baseline (Figure 4.3-18 and Figure 4.3-19). 
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Figure 4.3-18. Associating FACS-based macrophage parasitism parameters and patient mortality 
after 10 weeks of antifungal treatment.  
Statistical comparison of groups was performed using the Mann-Whitney test. Macrophage 
parasitism parameters were corrected for outliers by the MAD method. Boxplot presents the median 
with interquartile range. Data points outside the interquartile range are presented as clear dots. 
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Figure 4.3-19. Correlation between PI, IPR, ICL2, ICL18 and patients’ fungal load in the CSF at diagnosis.  
Data were presented as ratios of the respective isolate’s measurements against those of H99 in the same batch. Mean values were obtained 
from 2 biological replicates. P values and Rho (r) coefficients were from the Spearman test of correlation. Blue lines indicate most probable 
fitted linear correlation. No significant correlations were observed. 
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4.4. Chapter 4 Discussion 
Here I employed in vitro macrophage models previously developed by Ma Hansong [130] 
and Alexandre Alanio [136] with slight modifications to see whether I could detect 
differences in the pathogenic potential of C. neoformans var. grubii isolates from 
Vietnamese patients with different host immune-type associations. I expected that ST5 
strains, given that they can infect apparently immunocompetent patients, would have 
greater macrophage parasitism capacity. Using Ma’s method, I found that there was 
considerable variability in these measures throughout the whole isolate population and 
no detectable differences driven by major AFLP or MLST-defined lineages. However, 
subsequent subgroup analyses revealed statistically significant differences in IPR 
according to host immune phenotype. For instance, isolates from HIV-uninfected patients 
seemed to have significantly higher intracellular growth rate than did isolates from HIV-
infected patients. Specifically, the intracellular growth of ST5 isolates from HIV-uninfected 
patients was 30% higher than all other isolates (ST5 or non-ST5) from either HIV groups. 
Findings from the flow-cytometry method, however, did not reveal any significant 
differences. 
The higher rate of intracellular proliferation detected in ST5 isolates from HIV-uninfected 
patients has a number of implications: 
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First, ST5 isolates from HIV-uninfected patients have higher virulence potential than 
other ST5 or non-ST5 isolates from HIV-infected patients. It is possible that such isolates 
from immunocompetent patients also have greater virulence potential than isolates from 
patients with other forms of immunosuppression.  This is difficult to test, because other 
forms of immunosuppression are currently rare in Vietnam. This is likely to change as 
medical treatment advances. 
Second, as there is variability in the virulence potential of strains within the same ST5 
lineage, there may also be heterogeneity in virulence potential of other lineages. 
However any heterogeneity in virulence potential of lineages other than ST5 does not 
appear to be sufficient to result in disease in immunocompetent patients - we do not 
observe this in nature.  
Third, it is not clear how this increased virulence potential of ST5 strains develops. 
There are broadly 2 possibilities – the quality exists prior to human infection, driven by 
some environmental stress or adaptation, and disease occurs through selection by the 
human host, or the quality is induced during human infection by in-host factors present 
only within immunocompetent hosts.  
Fourthly, it is not clear from my work whether all, or only a subset, of ST5 isolates have 
the potential to cause disease in immunocompetent patients. While there is currently a 
trend for challenge studies in humans with other organisms, for example Salmonella 
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enterica serovar Typhi, and Plasmodium species, treatment for cryptococcal disease is 
currently too inefficient for this to be contemplated in humans, and as seen in chapter 3, 
the mouse model certainly seems to be inadequate for delineating differences between 
Vietnamese lineages that clearly correlate with host immune phenotype.  The ST5 lineage 
appears to have diverged many millions of years ago from other lineages but are still 
highly clonal [325]; it therefore seems likely that all strains should have similar virulence 
potential. This could reflect a similar evolutionary history since most cryptococcal 
virulence factors play important roles in survival/adaptation to environment stresses. 
Understanding how the virulence potential is regulated may enable the identification of 
novel drug targets. 
Another possibility is that this result was an artifact associated with the complex 
experimental design. In fact, the model’s applicability is based on several assumptions:  
(i) Test isolates must have similar baseline growth rate. This means that any 
differences in intracellular growth would be attributed to the isolates’ intrinsic ability to 
survive in an intracellular niche rather than an effect of differential generation time. Since 
there was no underlying genotype-specific difference in growth in YPD at either 30oC or 
37oC (described in Chapter 4), a different underlying growth rate could be ruled out as a 
confounding factor to any differences in IPR. 
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(ii) Extracellular yeasts must be effectively washed off since residual extracellular 
yeasts would severely affect downstream IPR calculation. However since the protocol 
was standardized and performed similarly for every isolates, it would be expected that 
any systematic artifacts due to unwashed extracellular yeasts would be similar for every 
isolates.  
(iii) Macrophage uptake must be high enough to assess intracellular proliferation. 
The model is less appropriate for screening of low-uptake isolates [130]. Low phagocytic 
uptake could be due to the isolate’s intrinsic anti-phagocytic capabilities (with or without 
opsonization). Phagocytosis of cryptococci occurs through 2 main routes: opsonin-
dependent (complement and antibody-mediated) and opsonin-independent (recognition 
of fungal cell wall components by pattern recognition receptors (PRR) on immune cells) 
[392]. Both routes are dependent upon a balance between the ability of the capsule to 
inhibit phagocytosis and the ability of the capsule to bind to opsonins at the capsular 
surface [24]. Since encapsulated C. neoformans yeasts are highly resistant to phagocytosis 
in the absence of opsonins, the yeasts in this study (Ma’s method) were opsonized in 20% 
pooled human serum from immunocompetent volunteers because we did not have 
enough anti-capsular monoclonal antibodies at this time. I did not determine the exact 
opsonic compositions of the pooled human serum used since IPR was reportedly 
independent of uptake routes (complements/antibody-mediated or via recognition of 
 191 | P a g e  
 
specific fungal cell wall components by immune cells)[130].  Given the points made 
above, I do not think the differences I detected are technical artifacts.  
I have previously demonstrated that in vitro capsular enlargement was more profound in 
ST5 yeasts under stimulating conditions compared to non-ST5s (data Chapter 2). It would 
not have been surprising to find that the ST5 yeasts were more resistant to phagocytosis, 
given the capsule’s anti-phagocytic properties [179,399].  However, I found no evidence 
supporting any differences in either phagocytic index or yeast uptake according to 
AFLP/MLST genotypes or HIV immune groups. It is possible that such differences were 
obfuscated within the model due to the fact that all test isolates were uniformly 
opsonized (either by serum or capsular-specific monoclonal antibody) in the phagocytosis 
assays. In other words, any potential intrinsic differences in anti-phagocytic capability 
between isolates from different lineages/HIV groups may have been neutralized by the 
use of opsonins.  
Alanio et al. previously reported that isolates with smooth colonies had higher PI and 
lower binding by capsular-specific monoclonal antibody, in contrast to mucoid colonies 
which had lower PI and high monoclonal antibody binding [136], indicating that capsular 
composition and structural configuration may affect opsonin binding and phagocytosis 
efficacy. Zaragora et al. reported that complement-mediated phagocytosis efficacy was 
inversely correlated with capsule volume, in contrast to IgG1-opsonized yeasts which 
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showed no correlation between phagocytic index and capsule volume [400]. Therefore 
the models I used could be inherently incapable of demonstrating differences in 
phagocytosis efficacy, even though ST5 isolates responded more rapidly to capsule-
inducing in vitro conditions (reported in Chapter 2) that would otherwise confer increased 
resistance to phagocytosis. 
While I found that serum-opsonized ST5 isolates from HIV-uninfected patients were 
actively replicating inside murine macrophages at a significantly higher rate than either 
ST5 or other non-ST5 isolates from HIV-infected patients (34% and 22% more rapidly, 
respectively), I demonstrated this only using Ma’s method. I could not replicate this 
difference using flow-cytometry experiment (Alanio’s method). This discrepancy could be 
due to the technical flaws while performing the flow-cytometry model, in which case 
more calibrations is needed. Alternatively, it could be due to the differences in 
opsonization method used in the two experiments i.e. the use of (highly specific) 
monoclonal antibodies versus human serum. Compared to complement, monoclonal 
antibody opsonization would result in a higher initial yeast uptake rate, which in turn 
could lead to increased competition for nutrients between intracellular cryptococci and 
subsequent stagnation of intracellular proliferation. In fact Sabiiti et al., (2014) observed 
that increased burden of 18B7 antibody-opsonized C. neoformans yeasts in macrophages 
was more a result of high initial uptake rather than subsequent intracellular proliferation 
[135].  
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While previously  IPR has been associated with the virulence of Vancouver outbreak C. 
gattii strains, this is in contrast with C. neoformans var. grubii, where initial yeast uptake 
by macrophages, not IPR, has been associated with higher fungal burdens and worse 
mortality [135]. This latter result, reported by Sabiiti and colleagues, contrasts with my 
findings. However, an important difference with Sabiiti’s study is that my study involves 
apparently immunocompetent patients, whereas his work focused on strains from 
patients with HIV-associated cryptococcal meningitis. C. gattii, especially the Vancouver 
outbreak strains, predominantly infect immunocompetent patients. It is perhaps not 
surprising that my findings, focused on strains from immunocompetent hosts, are 
consistent with the C. gattii data, and hint at a mechanism whereby Cryptococcus adapts 
to a more aggressive immune environment. The ST5 isolates’ increased intracellular 
replication in immortalized murine macrophages in vitro is consistent with the lineage 
having a higher virulence potential. However, I did not see increased mouse mortality in 
my previous murine survival experiment. Rather, the pattern of disease in mice was 
similar to that which we have reported in HIV patients [325]. This paradox could either be 
a consequence of lack of power in the murine model (I tested only 8 clinical strains), or be 
a consequence of the mouse model in fact being a poor model of disease in the 
immunocompetent human. Of note, murine inflammatory response in cryptococcal 
disease has been shown to be similar to that in HIV-infected patients [386].   
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The molecular mechanism explaining the increased IPR of ST5 C. neoformans var. grubii 
isolates from HIV-uninfected patients and its exact role in human disease is unknown. It is 
biologically plausible that an (30%) increase in IPR confers a pathogenic advantage. 
Intuitively, an increased replication rate within host macrophages suggests better 
adaptation to an intracellular lifestyle and the mammalian immune system. An increased 
IPR implies one or more efficient mechanisms of nutrient scavenging, higher resistance to 
reactive oxygen species in the lysosome, more effective immune avoidance and a 
potential advantage for in-host dissemination. Alanio and colleagues demonstrated worse 
outcomes for HIV patients infected with high-uptake/high-intracellular C. neoformans 
isolates – there was an increased risk of death by month 3 post diagnosis [136]. I was 
unable to detect any such significant clinical correlations using either method (Ma’s or 
Alanio). This might represent a lack of power on our part, given the relatively small 
number of isolates tested. Furthermore, work parallel to this PhD has reported that 
mortality at 10 weeks or 6 months in HIV-associated cryptococcal meningitis is similar for 
patients infected with ST5 or non-ST5 C. neoformans var. grubii, although CSF fungal 
burden at baseline was lower for those infected with ST5 strains [325]. However, my 
works here suggests that HIV ST5 strains may assume a ‘just good enough’, less virulent 
phenotype in less aggressive immune environments. 
Given the fact that disease outcome could be a result of the complex interactions 
between host macrophages and invading cryptococci, it could be the case that the higher 
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rate of intracellular growth, possibly at an early stage of cryptococcal colonization and 
dissemination in the human host, would result in increased CSF fungal burden and slower 
rate of clearance upon antifungal treatment among apparently immunocompetent 
patients infected with ST5 yeasts. Prospective screening of a larger number of isolates 
from both HIV-groups with more complete clinical data would potentially reveal any 
possible connections between macrophage parasitism and disease in humans.  
Lastly, the model did not take into account other important macrophage parasitism 
phenotypes such as vomocytosis (non-lytic expulsion of ingested yeasts) and lateral 
transfer (direct transfer of yeasts between adjacent host cells) which may play important 
roles in disease progression (i.e. non-lytic dissemination in the host without triggering 
immune retaliation or crossing the Blood-Brain-Barrier[130,131,393]). Vomocytosis 
occurs independent of uptake routes (antibody/serum opsonized and non-opsonized) in 
both J774 and primary human macrophages, though the vomocytosis rate in J774 (~10%) 
was lower than in human primary macrophages (~27%) [131]. Lateral transfer, in 
conjunction with vomocytosis, represent one of the mechanisms for dissemination and 
latency of cryptococci by hijacking host phagocytes [130]. Future studies should 
investigate this aspect of macrophage parasitism since colonization, dissemination, 
crossing the Blood-Brain-Barrier and latency could be among the underlying factors 
contributing to ST5-associated disease in apparently immunocompetent patients. 
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4.5. Chapter 4 Conclusion 
In this Chapter I employed and further refined an in vitro macrophage model of infection 
to compare virulence potential of C. neoformans var. grubii isolates associated with 
different host HIV immune types in Vietnam. I was able to demonstrate that ST5 isolates 
from HIV-uninfected patients could replicate more rapidly within macrophages, 
suggesting higher virulence potential. Whether this difference has any relevance from a 
clinical perspective could not be determined due to the small number of isolates tested 
and missing clinical information from the HIV-uninfected group. Based on these findings, 
it is possible that isolates from the ST5 lineage may be better suited to an intracellular 
lifestyle which facilitates host immune evasion and dissemination/latency. These 
properties may promote initial host infection and colonization, particularly within the 
immunocompetent patients. In the next chapter, I will use RNAseq to investigate 
genotype-specific genes and pathways that are differentially expressed which may 
contribute to differential metabolism and virulence potential. 
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Chapter 5 
COMPARATIVE TRANSCRIPTOMICS OF C. NEOFORMANS VAR. GRUBII FROM 
HIV-INFECTED AND HIV-UNINFECTED PATIENTS IN VIETNAM 
5.1. Chapter 5 Introduction 
Previously the AFLP-defined cluster of C. neoformans var. grubii VNI-γ that was associated 
with infection in the apparently immunocompetent [103] was revealed to be all sequence 
type (ST) 5 by Multi Locus Sequence Typing (MLST); the VNI-δ cluster included all other 
non-ST5 MLST sequence types in the Vietnamese C. neoformans var. grubii population 
[325] (also presented in Chapter 2). Comparative genomics further confirmed that ST5 
and non-ST5 isolates were phylogenetically distinguishable and both were distantly 
related to the reference strain H99 [325]. The findings that there are in total over 165kbp 
of sequence (in >500bp segments) specific for either the H99 reference or the VN strains, 
along with the absence of the unique H99 chromosomal rearrangement at chromosome 3 
and chromosome 11 among the Vietnamese strains suggested that they shared a more 
recent common ancestor than H99. Despite having significantly different capability to 
cause disease in apparently immunocompetent individuals, ST5 and non-ST5 strains 
shared common genomic architecture features such as comparable number of retro- 
transposons and repeat elements which were enriched proximal to telomeres and 
centromeres. Closer inspection of non-redundant lineage-specific coding sequences 
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identified a number of pleiotropic genes and proteins from known key metabolic 
processes that are also associated with virulence. Functional analysis has the potential to 
greatly enhance the understanding of lineage-specific genomic structures by providing 
information on differentially expressed genes.  
Therefore in this chapter I aimed to compare gene expression between ST4 and ST5 
lineages during log-phase growth in rich medium (YPD). The rationale for doing RNAseq in 
YPD but not in any stress conditions was that: (i) despite known genetic differences 
between ST4 and ST5, it is unclear how these genes/pathways are regulated and 
expressed, (ii) many cryptococcal virulence factors are also involved in basic metabolic 
processes/growth. Data from our group also suggest that C. neoformans cells express 
virulence-inducing genes during normal growth in YPD. 
5.2. Materials and Methods 
5.2.1. C. neoformans var. grubii isolates 
Two ST4 isolates: BK80, BK224 and two ST5 isolates: BMD854, BMD973 were selected 
from the same isolate collection described in previous chapters [103,307] for RNAseq 
profiling. All studies were approved by the Institutional Review Board of the Hospital for 
Tropical Diseases, Ho Chi Minh City, and the Oxford Tropical Ethics Committee or 
Liverpool School of Tropical Medicine UK. Bulk isolate archives from patient CSF were 
stored at -80oC using Microbank beads (Pro-Lab Diagnostics, UK). Mating type and 
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Amplified Fragment Length Polymorphism (AFLP) genotyping for each strain had been 
determined and published previously [10]. MLST genotyping was performed and 
presented in Chapter 2 of this thesis.  
5.2.2. Total RNA extraction and RNA sequencing 
All isolates were single-colony purified prior to experiments. From previous growth 
kinetics experiments, C. neoformans isolates from my collection reached mid log-phase 
growth in YPD broth at approximately 18 hours post-inoculation. Yeasts growing at mid-
log phase were propagated by incubating 106 yeast cells in YPD broth at 30oC with 
agitation for 18 hours. Six biological replicates were performed for each isolate [401]. 
Yeast pellets were collected by centrifugation and total RNA extracted using the Ribopure 
Yeast DNA Purification Kit (Ambion, USA) according to the manufacturer’s instructions. 
Extracted total RNA was stored in isopropanol and sent to Macrogen (Seoul, Republic of 
Korea) for RNA sequencing. Paired-end RNAseq library construction was performed using 
a TruSeq stranded mRNA preparation kit (Illumina, San Diego, CA). The cDNA libraries 
were sequenced on the Illumina HiSeq 2000 (Illumina, San Diego, CA) instrument. 
Assuming a transcriptome of 12 Mbp, I aimed for 20 million reads per experiment which 
would result in at least 150-fold coverage. 
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5.2.3. RNA sequencing and quantitative analysis 
The latest C. neoformans var. grubii H99 reference genome with annotations were 
downloaded from Fungidb database (www.fungidb.org). After initial quality check of 
sequencing using fastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), 
adapters and low quality regions were removed using Scythe 
(https://github.com/vsbuffalo/scythe) and Trimmomatic 
(http://www.usadellab.org/cms/?page=trimmomatic), respectively. Short reads were 
mapped to the H99 reference genome using HISAT2 (Hierarchical Indexing for Spliced 
Alignment of Transcripts) [402]. Output SAM (Sequences Alignment Map) files were 
converted to BAM (Binary Alignment Map) files using SAMtools [403]. Reads counting and 
assignment of mapped reads to genomic features on the reference genome were done 
using featureCounts [404]. In the subsequent quantitative analysis, 12 replicates were 
assigned for each of the two genotypes under comparison (ST4 and ST5), corresponding 
to 2 isolates x 6 biological replicates/ genotype. The R package Deseq2 was employed for 
differential gene expression analysis[405]. Un-normalized count matrices from 
featureCounts were used as input because Deseq2 internally corrects for library size.  
False Discovery Rate (FDR) was simulated using the R package qvalue and a critical value 
was selected as threshold [406]. Analysis process is summarized in Figure 5.2-1. 
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5.2.4. Gene Ontology (GO) enrichment analysis 
Gene Ontology (GO) is a collective set of universal vocabularies to facilitate the process of 
describing genes and gene products across all species [407]. The GO Consortium consists 
of three main umbrella categories: Biological Processes, Molecular functions and Cellular 
Components [407]. Biological processes describe specific biological objectives that 
genes/gene products contribute via their respective molecular functions (hydrolase, 
transport, DNA binding etc.) at specific cellular localizations (cellular components). 
Differential gene expression analysis identified sets of over-expressed or under-expressed 
genes, which can be further characterized and categorized into groups of biological 
relevance using GO enrichment. GO enrichment analysis, done using the R package 
topGO, detects which GO terms appear more frequently than would be expected by 
random chance when assessing the set of GO terms assigned to the input genes. A 
statistical test (e.g. Fisher’s Exact test), is performed to test whether a certain GO term is 
statistically enriched for the given set of genes. Correction for multiple testing is not 
needed as topGO takes into account GO term hierarchy which is considered in the 
resulting Fisher test. GO term hierarchy interrogation was done using QuickGO 
(https://www.ebi.ac.uk/QuickGO). 
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Figure 5.2-1. Overview of RNA sequencing and analysis workflow 
Mid-log phase growth in YPD broth (30oC)
(2 isolates x 6 biological replicates/ genotype)
Total RNA extraction and mRNA library preparation
(Truseq stranded mRNA kit)
Illumina Hiseq 2000
Map reads to 
C. neoformans var. grubii reference genome (H99) using featureCounts
Initial QC, reads alignment (HISAT)
Differential expression analysis 
(Deseq2)
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5.3. Chapter 5 results  
5.3.1. RNA Sequencing results 
For each of the two genotypes, 12 cDNA libraries (2 x 12 = 24) were constructed for high-
throughput Illumina mRNA sequencing. In total, more than 200 million reads were 
generated, representing on average more than 100X coverage of the C. neoformans var. 
grubii genome length for each sample. For most samples, more than 95% of sequencing 
reads were mapped to the C. neoformans var. grubii H99 reference genome (Table 5.3-1). 
Library sizes varied from 8 million to over 14 million reads across different samples. 
During the subsequent differential gene expression analysis, Deseq2 adjusted for 
differences in library size by automatically calculating a size factor for each library under 
investigation that would then be used for normalization and transformation of read 
counts.   
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Table 5.3-1. Number of RNA-seq reads for each sample and mapping results 
Sample MLST genotype Total reads Mapped reads % Mapped 
BK224-1 ST4 8,948,745 8,318,023 93% 
BK224-2 ST4 8,544,613 8,228,891 96% 
BK224-3 ST4 9,183,908 8,743,073 95% 
BK224-4 ST4 7,995,350 7,488,070 94% 
BK224-5 ST4 8,838,418 8,287,181 94% 
BK224-6 ST4 9,013,005 8,540,765 95% 
BK80-1 ST4 9,694,924 9,283,488 96% 
BK80-2 ST4 9,345,272 9,041,266 97% 
BK80-3 ST4 7,828,385 7,567,792 97% 
BK80-4 ST4 7,906,881 7,537,289 95% 
BK80-5 ST4 8,895,059 8,630,835 97% 
BK80-6 ST4 8,288,584 7,883,358 95% 
BMD854_1 ST5 10,904,916 10,554,533 97% 
BMD854_2 ST5 11,088,729 10,769,941 97% 
BMD854_3 ST5 10,649,622 10,346,549 97% 
BMD854_4 ST5 13,552,139 13,170,531 97% 
BMD854_5 ST5 14,489,682 14,050,898 97% 
BMD854_6 ST5 15,252,684 14,793,015 97% 
BMD973_1 ST5 12,802,306 12,400,641 97% 
BMD973_2 ST5 8,497,101 8,229,088 97% 
BMD973_3 ST5 12,523,132 12,142,748 97% 
BMD973_4 ST5 13,193,453 12,779,229 97% 
BMD973_5 ST5 6,513,845 6,313,054 97% 
BMD973_6 ST5 6,663,738 6,462,363 97% 
Total 240,614,491 231,562,621 96% 
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Figure 5.3-1 describes the distribution of counts per gene, which revealed a number of 
genes with zero counts. A pseudo-count of 1 was included prior to the log transformation 
to avoid minus infinite values resulting from these genes with no counts (null genes).  
Figure 5.3-2 shows the proportions of genes-with-zero-counts per samples. Such genes 
would be filtered out in the next quantitative steps.  
 
Figure 5.3-1. Distribution of transformed read counts per expressed genes across all samples. 
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Figure 5.3-2. Proportions of genes with zero counts (null genes) per sample 
  
Percentage of genes with zero counts
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5.3.2. Differential Gene Expression Analysis using Deseq2 
5.3.2.1. Samples clustering analysis  
 
Figure 5.3-3. Sample-to-sample distance matrix from regularized-logarithm transformation (rld) 
of read counts. 
Distance matrix-based dendrogram of all samples in the according to genotypes (ST4 (BK80 and 
BK224) and ST5 (BMD854, BMD973) indicates good technical reproducibility across all biological 
replicates. Color intensity (from blue to light green) indicates increasing number of read counts. 
No outliers were detected. 
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Figure 5.3-4. Samples clustering using Principle Component Analysis (PCA). 
PCA analysis using regularized-logarithm transformation (rld) of read counts suggests that high 
degree of variation in the dataset was primarily attributed to difference in genotypes, not 
technical variation in sequencing or intra-genotype variation. 
Euclidean distances between samples were calculated from regularized-logarithm 
transformation of counts per genes to avoid noises caused by a few highly variable genes, 
as well as providing a roughly equal contribution from all genes (Figure 5.3-3) [408]. 
Clustering of samples and respective replicates, as in Figure 5.3-3, agreed with the 
experimental design (ST4 vs ST5) since all samples were clustered with respect to their 
sequence type (ST5: BMD854, BMD973; ST4: BK80, BK224). Principle Component Analysis 
(PCA) revealed that most observed variation in the dataset was due to the difference in 
genotypes, indicated by PC1 (76% variance). Intra-group variation only accounted for 16% 
of all variance in the dataset. All biological replicates for each strain also closely clustered, 
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indicating good and robust sequencing efficiency. No outliers were detected in the 
dataset using either distance matrix or PCA clustering.  
Figure 5.3-5. The ratio of small p values (p<0.01) for genes binned by mean normalized 
count.  
 
Figure 5.3-5 demonstrates that genes with very low mean count have little or no power, 
and should be excluded from further testing. However it is also shown that a number of 
genes with ~7 normalized counts (i.e. weakly expressed) accounted for a considerable 
number of unadjusted small values. While these genes would be tested insignificant, they 
would potentially affect multiple testing robustness. 
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5.3.2.2.  Determining False Discovery Rate (FDR) cutoff 
 
Figure 5.3-6.Histogram of p-values and q-values at FDR=0.1 for all expressed genes (Deseq2 
mean normalized counts ≥1).  
Highly left-skewed histograms of p-values indicate extremely high power for detecting 
differentially expressed genes at the expense of increasing false discovery rates. 
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At the default FDR of 10%, more than 6000 differentially expressed genes (DEGs) were 
detected out of 8001 genes with at least 10 normalized counts assigned. As seen in 
Figure 5.3-6, the histograms of raw p-values, including FDR-adjusted p-values, are highly 
left-skewed, which possibly indicates a high rate of false positive discovery. We had a high 
number of biological replicates for each condition (i.e. 12 replicates per genotype), 
resulting in very high power to detect differentially expressed genes; however, this also 
increases the potential false discovery rate. Therefore, I needed to use a more stringent 
FDR cutoff to minimize the risk of false positive discoveries. I used an empirical method 
for the determination of p-value and FDR threshold with the qvalue package 
implemented in R.  
Using unadjusted p-values from a Wald test in Deseq2 as input, an estimation of the 
proportion of true null hypotheses (π0) in the current dataset was calculated (π0=0.135). 
The estimated proportion of true alternatives in this case would be 1- π0 (~ 0.865). A 
corresponding q-value for each p-value would then be calculated such that the q-value 
reflects the minimum FDR incurred when calling a test significant. For example, when 
calling all p-values ≤0.01 significant, a corresponding false discovery rate of 0.002 could 
be calculated. This false discovery rate is the equivalent of the maximum estimated q-
value among all p-values ≤0.01.  
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Figure 5.3-7. Simulation of false discovery rates using the qvalue package. 
 
Figure 5.3-7 demonstrates the relationship between the numbers of DEGs meeting 
statistical significance and the corresponding estimated false discovery rates. It can be 
observed that the number of false discoveries starts to rise as the number of DEGs 
exceeds 5000. The number of resulting DEGs and corresponding p-values, q-values and 
local FDR at various significant cutoffs are summarized in Table 5.3-2.  In order to 
minimize the number of false positive discoveries, I chose a local FDR cut off of 0.01. At 
local FDR<0.01 (i.e. less than 10 false positives per 1000 DEGs), 5036 genes were 
identified as significant DEGs. I chose an arbitrary level of biological significance of 
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difference in gene expression of log2FC±1 (i.e 2 fold up or regulation in gene expression). 
In other words, a gene would only be considered differentially expressed under a test 
condition when it was up or down-regulated at least two fold. Using these criteria, I 
identified 704 up-regulated (ST5 vs ST4) DEGs and 1362 down-regulated DEGs (ST5 vs 
ST4). I considered the remaining statistically significant DEGs to have little to no biological 
relevance due to the small degree of fold change in expression.  
 
Table 5.3-2. Cumulative number of DEGs at different significant threshold 
 of p-value, q-value and local FDR (generated from qvalue package) 
  <0 <10
-8
 <0.00001 <0.0001 <0.001 <0.01 <0.025 <0.05 <0.1 <1 
For p-value      0 3193 4034 4401 4852 5466 5758 6046 6330 8001 
For q-value      0 3322 4253 4670 5251 6087 6548 6994 7661 8001 
For lcFDR    0 0 3799 4095 4492 5036 5341 5605 5901 8001 
π0 = 0.135 (proportion of true null p-values) 
lcFDR is a Bayesian derived quantity measuring the probability that a significant test is a true null hypothesis 
(similar to adjusted p-values) 
  
 
 
 
 214 | P a g e  
 
 
Figure 5.3-8. MA plots showing the log2 fold changes attributable to a given variable over the 
mean of normalized counts for all the samples in the Deseq2 dataset in 2 different log2 Fold 
Change (log2FC) shrinkage methods (normal prior and apeglm).  
Points will be colored red if the adjusted p value is less than 0.01. Points which fall out of the 
window (i.e. off the scale) are plotted as triangles. Blue lines indicate log2 fold changes at -1 or 1.  
Figure 5.3-8 illustrates the process of log2FoldChange shrinkage implemented in Deseq2. 
The shrinkage method identifies the largest fold changes that are not due to low counts 
and uses these to inform a prior distribution. This way the large fold changes from genes 
with lots of statistical information are not shrunk, while the imprecise fold changes are 
shrunk. This allows comparison of all estimated fold changes across experiments, for 
example, which is not really feasible without the use of a prior. Since genotype-specific 
genes would be expected to be highly expressed, the default normal prior method would 
potentially over-shrink these. Therefore I elected to use the apeglm method, which takes 
into account the proportion of highly/over-expressed genes for log2FoldChange 
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shrinkage. Figure 5.3-9 demonstrates clustering of significant DEGs from individual 
samples and genotypes using transformed Z-scores.  
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Figure 5.3-9. Heatmap of the genes declared significant with DESeq2. 
Rows correspond to clusters of genes; columns correspond to individual samples. Heatmap 
intensity color corresponds to transformed Z-score (standard deviations away from the mean of 
expression of the reference). Higher Z-scores indicate higher expression of genes. 
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Table 5.3-3 summarizes the detailed components of detected DEGs. Overall 41% (n=2066) 
of the total number of detected DEGs (N=5036) were relevant DEGs (being at least 2 folds 
up or down regulated, n= 2066). Among the 2066 relevant DEGs, only 851 (41%) were 
annotated genes with known functions, the rest were either hypothetical proteins 
(n=787; 38%) or hypothetical RNAs with no coding capacity (n=428; 21%). More than 50% 
(n=2970) of the total number of detected DEGs (N=5036) were genes that were less than 
2 fold up or down-regulated. While a small difference in fold expression of genes implies 
less biological relevance, these genes may have other unknown pleiotropic functions 
contributing to ST5-associated metabolism and virulence. Within the scope of this study, I 
have focused on the more relevant DEGs that are at least 2 fold differentially expressed.  
Table 5.3-3. Summary of DEGs composition  
 log2FC ≥ 1 log2FC ≤ -1 0 < log2FC < 1 
or -1 < log2FC <0 
Total 
Annotated genes 474 377 1857 2708 
Hypothetical proteins 169 618 1038 1825 
Hypothetical RNAs 61 367 75 503 
Total 704 1362 2970 5036 
 All DEGs were either up or down regulated in all ST5 strains tested compared to ST4 strains 
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5.3.2.3. GO terms enrichment analysis of annotated genes up-regulated in ST5 
474 annotated DEGs that were up-regulated in ST5 were used as input for GO enrichment 
analysis over the total set of 8001 annotated genes in the H99 reference. All 3 main 
categories of Gene Ontology (Biological Processes, Molecular Functions and Cellular 
Components) were included in the analysis. The top 5 enriched biological processes 
associated with up-regulated genes in ST5 are presented in Figure 5.3-10 . 
 
Figure 5.3-10. Top 5 highest ranked GO-Biological Processes associated with up-regulated DEGs 
in ST5. 
The barplot describes the respective proportions of genes with relevant GO terms enriched in the 
input dataset. Asterisks indicate statistical significance by Fisher’s Exact test in topGO (significance 
level α=0.05). Biological processes were ranked by Fisher’s test significance (p-values in the order 
of most to least significant from left to right). 
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Table 5.3-4. Up-regulated genes associated with enriched Biological Processes 
Biological process Gene ID Product 
Basemean 
ST4* 
Basemean  
ST5* 
Log2FC 
Folic acid-containing 
compound 
biosynthesis  
(GO:0009396) 
CNAG_06645 Methylenetetrahydrofolate dehydrogenase [NAD(+)] 460 1255 8.847 
CNAG_07746 methylenetetrahydrofolate dehydrogenase (NADP) 1521 4425 10.571 
Nucleoside 
metabolic process 
(GO:0009116) 
CNAG_02285 nucleoside diphosphate kinase 3181 10434 11.636 
CNAG_01390 adenine phosphoribosyltransferase 471 2277 8.883 
CNAG_02546 transferase 550 1447 9.107 
CNAG_02794 dihydroorotate dehydrogenase (fumarate) 1565 2026 10.613 
CNAG_02853 amidophosphoribosyltransferase 1390 2345 10.442 
CNAG_04577 nucleoside-diphosphate kinase 2203 2713 11.106 
CNAG_04961 orotidine-5'-phosphate decarboxylase 827 1151 9.694 
Methionine 
biosynthetic process 
(GO:0009086) 
CNAG_00256 aspartate-semialdehyde dehydrogenase 1177 2378 10.202 
CNAG_02686 cystathionine beta-lyase 1503 1716 10.555 
CNAG_03898 phosphoadenosine phosphosulfate reductase 229 697 7.847 
Cellular protein 
metabolic process 
(GO:0044267) 
CNAG_01148 peptidyl-prolyl cis-trans isomerase 1382 6270 10.434 
CNAG_00058 T-complex protein 1 subunit epsilon 1717 3396 10.746 
CNAG_00252 transcription elongation factor B 119 83 6.912 
CNAG_00829 E3 ubiquitin ligase complex SCF subunit sconC 1435 1666 10.488 
CNAG_01209 1-phosphatidylinositol-3-phosphate 5-kinase 615 419 9.267 
CNAG_01522 phenylalanine-tRNA ligase 580 1090 9.181 
CNAG_02471 hypothetical protein 212 338 7.734 
CNAG_02710 T-complex protein 1 subunit gamma 2141 4195 11.065 
CNAG_00447 T-complex protein 1 subunit beta 1909 4212 10.899 
CNAG_02736 T-complex protein 1 subunit theta 1835 3893 10.842 
CNAG_03459 T-complex protein 1 subunit delta 1673 3620 10.709 
CNAG_04304 T-complex protein 1 subunit zeta 2714 7049 11.407 
CNAG_03188 histone-lysine N-methyltransferase, H3 lysine-36 specific 411 652 8.685 
CNAG_03891 hsp60-like protein 8664 17468 13.081 
CNAG_04822 deoxyhypusine synthase 183 306 7.523 
 
CNAG_04958 ubiquitin fusion degradation protein 1 926 766 9.857 
 
CNAG_04997 cytoplasmic protein 259 375 8.023 
 
CNAG_05195 ubiquitin-conjugation factor E4 B 1473 1111 10.525 
 
CNAG_06174 PEK/GCN2 protein kinase 545 786 9.092 
 
CNAG_06782 putative alpha-1,2-mannosyltransferase 850 591 9.733 
 
CNAG_07346 T-complex protein 1 subunit eta 2159 3896 11.077 
 
CNAG_00873 hypothetical protein 1205 441 10.236 
(*) Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
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Figure 5.3-11. Top 10 highest ranked GO-Molecular Functions associated with up-regulated 
DEGs in ST5.  
Barplot describes the respective proportions of genes with relevant GO terms enriched in the 
input dataset. GO terms were ranked by Fisher’s test significance. P-values were in the order of 
most to least significant from left to right. Asterisks indicate statistical significance by Fisher’s 
Exact test.   
The four most significantly enriched GO Biological Processes included biosynthesis of folic 
acid-containing compound (GO:0009396, p=0.007), nucleoside metabolism (GO:0009116, 
p=0.02), methionine biosynthesis (GO:0009086, p=0.02) and general cellular protein 
metabolism (GO:0044267, p=0.03). Purine nucleotide biosynthesis process was not 
significantly enriched (p=0.08). Over-represented GO terms related to molecular 
functions among up-regulated ST5 DEGs were summarized in Figure 5.3-11. These 
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included: structural constituent of ribosome (GO:0003735 p<0.0001), RNA binding 
(GO:0003723, p=0.0007), pseudouridine synthase activity (GO:0009982 p=0.002), rRNA 
binding (GO:0019843, p=0.01), nucleic acid binding (GO:0003676, p=0.03) and unfolded 
protein binding (GO:0051082, p=0.05). The remaining 4 functions were not significantly 
enriched (p>0.05).  
5.3.2.4. Virulence-associated DEGs in ST5 
Two main groups of DEGs of particular interest were transcription factors and kinases 
which form complex regulatory networks and signaling cascades that govern many 
essential aspects of cryptococcal growth and virulence. Here I detected 29 proteins with 
known transcription regulation activities that were differentially expressed (Table 5.3-5). 
These included 8 up-regulated and 20 down-regulated transcription factors in ST5. These 
factors and their targets have previously been identified as being able to 
positively/negatively regulate various virulence-associated phenotypes of C. neoformans 
[216].  
Table 5.3-6 summarizes 27 detected kinases that were differentially expressed in ST5 and 
ST4 strains. For ST5 these include 14 up-regulated and 13 down-regulated kinases.  
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Table 5.3-5. DEGs that were identified as Transcription factors 
No Gene ID Transcription Factor name 
Basemean 
ST4* 
Basemean 
ST5* 
log2FC 
1 CNAG_06871 FZC41 4 931 7.762 
2 CNAG_04837 MLN1 22 102 2.012 
3 CNAG_01626 ADA2 276 783 1.503 
4 CNAG_05436 putative transcription factor 27 70 1.358 
5 CNAG_05311 putative transcription factor 1352 2966 1.130 
6 CNAG_03018 ASG101 201 432 1.098 
7 CNAG_01438 MBS2 386 803 1.053 
8 CNAG_04345 ARO8001 296 617 1.040 
9 CNAG_05861 FKH101 175 78 -1.165 
10 CNAG_02516 HLH5 99 43 -1.198 
11 CNAG_00505 FZC28 219 90 -1.263 
12 CNAG_05186 GRF1 325 133 -1.265 
13 CNAG_04036 HSF3 98 39 -1.292 
14 CNAG_01551 GAT201 417 157 -1.396 
15 CNAG_04630 YAP2 4438 1521 -1.516 
16 CNAG_04807 FZC8 1058 343 -1.579 
17 CNAG_04804 SRE1 1670 547 -1.606 
18 CNAG_06762 GAT204 571 183 -1.641 
19 CNAG_03132 FZC5 31 9 -1.767 
20 CNAG_01883 GAT8 23 7 -1.794 
22 CNAG_01841 GLN3 74 20 -1.874 
23 CNAG_06097 putative transcription factor 1021 241 -2.005 
24 CNAG_00883 putative transcription factor 1033 251 -2.028 
25 CNAG_00332 SIP4 390 93 -2.036 
26 CNAG_00039 ZFC6 931 220 -2.058 
27 CNAG_04457 FZC30 120 17 -2.426 
28 CNAG_00871 CLR3 127 17 -2.870 
29 CNAG_00791 HLH1 570 65 -3.061 
(*) Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
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Table 5.3-6. Annotated kinases that were differentially expressed 
No. Gene ID Product Gene 
Name  
Basemean 
ST4* 
Basemean 
ST5* 
Log2FC 
1 CNAG_04007 septin ring protein  N/A 1 32 4.613 
2 CNAG_04927 hypothetical protein  YFH701  3 23 2.969 
3 CNAG_04217 phosphoenolpyruvate carboxykinase (ATP) N/A 400 3442 3.075 
4 CNAG_02285 nucleoside diphosphate kinase  N/A 3181 10434 1.700 
5 CNAG_04230 hydroxyethylthiazole kinase  THI6  471 1532 1.662 
6 CNAG_04347 aspartate kinase  N/A 1077 3429 1.617 
7 CNAG_03592 phosphomethylpyrimidine kinase  THI20  691 2042 1.555 
8 CNAG_01364 guanylate kinase  N/A 622 1806 1.525 
9 CNAG_06489 adenosine kinase  N/A 2147 5394 1.321 
10 CNAG_01907 PLK/PLK1 protein kinase  N/A 258 676 1.302 
11 CNAG_03167 CAMK/CAMKL/Chk1 protein kinase  CHK1  225 523 1.207 
12 CNAG_01165 D-erythro-sphingosine kinase  LCB5  176 395 1.171 
13 CNAG_05125 diphosphomevalonate decarboxylase  N/A 636 1406 1.137 
14 CNAG_02847 thymidylate kinase  N/A 121 247 1.032 
15 CNAG_05220 phosphatidylinositol 3-kinase  TLK1  108 49 -1.115 
16 CNAG_00130 CAMK/CAMK1/CAMK1-RCK protein kinase  HRK1  8803 3812 -1.199 
17 CNAG_02531 CMGC/MAPK protein kinase  CPK2  95 40 -1.259 
18 CNAG_04755 STE/STE11/BCK1 protein kinase  BCK1  1993 797 -1.317 
19 CNAG_02542 fructosamine kinase  IRK2  11179 4366 -1.330 
20 CNAG_06432 acetate kinase  N/A 11377 4453 -1.338 
21 CNAG_03355 hypothetical protein  TCO4  3881 1526 -1.342 
22 CNAG_06632 Atypical/ABC1 protein kinase  ABC1  1459 558 -1.375 
23 CNAG_06051 galactokinase  GAL1  826 291 -1.475 
24 CNAG_06310 CAMK/CAMKL protein kinase  IRK7  226 71 -1.643 
25 CNAG_02551 dihydroxyacetone kinase 1  DAK102  217 66 -1.690 
26 CNAG_05104 CAMK protein kinase  FRK101  24 7 -1.778 
27 CNAG_00454 hypothetical protein  N/A 316 43 -2.887 
(*) Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
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Transporters are among the most expressed genes in metabolically active yeasts.  16 
transporters involved in trafficking and metabolism of different were up-regulated in ST5 
(Table 5.3-7). At least five sugars transporters were detected (CNAG_05387, 
CNAG_04784, CNAG_01683, CNAG_05662 and CNAG_06963) and were likely involved in 
carbon utilization. Of note, CNAG_04217 (PCK1, phosphoenolpyruvate carboxykinase), 
one of the genes involved in regulation of gluconeogenesis, was highly up-regulated in 
ST5. PCK1 has previously been associated with fungal survival in the host lung due to the 
limited availability of glucose at that site [228].  
Table 5.3-7. Annotated transporters up-regulated in ST5 
No. Gene ID Product 
Basemean 
ST4* 
Basemean 
ST5* 
log2FC 
1 CNAG_07799 ABC transporter 333 871 1.349 
2 CNAG_05387 galactose transporter 3139 8765 1.404 
3 CNAG_06140 long-chain fatty acid transporter 1549 3891 1.324 
4 CNAG_02361 MFS transporter, ACS family, pantothenate transporter 490 1193 1.262 
5 CNAG_04784 monosaccharide transporter 31 637 4.058 
6 CNAG_03910 myo-inositol transporter 342 2277 2.706 
7 CNAG_06545 pim1 protein RNA transporter 2 741 1723 1.209 
8 CNAG_01683 putative monosaccharide transporter 1894 9884 2.254 
9 
CNAG_01461 
sodium/bile acid cotransporter 7-B/bile acid 
cotransporter 7-B 
65 277 2.104 
10 
CNAG_01752 
solute carrier family 25 (mitochondrial 2-
oxodicarboxylate transporter), member 21 
1356 3437 1.329 
11 
CNAG_01769 
solute carrier family 25 (mitochondrial 
aspartate/glutamate transporter), member 12/13 
681 1677 1.296 
12 
CNAG_02522 
solute carrier family 25 (mitochondrial iron transporter), 
member 28/37 
430 870 1.013 
13 CNAG_02561 spermine transporter 190 440 1.160 
14 CNAG_05662 polyol transporter protein 1 (ptp1) 197 2160 3.354 
15 CNAG_06963 sugar transporter 994 2408 1.264 
16 CNAG_04142 tartrate transporter 78 735 3.144 
(*) Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
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Table 5.3-8. DEGs involved in capsular polysaccharide and cell wall biosynthesis 
No. Gene ID Product 
Gene 
name 
Basemean 
ST4* 
Basemean 
ST5* 
Log2FC 
1 CNAG_07736 glucan endo-1,3-alpha-glucosidase agn1 Agn1 13 164 3.52 
2 CNAG_00697 UDP-glucose 4-epimerase Uge1 1119 3049 1.426 
3 CNAG_04320 polysaccharide synthase Cps1p Cps1 2604 1247 -1.046 
4 CNAG_06016 alpha-1,3-mannosyltransferase Cap6 980 454 -1.097 
5 CNAG_01654 putative capsule structure designer protein Cas34 494 195 -1.324 
6 CNAG_00596 hypothetical protein Utr2 115 39 -1.544 
7 CNAG_02797 hypothetical protein Cpl1 687 215 -1.642 
8 CNAG_03644 capsule related protein Cas3 52 10 -2.321 
9 CNAG_04245 Chitinase CHI22 Chi22 4555 11590 1.282 
10 CNAG_05818 CHS5 chitin synthase Chs5 2452 898 -1.433 
11 CNAG_01239 CDA3 chitin deacetylase Cda3 3697 1273 -1.529 
12 CNAG_05799 CDA1 chitin deacetylase Cda1 15853 4655 -1.764 
13 CNAG_00546 Chitin synthase 6 Chs4 1694 457 -1.877 
14 CNAG_00897 SKN1 β-(1,6)-glucan synthase protein Skn1 3069 485 -2.656 
15 CNAG_06835 KRE61 β-(1,6)-glucan synthesis protein Kre61 1425 110 -3.670 
(*) Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
Differentially expressed genes previously known to be involved in biosynthesis of the 
polysaccharide capsule and cell wall of C. neoformans are showed in Table 5.3-8.  
5.3.2.5. ST5-specific gene expression 
Our group has identified genotype-specific genes were previously described from ST5 and 
non-ST5 C. neoformans var. grubii from Vietnam [325]. Their expression in ST5 is 
confirmed by this RNAseq experiment. They included 13 annotated genes, 22 
hypothetical proteins and 4 hypothetical RNAs. (Table 5.3-9 and Table 5.3-10).  
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Table 5.3-9. Expression of ST5-specific genes with annotated homologs in H99 
No. H99 Gene ID Chr Product Basemean 
 ST4 
Basemean  
ST5 
1 CNAG_00003 1 drug transporter 1 1742 
2 CNAG_00005 1 TPR repeat-containing protein: carboxylic ester hydrolases 1 35 
3 CNAG_03084 8 endoribonuclease L-PSP 1 32 
4 CNAG_04007 2 septin ring protein 0 83 
5 CNAG_04931 10 putative hexose transporter 0 113 
6 CNAG_05991 12 glycosyl hydrolase family 88 variant 2 931 
7 CNAG_06871 5 FZC41 transcription factor 0 122 
8 CNAG_06872 5 5-oxoprolinase 0 135 
9 CNAG_06873 5 5-oxoprolinase 0 190 
10 CNAG_06874 5 HpcH/HpaI aldolase/citrate lyase family protein 1 71 
11 CNAG_06875 5 allantoate permease 0 132 
12 CNAG_06876 5 alpha-ketoglutarate-dependent taurine dioxygenase 
0 394 
13 CNAG_07651 6 DEAD-box ATP-dependent RNA helicase 26, variant 
0 125 
(*) Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
The identified ST5-specific genes included a DEAD- box ATP-dependent RNA helicase 
variant, a number of secreted enzymes, and several membrane transport proteins. 
Notably, 6 consecutive genes in the sub-telomeric region on chromosome 5 (>10kb) were 
detected (CNAG_06871 to CNAG_06876), including the transcription factor FZC41 
(CNAG_06871) and adjacent genes encoding several proteases, dioxygenases and 
hydrolases.  
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Table 5.3-10. Expression of ST5-specific genes coding proteins with unknown functions 
No. H99 Gene ID Chr Product Basemean 
 ST4
$ 
Basemean 
ST5
$ 
1 CNAG_00001 1 hypothetical protein 3 35 
2 CNAG_00002 1 hypothetical protein 0 18 
3 CNAG_00004* 1 hypothetical protein: DNA binding, transcription regulator 0 276 
4 CNAG_01349 5 hypothetical protein 3 70 
5 CNAG_01901 11 hypothetical protein 1 16 
6 CNAG_04932 4 hypothetical protein 0 61 
7 CNAG_05331 4 hypothetical protein 0 38 
8 CNAG_05911* 7 hypothetical protein: transmembrane, signal peptide, non-
cytoplasmic 
1 252 
9 CNAG_05990* 12 hypothetical protein: transcription, DNA binding 0 176 
10 CNAG_06307 13 hypothetical protein 2 36 
11 CNAG_06521* 13 hypothetical protein: transmembrane transport 0 15 
12 CNAG_06802 2 hypothetical protein 0 10 
13 CNAG_06953 9 hypothetical protein 0 19 
14 CNAG_07043 13 hypothetical protein 0 113 
15 CNAG_07305 1 hypothetical protein 0 16 
16 CNAG_07459 2 hypothetical protein 0 93 
17 CNAG_07918 12 hypothetical protein 1 59 
18 CNAG_07931* 13 hypothetical protein: transmembrane both cytoplasmic-non 
cytoplasmic 
2 18 
19 CNAG_07945* 13 hypothetical protein: disordered 0 12 
20 CNAG_07946* 13 hypothetical protein: transmembrane both cytoplasmic + 
non cytoplasmic 
2 22 
21 CNAG_07990* 7 hypothetical protein: transmembrane, both cytoplasmic + 
non-cytoplasmic 
8 373 
22 CNAG_08001* 11 hypothetical protein: disordered, transmembrane 0 11 
23 CNAG_12000 1 hypothetical RNA 0 30 
24 CNAG_12212 3 hypothetical RNA 0 43 
25 CNAG_12408 5 hypothetical RNA 0 15 
26 CNAG_13142 13 hypothetical RNA 
 
0 98 
* indicates hypothetical proteins with manually curated molecular functions/cellular location using InterPro Scan 
(https://www.ebi.ac.uk/interpro/search/sequence-search). 
$
 Basemean is the mean of normalized counts of all samples, normalizing for sequencing depth 
  
 228 | P a g e  
 
5.4. Chapter 5 discussion 
VNI-γ/ST5 and VNI-δ/non-ST5 are genetically distinct clusters of C. neoformans var. grubii 
from Vietnam with markedly different host immune type disposition [103,325]. A number 
of chromosomal rearrangements and genes insertions/disruptions previously associated 
with virulence and fungal adaptation were detected in both lineages (VNI-γ/ST5 and VNI-
δ/non-ST5), suggesting different evolutionary histories and virulence potential [325]. 
Differences in gene expression are implicated as one of the mechanisms regulating 
cryptococcal virulence [198,409]. In this chapter I characterized and described differences 
in key metabolic processes between ST4 and ST5 by comparing their transcriptomes at 
log-phase growth in rich medium. The majority of cryptococcal virulence-associated genes 
and pathways are pleiotropic, which means they are involved in key aspects of 
cryptococcal growth/survival that ultimately contributed to virulence in a facultative host 
[324,409–411]. Therefore, understanding the underlying gene expression differences 
between C. neoformans var. grubii lineages with different abilities to infect hosts with 
different immune phenotypes can potentially reveal insights into the development of 
lineage-specific virulence potential, selection for survival in adverse environmental niches 
and ultimately colonization/infection of mammalian hosts. 
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5.4.1. Up-regulated DEGs in ST5 are involved in nitrogen metabolism and amino 
acid biosynthesis 
A search into GO term hierarchy revealed that biosynthesis of folic acid-containing 
compounds is associated with downstream nitrogen metabolism, biosynthesis of cellular 
cyclic/heterocyclic compounds and other important cellular cofactors/coenzymes. 
Nitrogen metabolism has been identified as an important factor governing cryptococcal 
virulence and survival in the environment [412]. Eight amino acid permeases were 
previously characterized in C. neoformans var. grubii, the regulatory mechanisms of which 
are similar to pathways that govern nitrogen and carbon source quality, amino acid 
availability in the extracellular environment and other nutritional starvation conditions in 
other fungi [413]. Amino acid permeases that were significantly up-regulated in 
Vietnamese ST5 C. neoformans var. grubii strains included: CNAG_01946 (allantoate 
permease, FC=3), CNAG_04276 (cytosine-purine permease), CNAG_04982 (putative 
cytosine-purine permease), CNAG_06875 (allantoate permease). Interestingly, contrary to 
S. cerevisiae which depended on amino acid scavenging from the environment, C. 
neoformans appeared to be more dependent upon amino acid biosynthesis than uptake 
[413]. As aforementioned, methionine biosynthesis was among the most significantly up-
regulated amino acid biosynthesis process in ST5 strains. Whilst the methionine 
biosynthesis pathway is not particularly essential for normal growth of C. neoformans, 
mutants lacking methionine genes appeared attenuated in mice [414].  
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5.4.2. Roles of differentially expressed transcription factors  
The signaling cascades governing the general biology and pathogenicity of  
C. neoformans have been subjects of extensive investigation over the past decades 
[198,409,415,416]. Repertoires of transcription factors are often the most divergent sets 
of signaling components in C. neoformans var. grubii [417]. A number of differentially 
expressed transcription factors were detected in ST5, likely involved in positive/negative 
regulation of gene expression. 
The transcription factor FZC41, which was ST5-specific and was highly expressed, belongs 
to the family of Zn2Cys6 transcription factors specific for fungi [418,419]. Zn2Cys6 
transcription factors are involved in regulation of growth, asexual development, conidia 
germination and pathogenicity in the rice blast fungus Magnaporthe oryzae [420]. 
Interestingly, C. neoformans var. grubii mutants lacking the FZC41 transcription factor 
were more susceptible to fludioxonil, a new fungicide that acts by inhibiting 
phosphorylation of glucose, which reduces mycelial growth rate in other filamentous 
fungi [418,421]. This suggests sugars assimilation and carbon metabolism as one of the 
regulation targets of FZC41. The facts that ST4 strains lack this whole >10 kb sub-
telomeric DNA fragment on chromosome 5 could have been a result of chromosomal 
rearrangement during divergence of ST5 and ST4 from a most recent common ancestor. 
This is further supported by the finding that sub-telomeric regions in C. neoformans 
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encode numerous targets of selection across different lineages [422]. Previously 
cryptococcal sub-telomeric regions have been found to be heavily enriched with hexose 
transporters [124] as well as fungal transcription factors such as FZC20, FZC41, SIP402, 
and FZC22, the last of which has been shown to result in virulence attenuation in mice 
when deleted [418,422]. 
Another transcription factor highly up-regulated in ST5 is ADA2 (CNAG_01626). Increased 
expression of  CNAG_01626 in H99 has been previously correlated with increased capsule 
size [224], consistent with the in vitro phenotype of capsular enlargement previously 
observed in ST5 isolates. ADA2Δ mutants displayed marked defects in sexual 
development, capsule formation, stress response, and virulence [216,224].   
GAT201 (CNAG_01551) is a GATA family transcription factor reported to act as a positive 
regulator of capsule. Interestingly, there was significant overlap in the genes that are 
directly activated by ADA2 and those that are direct targets of GAT201, including the 
antiphagocytic genes BLP1 and GAT204 [418]. Since the SAGA complex typically works in 
concert with other transcription factors, this suggests that ADA2 may work with GAT201 
to activate transcription. A proposed regulatory model for capsule size involving ADA2, 
GAT201 and other transcription factor is summarized in Figure 5.4-1 (adapted from Ding 
et al., (2016) [423]. My current data, though incomplete, indicate different lineages of C. 
neoformans var. grubii from Vietnam (ST4 and ST5) utilize different set of regulatory 
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transcription factors/networks. Extensive characterization of these networks with regards 
to lineage-specific biological aspects and virulence would be required for a more 
complete picture of gene expression and regulation of transcription.  
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Figure 5.4-1. A network of transcription factors affecting capsule size in Cryptococcus neoformans (adapted from Ding et al., (2016))[423]. 
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5.4.3. Roles of differentially expressed kinases  
Kinases have pivotal roles in growth, cell cycle control, differentiation, development, the 
stress response and many other cryptococcal cellular functions, affecting 30% of cellular 
proteins by phosphorylation [424]. The pathobiological networks of C. neoformans 
remains incomplete, mainly because functions of kinases which have a central role in key 
signaling and metabolic pathways, have not been fully characterized on a genome-wide 
scale. 
Among pathogenicity-related kinases previously characterized, kinases involved in the cell 
cycle and growth control were identified most frequently. These include CDC7, MPS1, 
PIK1, CDC2801, MEC1, BUD32, and CKA1 [424]. These kinases didn’t seem to be 
differentially expressed in my dataset, which should reflect the fact that ST4 and ST5 
shared evolutionary conserved kinases functionalities.  
Basal and stress-induced expressions of HRK1 are governed by the Hog1 MAPK. An 
unknown signaling component upstream of the Ssk2 MAPKKK, other than the Ssk1 
response regulator, may trigger the Hog1 MAPK module (Ssk2-Pbs2-Hog1) in response to 
osmotic and oxidative stresses. Hrk1 is involved in intracellular glycerol synthesis upon 
fludioxonil treatment via the HOG pathway. However, Hrk1 appears to play several Hog1-
independent roles. Independent of the HOG pathway modulating ergosterol biosynthesis, 
Hrk1 promotes susceptibility to polyene and azole drugs. Furthermore, Hrk1 is partly 
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involved in promoting resistance to oxidative damaging agents, such as diamide, and 
melanin biosynthesis, which is in stark contrast to Hog1. In conclusion, Hrk1 plays both 
Hog1-dependent and –independent roles in C. neoformans. A proposed network of 
kinases interaction and regulation target is summarized in Figure 5.4-2 (adapted from Lee 
et al., (2016)) [424]. 
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Figure 5.4-2.  Network-based functional relationships among 63 pathogenicity-related kinases (adapted from Lee et al., (2016)) [424]. 
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5.4.4. The implicated roles of ST5-specific genes in virulence and adaptation 
ST5 isolates possess a number of highly expressed, genotype-specific genes that were 
absent in ST4. These include a number of transporters, 5-oxoprolinases and a notable 
DEAD-box RNA helicase variant. Previously, 5-oxoprolinase was demonstrated to be 
required for conidiation, sexual reproduction, virulence and mycotoxin production of the 
phytopathogenic fungus Fusarium graminearum [420].  
The 6 genotype-specific genes on Chromosome 5 were co-located and expressed in ST5 
isolates. In fact, an intriguing aspect of co-regulated/co-expressed eukaryotic genes is 
that they tend to be syntenic and conserved across different taxa/genera, suggesting that 
they are functionally advantageous and were therefore favored by natural selection 
[425,426]. Furthermore, genes involved in the similar bio-chemical pathways tend to be 
clustered together in a number of eukaryotic genomes [427]. A correlation between gene 
proximity and regulation of gene expression is evident in the yeast genome [428]. For 
example, it was previously observed that expression of adjacent genes in Saccharomyces 
cerevisiae is frequently initiated in the same phase of the cell cycle [429]. Thus, insertions 
and deletions such as this in different lineages of C. neoformans may be related to natural 
selection for adaptation to one or more special environmental niches, which 
subsequently resulted in differential virulence potential in human hosts via a “by-stander-
effect”. 
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The DEAD-box ATP-dependent RNA helicase (CNAG_07651), a truncated variant from the 
previously described DEAD-box helicase in H99 (VAD1) [430],  was extremely highly 
expressed in ST5 isolates from Vietnam, indicating an important role in metabolism and 
potential pleiotropic functions in ST5-associated virulence compared with ST4. Several 
studies have demonstrated that DEAD-box proteins are involved in essential signaling 
pathways that mediate host-pathogen interactions. For example, the putative DEAD-box 
helicase HelTc in the parasite Trypanosoma cruzi that causes Chagas disease in humans, is 
highly up-regulated at the infective-stage of trypomastigotes [431]. The role of the first 
DEAD-box helicase characterized in H99 involved sensing stresses within the host during 
initial infection, in-host responses for survival and regulating known virulence factors 
[430].  
Expression of a septin ring protein (CNAG_04007) was also detected specifically for ST5. 
There is evidence that septins in C. neoformans are essential for the proper development 
of the dikaryotic post-mating hyphae, and hyphae resulting from monokaryotic fruiting. 
Specifically, septins are needed for the formation of spore chains, fusion of clamp cells, 
and proper nuclear distribution within hyphae. In addition, septins were found to 
contribute directly to virulence of C. neoformans by being essential for the survival of the 
yeast cells within the host, or indirectly by being necessary for the production of spores, 
the presumed infectious propagules [432]. The latter may therefore be important in 
initiating infection in the mammalian host. 
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5.4.5. Hypothetical proteins and hypothetical RNAs 
Most hypothetical proteins specific for ST5 possess transmembrane domains, suggesting 
putative involvement in transmembrane transporting. Two hypothetical proteins had 
DNA-binding and transcription regulating domains (CNAG_00004 and CNAG_05990), 
indicating their roles as putative transcription factors.  
Among the 90 DEGs which were down-regulated more than 10 fold in ST5, most appeared 
to be genotype-specific (i.e. absent in ST4), as previously reported [325]. These included 
only 5 genes with annotated functions. The rest were hypothetical proteins (n=37) and 
hypothetical RNA (n=50). The extremely high number of hypothetical RNAs without 
protein coding capacity (ncRNAs) that appeared to be absent in ST5 might indicate a 
genotype-specific difference in ncRNA-associated transcription regulation. Most ncRNAs 
observed here are considered long non-coding RNAs (lncRNAs) based on their respective 
length (>200bp) [433]. Eukaryotic lncRNAs have a broad repertoire of regulating 
functions, including chromatin structure,  telomere biology, subcellular structural 
organization as well as controlling expression of neighboring protein-coding genes 
[433,434]. In fact, four ncRNAs were among the ST5-specific up-regulated DEGs that 
appeared to be localized at the sub-telomeric regions. Specifically, except for 
CNAG_13142 (~485bp), the other three ncRNAs, including CNAG_12000 (~2kb), 
CNAG_12212 (~1kb) and CNAG_12408 (669bp), were located in the sub-telomeric regions 
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of 36kb from chromosome ends [18]). Since a specific class of ncRNAs in the telomeric 
region of Saccharomyces cerevisiae called “Telomeric Repeat associated cryptic ncRNAs” 
(TERRAs), was previously shown to be involved in controlling telomere length [435], it 
could be possible that these ST5-specific ncRNAs have similar roles in telomere biology. 
Furthermore, most functionally characterized lncRNAs in higher eukaryotes are involved 
in growth, development, and differentiation [436,437]. In fungi such as Neurospora crassa 
and Aspergillus flavus, natural antisense transcripts (NATs) and lncRNAs are found to be 
differentially expressed in response to specific stimuli that induce developmental changes 
[438,439]. ncRNAs were previously detected and characterized in C. neoformans var. 
grubii (H99) though their exact functions need further investigation [417]. The regulatory 
role of ncRNAs is demonstrated by the fact that they are mainly consist of the antisense 
of a coding gene or another ncRNA. For example, CNAG_12000 is antisense to the 
transporter CNAG_00005 on Chromosome 1, both of which are highly up-regulated in ST5 
during log-phase YPD growth. While expression of CNAG_00005 could be due to other 
regulatory factors, it is possible that positive gene regulation through an antisense 
transcript is also involved, in addition to the more common negative gene regulation role 
of antisense RNAs. Another example is the highly overexpressed ncRNA CNAG_12019 on 
Chromosome 1, which was ST4-specific and was antisense to another ST4-specific and 
highly expressed hypothetical protein (CNAG_00128). The involvement of ncRNAs in 
regulating cryptococcal developmental changes has been reported, in which the ncRNA 
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acted as a critical morphologic switch between the yeast and hyphal form of C. 
neoformans var. grubii [440].  
5.5. Chapter 5 Conclusion 
Though closely related and morphologically similar, ST4 and ST5 C. neoformans var. grubii 
isolates from Vietnam with different host immune type disposition were previously 
shown to be genetically distinct. In this chapter I have identified and described 
differences in in vitro gene expression of key metabolic processes that are essential for 
growth and virulence of the two most prevailing genotypes among the C. neoformans var. 
grubii population from Vietnam. Future investigation of gene expression at the site of 
human infection would help validate current findings and provide more insight into 
cryptococcal pathogenesis. 
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Chapter 6 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
6.1. Introduction 
The two sister species of Cryptococcus: Cryptococcus neoformans, commonly associated 
with disease in HIV-infected patients, and Cryptococcus gattii, now considered a primary 
human pathogen with a propensity to cause disease in apparently immunocompetent 
patients, are the main etiological agents  responsible for the majority of cryptococcal 
meningitis cases globally. Intriguingly, paradoxical infection in apparently healthy, 
immunocompetent patients due to C. neoformans var. grubii is also reported, especially 
more significant from East/Southeast Asia than anywhere else. Why this variety of C. 
neoformans, traditionally considered an opportunistic pathogen in immunocompromised 
patients, is able to cause disease in individuals with no apparent immunosuppression in 
Vietnam is unclear and this thesis aimed to improve our understanding of this 
phenomenon.  
A paradoxically higher prevalence of a subgroup of C. neoformans var. grubii yeasts in 
apparently immunocompetent hosts indicates has two potential explanations: either 1) 
increased virulence potential of the subgroup compared with other groups, or 2) an as yet 
unidentified host immune defect that confers increased susceptibility to the organism. In 
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this PhD thesis, I investigated the former hypothesis by systematically assessing the 
genetic composition, population structure, in vitro and in vivo virulence-associated 
phenotypes as well as comparative transcriptomics of C. neoformans var. grubii isolates 
from HIV-infected and HIV-uninfected patients in Vietnam. This is, to my knowledge, is 
one of the first studies to systematically tackle this issue. Findings from my study will help 
further the current understanding of cryptococcal disease and identify further areas for 
investigation. 
6.2. Principal findings 
1. The clinical population of C. neoformans var. grubii in Vietnam is an integrated 
part of the clonal Asian population, with ST4, ST5, ST6 and ST93 being the 
predominant genotypes. 
2. AFLP-defined VNI-γ strains, which were almost entirely responsible for disease 
in immunocompetent patients, corresponded exactly with the single MLST 
sequence type: ST5; the VNI-δ cluster included a variety of different sequence 
types. 
3. ST4/ST6 and ST5 belong to separate but closely related lineages of  
C. neoformans var. grubii. 
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4. The proportion of predominant genotypes (ST4, ST5, ST6 and ST93) changes in 
a geographical arc that runs South/Southwest and East/Northeast from 
Southeast Asia to East Asia. 
5. The population structure of C. neoformans var. grubii in Vietnam is 
intermediate between populations from Southeast Asia and those from East 
Asia, and is remarkable for having more than a single dominant circulating 
lineage. 
6. ST5 isolates tend to produce larger capsules compared to other strains when 
grown on capsule inducing agar and in in vivo models of infection. Further, 
they demonstrate increased heterogeneity in cell size. 
7. Apart from capsular enlargement, ST5 isolates displayed similar key in vitro 
virulence-associated phenotypes with  non-ST5s (i.e. melanization, urease, 
phospholipase, growth in ex vivo CSF, thermotolerance) 
8. ST5 isolates induced significantly less morbidity and mortality in the murine 
(A/J) model of infection. 
9. ST5 isolates induced significantly stronger TNF-α response at an earlier time 
point during murine (A/J) infection. 
10. VNI-γ/ST5 strains, though appeared a genetically homogenous group, 
displayed remarkable heterogeneity in virulence-associated phenotypes, both 
in vitro and in vivo. 
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11. ST5 isolates from HIV-uninfected patients displayed significantly higher rates 
of growth inside macrophages than ST5 isolates from HIV infected patients, 
and from non-ST5 strains. 
12. ST5s differed from ST4s in expression of key metabolic genes and processes 
essential for both growth/survival and virulence. 
6.3. Insights into ST5 virulence potential and its implications in apparently 
immunocompetent hosts 
The main objective of this study was to investigate whether the high prevalence of AFLP-
defined VNI-γ C. neoformans var. grubii among HIV-uninfected patients in Vietnam was 
associated with previously identified in vitro and in vivo virulence factors. ST5 strains are 
closely related but genetically distinct from other STs; this must confer their unique ability 
to infect the immunocompetent and defines their pathogenic potential. However, my 
results revealed that the ability of VNI-γ C. neoformans var. grubii ST5 strains to infect and 
cause disease in apparently immunocompetent hosts is not necessarily associated with 
the capacity to cause greater in-host damage – despite stimulating an initial more robust 
inflammatory response, mice infected with ST5 strains had better survival than those 
infected with non-ST5 strains. This picture is mirrored by that seen in HIV infected 
patients, where the disease course resulting from ST5 infection does not appear to be 
more severe than that due to other sequence types .  My results highlight the sheer 
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complexity of this ST5-related clinical phenotype. There are 3 important aspects to 
consider out of these findings: 
First, the in vivo ST5-induced phenotype in A/J mice may reflect a later stage of 
cryptococcosis – i.e established disease rather than initial infection. Indeed, 
cryptococcal disease in humans is a long and complicated process that can be considered 
to consist of at least 6 different stages:  
(1) Initial colonization of the exposed host;  
(2) Establish localized infection in the lungs and other host tissues;  
(3) Survival of the initial immune response and establishment of dormancy;  
(4) Reactivation from dormancy;  
(5) Dissemination to other host tissues including breaching the Blood-Brain-Barrier 
(6) Proliferation in the CSF.  
The mouse model aims to simulate and provide a brief description of cryptococcal 
pathogenesis through all stages, from colonization to dissemination and CSF proliferation. 
It necessarily involves administration of a large, concentrated infecting inoculum, which 
likely poorly represents what happens in nature. Moreover, it is a model of disseminated 
infection rather than predominant brain disease. As mentioned previously, the between 
lineage differences I observed somewhat model the pattern of disease seen in HIV 
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infected adults. Consistent with this, the immune response I observed in the A/J mice 
model (which is technically moderately immunocompromised due to an impaired 
complement response), reflected that of the later stages of HIV-infected patients with 
cryptococcal meningitis [386]. The lack of clear lineage specific differences in disease 
phenotype seen in both HIV patients and mice raises the question of whether ST5 has an 
advantage compared with other lineages at the earlier stages of infection, including initial 
host immune response evasion and establishing latency. This idea is supported by results 
from my macrophage model, which is a simulation of interaction with the host innate 
immunity. Here, I found that the ST5 isolates have increased macrophage parasitism 
capacity, evidence by their high intracellular proliferation rates. Furthermore, works 
parallel to this thesis within OUCRU have shown that ST5 strains from HIV-uninfected 
patients induce higher mortality in the Galleria model (the greater wax-moth). The 
Galleria model is another model of innate immunity.  
Second, phenotypic heterogeneity observed in ST5 is potentially an evolutionary 
advantage. In Chapter 3 I found that ST5 strains, seemingly a genetically homogeneous 
phylogeny group, display marked intra-genotype variation in a number of in vitro and in 
vivo virulence-associated phenotypes, when compared to non-ST5 strains. Indeed, it has 
been demonstrated that population heterogeneity is positively related to survival of 
different fungi species in adverse environmental conditions [441]. From an evolutionary 
perspective phenotypic heterogeneity is an advantageous trait when populations face a 
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chronic selection pressure [442]. The results from this interaction dictate evolutionary 
trajectories at the genomic level and facilitate evolutionary rescue from deteriorating 
environmental niches [442]. It is intriguing to recall results from our previous WGS study 
comparing VNI-γ and VNI-δ strains in which we detected a number of VNI-γ-specific genes 
which appeared to be clustered at the sub-telomeric regions [325]. My RNAseq data 
confirmed that these genes were expressed at high levels in ST5 strains at log-phase 
growth in YPD but were altogether absent in ST4 strains. Chow et al., (2012) reported that 
genes in the telomere and sub-telomere regions are linked to fungal adaptation to 
environmental stresses [124]; Desjardins et al., (2017) demonstrated that the genes in the 
sub-telomeric regions of VNI C. neoformans var. grubii are under significantly higher 
selection pressure than in the VNII or VNB lineages [90]. This observation suggests that 
strains from the ST5 lineage could occupy diverse and potentially adverse environmental 
niches, resulting in an increased likelihood of selection of strains with enhanced 
“virulence potential”, enabling infection in immunocompetent hosts (possibly through a 
“by-stander” mode of action). Given that most virulence genes in Cryptococcus also have 
other pleiotropic functions, it is likely that polyploidy of such genes and pathways might 
actively confer to cryptococcal virulence [90].  
Third, higher rates of ST5-associated disease in immunocompetent, HIV-uninfected 
patients may not be associated with higher in-host damage but rather better host 
colonization. This idea is supported by several lines of evidence:  
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(i) ST5 strains in my study responded better to in vitro capsular enlargement signals, 
which could potentially lead to increased sporulation as capsule biosynthesis genes are 
required for both efficient sexual development, spore formation and dispersal [443]. 
Increased number of ST5-spores at a given time means higher exposure rate to exposed 
and (potentially) immunocompetent hosts. Higher frequency of ST5-specific infectious 
propagules with better capacity to colonize and establish infection in such hosts would 
result in higher prevalence of ST5-related infection;  
(ii) My in vitro macrophage model results, and works parallel to this thesis, suggest 
that ST5 strains seemed to be better at coping with host innate immunity at early stages 
of infection and dissemination. This is an interesting hypothesis that needs further 
investigation. Specifically, future works addressing this hypothesis should shift focus to 
other aspects of cryptococcal virulence not thoroughly investigated in this thesis, 
including: same sex mating (given the facts that all our strains were MATα) and 
sporulation capacity, spore virulence compared to the yeast form.  
Fourth, an as-yet identified host immune defect specific for the East Asian lineage that 
confers increased susceptibility to cryptococcosis remains possible. The fact that the 
majority of reported cases of C. neoformans var. grubii infection in apparently 
immunocompetent, HIV-uninfected patients were reported from Southeast/East Asia 
raised the question of whether this lineage of human host possesses unique immune 
defects that are associated with increased susceptibility to infection by C. neoformans 
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var. grubii. For instance, IgM-producing B-cell deficiency and adult onset autoantibodies 
to IFN-γ and GM-CSF have been suggested as some of the possible non-HIV 
immunocompromising conditions associated with increased risk of acquiring active 
cryptococcosis [288,444,445]. However, this would not explain why it is only ST5 strains 
that cause disease in immunocompetent patients. 
Ecological factors are implicated as the main driving forces for differential population 
structures in Vietnam and elsewhere in Asia  
Another focus of this thesis was to study the genetic composition of the clinical  
C. neoformans var. grubii population in Vietnam and how it relates to other populations 
across the globe. Understanding the local population structure within a global context 
would potentially provide more insights into the origin and spread of specific lineages of 
interest. Populations from different countries with different geographical/ecological 
conditions across Asia shared a few similar predominant MLST genotypes (ST4, ST5, ST6 
and ST93) albeit in different proportions. I detected a gradual change in the relative 
proportion of these 4 predominant STs in a South/Southwest Asia – East/Northeast Asia 
arc, from which the C. neoformans var. grubii population from Vietnam represents an 
intermediate. Ecological and human factors may have important roles in shaping the local 
and global cryptococcal populations. Climate and geography in Asia vary greatly, from the 
subtropical and tropical wet plains of Southeast Asia to the more temperate regions of 
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East Asia, presenting vastly different and diverse ecological niches. The different 
proportions of STs from each country/region, therefore, may suggest different fitness and 
adaptation of different STs to particular environmental niches. Human factors may not 
have an active role in determining population structures or dispersal of different lineages 
of C. neoformans var. grubii, given the fact that there is no human to human transmission 
of cryptococcosis. However, human activities such as irrigation, deforestation, 
domestication of feral pigeons and other unknown potential carriers of Cryptococcus may 
disrupt and alter traditional ecological niches of Cryptococcus species and may as well 
increase human exposure to pathogenic C. neoformans lineages.  
6.4. ST174 as a putative most recent common ancestor of Asian C. neoformans var. 
grubii lineages 
Maximum likelihood and goeBURST  analysis suggested ST174 as the most parsimonious 
candidate for most recent common ancestor of all major lineages of C. neoformans var. 
grubii observed in Asia. ST174 and its close progenies accounted for the majority of 
isolates from the Middle East (Kuwait and Qatar) and South Asia (India). Interestingly, a 
recent study by Mathieu Vanhove and colleagues (2017) described an actively 
recombining cluster of VNI C. neoformans var. grubii which included a mixture of strains 
from Africa and India [89]. The high genetic diversity and the lack of population 
differentiation between this cluster and other VNI clusters could indicate that worldwide 
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dissemination of VNI isolates might have originate from this cluster [89]. Currently it is 
not known whether ST174 is related to the cluster identified in Vanhove’s study. In fact, 
though current data suggest an “out of Africa” mode of global expansion for C. 
neoformans VNI, it is unlikely that the population in Vietnam and Asia arose from single 
African ancestral type but rather through various intermediate common ancestors. In 
essence, ST174 is potentially one of such ancestral types. Future works involving whole 
genome sequencing of a larger number of environmental and clinical isolates from 
different regions may shed more light into the complex evolutionary history of C. 
neoformans and the rise of pathogenic lineages. 
6.5. Future works 
This thesis has provided me with a number of possible avenues which I could explore in 
the future. The most important that I would be interested to take forward are:  
1. Systematic assessment of in vitro virulence-associated phenotypes for a larger 
collection of C. neoformans var. grubii isolates from Vietnam and elsewhere. 
I would be interested to understand the variability in phenotypes in the ST5 and non-ST5 
strains with more precision, to ensure that the heterogeneity I saw in ST5 strains, 
particularly in the mouse model, is real. This would involve passaging a large number of 
clinical strains through these models. 
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2. Investigate C. neoformans var. grubii interaction with the host at different stages of 
infection using different models of infection. 
The major problem with the mouse model is the mode of infection, which is likely 
unrealistic. Infection is believed to occur through inhalation of infectious propagules – 
either yeasts or spores. Aerobiology facilities, such as those at Duke University Medical 
College, would enable a more realistic mode if infection to be assessed by lineage, 
including different types of propagule. In addition, I would be interested to test the ‘dose’ 
of each lineage which can effectively establish infection. Furthermore, I would also like to 
investigate the interaction of different lineages of C. neoformans with epithelial cells 
(pulmonary alveolar cells, Blood-Brain-Barrier cells etc.). 
3. Making a mutants library for phenotype screening   
Using RNAseq I identified a number of genes that are differently expressed between ST5 
and non-ST5 strains, some of which were genes involved in essential biological functions 
and virulence, the remaining were are hypothetical proteins. Charactering the phenotypic 
effects of knockouts on the hypothetical genes would potentially provide more insights 
into functionality of these genes. 
4. Investigate in vivo C. neoformans var. grubii gene expression at the site of human 
infection. 
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The cerebrospinal fluid fungal burden in patients with cryptococcal meningitis in Vietnam 
is often high, which offers the potential for in situ RNAseq. Validating the differential 
expression of the genes of interest from my RNAseq data in patients would provide more 
insights into how different lineages of C. neoformans response to a potentially hostile 
environment in the host. 
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Appendices 
Appendix 1. Pooled dataset for MLST analyses 
Isolate ID Specimen Location HIV ST goeBURST Region References 
103 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
113 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
130 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
134 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
148 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
206 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
205 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
264 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
313 CSF South 
Africa 
Positive 4 4 Africa Beale MA et al, Plos 
NTD,2015 
321 CSF South 
Africa 
Positive 6 4 Africa Beale MA et al, Plos 
NTD,2015 
107 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
101 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
118 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
133 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
145 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
229 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
337 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
204 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
326 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
339 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
341 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
401 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
428 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
437 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
468 CSF South Positive 5 5 Africa Beale MA et al, Plos 
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Africa NTD,2015 
478 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
314 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
343 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
425 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
457 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
470 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
420 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
424 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
443 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
447 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
465 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
475 CSF South 
Africa 
Positive 5 5 Africa Beale MA et al, Plos 
NTD,2015 
218 CSF South 
Africa 
Positive 202 5 Africa Beale MA et al, Plos 
NTD,2015 
219 CSF South 
Africa 
Positive 202 5 Africa Beale MA et al, Plos 
NTD,2015 
263 CSF South 
Africa 
Positive 202 5 Africa Beale MA et al, Plos 
NTD,2015 
257 CSF South 
Africa 
Positive 3 31 Africa Beale MA et al, Plos 
NTD,2015 
370 CSF South 
Africa 
Positive 31 31 Africa Beale MA et al, Plos 
NTD,2015 
469 CSF South 
Africa 
Positive 31 31 Africa Beale MA et al, Plos 
NTD,2015 
471 CSF South 
Africa 
Positive 31 31 Africa Beale MA et al, Plos 
NTD,2015 
106 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
109 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
116 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
121 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
122 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
123 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
124 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
136 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
137 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
143 CSF South Positive 32 31 Africa Beale MA et al, Plos 
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Africa NTD,2015 
243 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
238 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
247 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
252 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
369 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
346 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
463 CSF South 
Africa 
Positive 32 31 Africa Beale MA et al, Plos 
NTD,2015 
360 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
301 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
328 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
333 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
367 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
410 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
419 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
312 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
319 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
324 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
330 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
344 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
345 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
348 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
358 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
373 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
304 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
322 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
327 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
338 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
342 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
355 CSF South Positive 93 31 Africa Beale MA et al, Plos 
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Africa NTD,2015 
359 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
366 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
368 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
380 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
320 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
363 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
375 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
417 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
459 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
477 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
486 CSF South 
Africa 
Positive 93 31 Africa Beale MA et al, Plos 
NTD,2015 
444 CSF South 
Africa 
Positive 185 31 Africa Beale MA et al, Plos 
NTD,2015 
217 CSF South 
Africa 
Positive 199 31 Africa Beale MA et al, Plos 
NTD,2015 
261 CSF South 
Africa 
Positive 199 31 Africa Beale MA et al, Plos 
NTD,2015 
244 CSF South 
Africa 
Positive 199 31 Africa Beale MA et al, Plos 
NTD,2015 
141 CSF South 
Africa 
Positive 200 31 Africa Beale MA et al, Plos 
NTD,2015 
329 CSF South 
Africa 
Positive 236 31 Africa Beale MA et al, Plos 
NTD,2015 
110 CSF South 
Africa 
Positive 237 31 Africa Beale MA et al, Plos 
NTD,2015 
354 CSF South 
Africa 
Positive 238 31 Africa Beale MA et al, Plos 
NTD,2015 
406 CSF South 
Africa 
Positive 239 31 Africa Beale MA et al, Plos 
NTD,2015 
140 CSF South 
Africa 
Positive 240 31 Africa Beale MA et al, Plos 
NTD,2015 
336 CSF South 
Africa 
Positive 241 31 Africa Beale MA et al, Plos 
NTD,2015 
246 CSF South 
Africa 
Positive 2 63 Africa Beale MA et al, Plos 
NTD,2015 
308 CSF South 
Africa 
Positive 2 63 Africa Beale MA et al, Plos 
NTD,2015 
472 CSF South 
Africa 
Positive 2 63 Africa Beale MA et al, Plos 
NTD,2015 
310 CSF South 
Africa 
Positive 2 63 Africa Beale MA et al, Plos 
NTD,2015 
102 CSF South 
Africa 
Positive 58 63 Africa Beale MA et al, Plos 
NTD,2015 
256 CSF South 
Africa 
Positive 58 63 Africa Beale MA et al, Plos 
NTD,2015 
250 CSF South Positive 67 63 Africa Beale MA et al, Plos 
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Africa NTD,2015 
127 CSF South 
Africa 
Positive 234 63 Africa Beale MA et al, Plos 
NTD,2015 
119 CSF South 
Africa 
Positive 235 63 Africa Beale MA et al, Plos 
NTD,2015 
260 CSF South 
Africa 
Positive 246 63 Africa Beale MA et al, Plos 
NTD,2015 
154 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
210 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
258 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
212 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
223 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
251 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
412 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
316 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
357 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
362 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
352 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
403 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
415 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
461 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
433 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
442 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
481 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
483 CSF South 
Africa 
Positive 23 63 Africa Beale MA et al, Plos 
NTD,2015 
147 CSF South 
Africa 
Positive 247 63 Africa Beale MA et al, Plos 
NTD,2015 
254 CSF South 
Africa 
Positive 248 63 Africa Beale MA et al, Plos 
NTD,2015 
216 CSF South 
Africa 
Positive 63 63 Africa Beale MA et al, Plos 
NTD,2015 
224 CSF South 
Africa 
Positive 63 63 Africa Beale MA et al, Plos 
NTD,2015 
249 CSF South 
Africa 
Positive 63 63 Africa Beale MA et al, Plos 
NTD,2015 
104 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
146 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
125 CSF South Positive 69 63 Africa Beale MA et al, Plos 
 260 | P a g e  
 
Africa NTD,2015 
126 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
129 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
135 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
139 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
207 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
208 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
235 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
241 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
253 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
255 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
202 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
203 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
225 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
231 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
232 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
233 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
245 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
262 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
365 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
371 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
402 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
436 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
439 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
318 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
413 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
416 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
464 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
405 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
414 CSF South Positive 69 63 Africa Beale MA et al, Plos 
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Africa NTD,2015 
418 CSF South 
Africa 
Positive 69 63 Africa Beale MA et al, Plos 
NTD,2015 
112 CSF South 
Africa 
Positive 212 63 Africa Beale MA et al, Plos 
NTD,2015 
213 CSF South 
Africa 
Positive 218 63 Africa Beale MA et al, Plos 
NTD,2015 
227 CSF South 
Africa 
Positive 218 63 Africa Beale MA et al, Plos 
NTD,2015 
215 CSF South 
Africa 
Positive 218 63 Africa Beale MA et al, Plos 
NTD,2015 
NRHc5025.ENR.STOR CSF Botswana Positive 5 5 Africa Chen et al., (2016) 
NRHc5028.ENR.STOR CSF Botswana Positive 3 31 Africa Chen et al., (2016) 
NRHc5036.ENR CSF Botswana Positive 77 31 Africa Chen et al., (2016) 
NRHc5044.REL.INI.CLIN.ISO CSF Botswana Positive 77 31 Africa Chen et al., (2016) 
PMHc1039.ENR.STOR CSF Botswana Positive 77 31 Africa Chen et al., (2016) 
PMHc1018.CLIN.1 CSF Botswana Positive 32 31 Africa Chen et al., (2016) 
PMHc1052.ENR.STOR CSF Botswana Positive 9 N/A Africa Chen et al., (2016) 
PMHc1023.ENR CSF Botswana Positive 40 N/A Africa Chen et al., (2016) 
NRHc5048.ENR.ISO CSF Botswana Positive 80 N/A Africa Chen et al., (2016) 
PMHc1043.ENR.STOR CSF Botswana Positive 80 N/A Africa Chen et al., (2016) 
PMHc1034.ENR.STOR CSF Botswana Positive 89 N/A Africa Chen et al., (2016) 
NRHc5031.ENR.CLIN.ISO CSF Botswana Positive 143 N/A Africa Chen et al., (2016) 
NRHc5017.ENR CSF Botswana Positive 317 N/A Africa Chen et al., (2016) 
NRHc5001.ENR CSF Botswana Positive 378 N/A Africa Chen et al., (2016) 
PMHc1031A.ENR.INI.LP CSF Botswana Positive 379 N/A Africa Chen et al., (2016) 
PMHc1020.CLIN.1 CSF Botswana Positive 380 N/A Africa Chen et al., (2016) 
NRHc5041.ENR.CLIN.ISO CSF Botswana Positive 384 N/A Africa Chen et al., (2016) 
PMHc1038.ENR.CLIN1 CSF Botswana Positive 385 N/A Africa Chen et al., (2016) 
NRHc5030.ENR.CLIN.ISO CSF Botswana Positive 386 N/A Africa Chen et al., (2016) 
NRHc5013.ENR CSF Botswana Positive 387 N/A Africa Chen et al., (2016) 
PMHc1001.ENR CSF Botswana Positive 389 N/A Africa Chen et al., (2016) 
NRHc5009.ENR CSF Botswana Positive 392 N/A Africa Chen et al., (2016) 
NRHc5037.ENR.CLIN1 CSF Botswana Positive 394 N/A Africa Chen et al., (2016) 
PMHc1014.ENR CSF Botswana Positive 396 N/A Africa Chen et al., (2016) 
NRHc5005.ENR CSF Botswana Positive 398 N/A Africa Chen et al., (2016) 
PMHc1030.ENR.CLIN.ISO CSF Botswana Positive 402 N/A Africa Chen et al., (2016) 
NRHc5006.CLIN.1 CSF Botswana Positive 403 N/A Africa Chen et al., (2016) 
NRHc5008.ENR CSF Botswana Positive 407 N/A Africa Chen et al., (2016) 
PMHc1047.ENR.CLIN1 CSF Botswana Positive 408 N/A Africa Chen et al., (2016) 
PMHc1024.CLIN.1 CSF Botswana Positive 409 N/A Africa Chen et al., (2016) 
PMHc1033.ENR CSF Botswana Positive 410 N/A Africa Chen et al., (2016) 
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PMHc1035.ENR.STOR CSF Botswana Positive 411 N/A Africa Chen et al., (2016) 
NRHc5040.ENR.CLIN.ISO CSF Botswana Positive 415 N/A Africa Chen et al., (2016) 
NRHc5026.ENR.CLIN.ISO CSF Botswana Positive 416 N/A Africa Chen et al., (2016) 
PMHc1050.ENR.CLIN1 CSF Botswana Positive 417 N/A Africa Chen et al., (2016) 
NRHc5019.ENR CSF Botswana Positive 419 N/A Africa Chen et al., (2016) 
NRHc5023.ENR CSF Botswana Positive 421 N/A Africa Chen et al., (2016) 
PMHc1026.ENR CSF Botswana Positive 422 N/A Africa Chen et al., (2016) 
NRHc5020.CLIN.1 CSF Botswana Positive 424 N/A Africa Chen et al., (2016) 
NRHc5011.ENR CSF Botswana Positive 427 N/A Africa Chen et al., (2016) 
NRHc5032.ENR.CLIN.ISO CSF Botswana Positive 428 N/A Africa Chen et al., (2016) 
NRHc5021.CLIN.1 CSF Botswana Positive 429 N/A Africa Chen et al., (2016) 
NRHc5029.ENR.CLIN.ISO CSF Botswana Positive 432 N/A Africa Chen et al., (2016) 
NRHc5039.ENR.CLIN.ISO CSF Botswana Positive 433 N/A Africa Chen et al., (2016) 
NRHc5024.ENR.CLIN.1 CSF Botswana Positive 434 N/A Africa Chen et al., (2016) 
NRHc5004.ENR CSF Botswana Positive 435 N/A Africa Chen et al., (2016) 
NRHc5045.ENR.CLIN.ISO CSF Botswana Positive 436 N/A Africa Chen et al., (2016) 
NRHc5035.ENR.CLIN.ISO CSF Botswana Positive 438 N/A Africa Chen et al., (2016) 
NRHc5042.ENR.STOR CSF Botswana Positive 447 N/A Africa Chen et al., (2016) 
NRHc5015.ENR CSF Botswana Positive 449 N/A Africa Chen et al., (2016) 
PMHc1022.ENR CSF Botswana Positive 449 N/A Africa Chen et al., (2016) 
PMHc1032.ENR CSF Botswana Positive 449 N/A Africa Chen et al., (2016) 
NRHc5012.CLIN.1 CSF Botswana Positive 450 N/A Africa Chen et al., (2016) 
NRHc5014.ENR CSF Botswana Positive 451 N/A Africa Chen et al., (2016) 
PMHc1049.THER1.STOR CSF Botswana Positive 460 N/A Africa Chen et al., (2016) 
PMHc1011.ENR CSF Botswana Positive 464 N/A Africa Chen et al., (2016) 
NRHc5027.ENR.CLIN1 CSF Botswana Positive 465 N/A Africa Chen et al., (2016) 
PMHc1045.ENR.STOR CSF Botswana Positive 467 N/A Africa Chen et al., (2016) 
PMHc1002.ENR CSF Botswana Positive 468 N/A Africa Chen et al., (2016) 
PMHc1009.ENR CSF Botswana Positive 469 N/A Africa Chen et al., (2016) 
NRHc5022.ENR CSF Botswana Positive 472 N/A Africa Chen et al., (2016) 
PMHc1029.ENR.STOR CSF Botswana Positive 478 N/A Africa Chen et al., (2016) 
PMHc1040.ENR.STOR CSF Botswana Positive 483 N/A Africa Chen et al., (2016) 
NRHc5010.ENR CSF Botswana Positive 484 N/A Africa Chen et al., (2016) 
Gbc16-1 dead tree Botswana NA 80 N/A Africa Chen et al., (2016) 
Ftc95-3 Mopane tree Botswana NA 89 N/A Africa Chen et al., (2016) 
Ftc98-1 Mopane tree Botswana NA 377 N/A Africa Chen et al., (2016) 
Gbc51-2 Acacia sp.  Botswana NA 378 N/A Africa Chen et al., (2016) 
Gbc42-2 Acacia sp.  Botswana NA 381 N/A Africa Chen et al., (2016) 
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Ftc321-1 Mopane tree Botswana NA 382 N/A Africa Chen et al., (2016) 
Gbc39-1 Acacia sp.  Botswana NA 383 N/A Africa Chen et al., (2016) 
Ftc103-1 Mopane tree Botswana NA 388 N/A Africa Chen et al., (2016) 
Ftc170-1 Mopane tree Botswana NA 390 N/A Africa Chen et al., (2016) 
Ftc102-1 Mopane tree Botswana NA 391 N/A Africa Chen et al., (2016) 
Ftc322-1 Mopane tree Botswana NA 393 N/A Africa Chen et al., (2016) 
Ftc327-1 Mopane tree Botswana NA 393 N/A Africa Chen et al., (2016) 
Ftc195-1 Mopane tree Botswana NA 395 N/A Africa Chen et al., (2016) 
Muc525-1 soil  Botswana NA 397 N/A Africa Chen et al., (2016) 
Ftc239-1 Mopane tree Botswana NA 399 N/A Africa Chen et al., (2016) 
Ftc214-1 Mopane tree Botswana NA 400 N/A Africa Chen et al., (2016) 
Ftc209-1 Mopane tree Botswana NA 401 N/A Africa Chen et al., (2016) 
Ftc241-1 Mopane tree Botswana NA 404 N/A Africa Chen et al., (2016) 
Ftc217-1 Mopane tree Botswana NA 405 N/A Africa Chen et al., (2016) 
Ftc211-1 Mopane tree Botswana NA 406 N/A Africa Chen et al., (2016) 
Ftc158-1 Avian guano Botswana NA 412 N/A Africa Chen et al., (2016) 
Ftc167-1 Mopane tree Botswana NA 413 N/A Africa Chen et al., (2016) 
Ftc267-1 Mopane tree Botswana NA 413 N/A Africa Chen et al., (2016) 
Muc402-1 Mopane tree Botswana NA 414 N/A Africa Chen et al., (2016) 
Gbc574-1 Ziziphus 
mucronata 
Botswana NA 418 N/A Africa Chen et al., (2016) 
Muc470-1 Mopane tree Botswana NA 418 N/A Africa Chen et al., (2016) 
Muc479-1 Mopane tree Botswana NA 420 N/A Africa Chen et al., (2016) 
Muc416-1 Acacia sp.  Botswana NA 423 N/A Africa Chen et al., (2016) 
Muc468-1 Mopane tree Botswana NA 423 N/A Africa Chen et al., (2016) 
Ftc200-1 Mopane tree Botswana NA 425 N/A Africa Chen et al., (2016) 
Ftc192-1 Mopane tree Botswana NA 426 N/A Africa Chen et al., (2016) 
Ftc222-1 Mopane tree Botswana NA 430 N/A Africa Chen et al., (2016) 
Ftc257-1 Mopane tree Botswana NA 431 N/A Africa Chen et al., (2016) 
Gbc44-1 Acacia sp.  Botswana NA 437 N/A Africa Chen et al., (2016) 
Ftc168-1 Mopane tree Botswana NA 439 N/A Africa Chen et al., (2016) 
Gbc573-1 Ziziphus 
mucronata 
Botswana NA 440 N/A Africa Chen et al., (2016) 
Muc449-1 Ziziphus 
mucronata 
Botswana NA 441 N/A Africa Chen et al., (2016) 
Muc498-1 Mopane tree Botswana NA 441 N/A Africa Chen et al., (2016) 
Muc499-1 Mopane tree Botswana NA 441 N/A Africa Chen et al., (2016) 
Ftc555-1 Mopane tree Botswana NA 442 N/A Africa Chen et al., (2016) 
Muc418-1 Acacia sp.  Botswana NA 443 N/A Africa Chen et al., (2016) 
Muc421-3 Acacia sp.  Botswana NA 443 N/A Africa Chen et al., (2016) 
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Muc460-1 Mopane tree Botswana NA 443 N/A Africa Chen et al., (2016) 
Ftc146-1 Mopane tree Botswana NA 444 N/A Africa Chen et al., (2016) 
Muc364-1 Mopane tree Botswana NA 445 N/A Africa Chen et al., (2016) 
Ftc109-1 Mopane tree Botswana NA 446 N/A Africa Chen et al., (2016) 
Ftc260-1 Mopane tree Botswana NA 448 N/A Africa Chen et al., (2016) 
Ftc151-1 Mopane tree Botswana NA 452 N/A Africa Chen et al., (2016) 
Ftc153-1 Mopane tree Botswana NA 453 N/A Africa Chen et al., (2016) 
Ftc132-1 Mopane tree Botswana NA 454 N/A Africa Chen et al., (2016) 
Ftc134-1 Mopane tree Botswana NA 454 N/A Africa Chen et al., (2016) 
Ftc225-1 Mopane tree Botswana NA 455 N/A Africa Chen et al., (2016) 
Muc451-1 Mopane tree Botswana NA 456 N/A Africa Chen et al., (2016) 
Ftc137-1 Mopane tree Botswana NA 457 N/A Africa Chen et al., (2016) 
Ftc152-2 Mopane tree Botswana NA 457 N/A Africa Chen et al., (2016) 
Ftc111-1 Mopane tree Botswana NA 458 N/A Africa Chen et al., (2016) 
Ftc173-1 Mopane tree Botswana NA 459 N/A Africa Chen et al., (2016) 
Muc387-1 Mopane tree Botswana NA 461 N/A Africa Chen et al., (2016) 
Muc437-1 Ziziphus 
mucronata 
Botswana NA 462 N/A Africa Chen et al., (2016) 
Muc367-1 Mopane tree Botswana NA 463 N/A Africa Chen et al., (2016) 
Muc466-1 Mopane tree Botswana NA 466 N/A Africa Chen et al., (2016) 
Muc415-1 Mopane tree Botswana NA 470 N/A Africa Chen et al., (2016) 
Muc450-1 Mopane tree Botswana NA 471 N/A Africa Chen et al., (2016) 
Muc489-1 Mopane tree Botswana NA 471 N/A Africa Chen et al., (2016) 
Muc504-1 Mopane tree Botswana NA 471 N/A Africa Chen et al., (2016) 
Muc529-1 Mopane tree Botswana NA 471 N/A Africa Chen et al., (2016) 
Ftc207-1 Mopane tree Botswana NA 473 N/A Africa Chen et al., (2016) 
Ftc236-1 Mopane tree Botswana NA 474 N/A Africa Chen et al., (2016) 
Muc463-2 Mopane tree Botswana NA 475 N/A Africa Chen et al., (2016) 
Muc507-1 Mopane tree Botswana NA 476 N/A Africa Chen et al., (2016) 
Ftc154-1 Mopane tree Botswana NA 477 N/A Africa Chen et al., (2016) 
Muc503-1 Mopane tree Botswana NA 479 N/A Africa Chen et al., (2016) 
Muc433-1 Acacia sp.  Botswana NA 480 N/A Africa Chen et al., (2016) 
Muc457-1 Mopane tree Botswana NA 480 N/A Africa Chen et al., (2016) 
Muc458-1 Mopane tree Botswana NA 480 N/A Africa Chen et al., (2016) 
Muc516-1 Mopane tree Botswana NA 481 N/A Africa Chen et al., (2016) 
Ftc202-1 Mopane tree Botswana NA 482 N/A Africa Chen et al., (2016) 
mal 104 Blood Malawi Positive 4 4 Africa Litvintseva et al. Genetics. 
2006 
Tn148 Blood Tanzania Positive 4 4 Africa Litvintseva et al. Genetics. 
2006 
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ug2463 CSF Uganda Positive 6 4 Africa Litvintseva et al. Genetics. 
2006 
bt134 CSF Botswana Positive 25 5 Africa Litvintseva et al. Genetics. 
2006 
bt130 CSF Botswana Positive 13 31 Africa Litvintseva et al. Genetics. 
2006 
bt104 CSF Botswana Positive 22 31 Africa Litvintseva et al. Genetics. 
2006 
JH125.91 Clinical Tanzania Unknown 3 31 Africa Litvintseva et al. Genetics. 
2006 
mal 9 Blood Malawi Positive 30 31 Africa Litvintseva et al. Genetics. 
2006 
Tn10 Blood Tanzania Positive 32 31 Africa Litvintseva et al. Genetics. 
2006 
ug2458 CSF Uganda Positive 32 31 Africa Litvintseva et al. Genetics. 
2006 
za1346 CSF Zaire Positive 32 31 Africa Litvintseva et al. Genetics. 
2006 
mal 120 Blood Malawi Positive 2 63 Africa Litvintseva et al. Genetics. 
2006 
Tn470 Blood Tanzania Positive 2 63 Africa Litvintseva et al. Genetics. 
2006 
ug2459 CSF Uganda Positive 23 63 Africa Litvintseva et al. Genetics. 
2006 
bt150 CSF Botswana Positive 21 N/A Africa Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
bt121 CSF Botswana Positive 34 N/A Africa Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
bt9 CSF Botswana Positive 36 N/A Africa Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
UgCl018 CSF Uganda Positive 4 4 Africa Wiesner et al. mBio. 2012 
UgCl021 CSF Uganda Positive 5 5 Africa Wiesner et al. mBio. 2012 
UgCl076 CSF Uganda Positive 31 31 Africa Wiesner et al. mBio. 2012 
UgCl037 CSF Uganda Positive 39 31 Africa Wiesner et al. mBio. 2012 
UgCl040 CSF Uganda Positive 78 31 Africa Wiesner et al. mBio. 2012 
UgCl107 CSF Uganda Positive 91 31 Africa Wiesner et al. mBio. 2012 
UgCl122 CSF Uganda Positive 92 31 Africa Wiesner et al. mBio. 2012 
UgCl001 CSF Uganda Positive 93 31 Africa Wiesner et al. mBio. 2012 
UgCl011 CSF Uganda Positive 77 31 Africa Wiesner et al. mBio. 2012 
UgCl036 CSF Uganda Positive 94 31 Africa Wiesner et al. mBio. 2012 
UgCl074 CSF Uganda Positive 95 31 Africa Wiesner et al. mBio. 2012 
UgCl057 CSF Uganda Positive 63 63 Africa Wiesner et al. mBio. 2012 
UgCl030 CSF Uganda Positive 69 63 Africa Wiesner et al. mBio. 2012 
WM 148 CSF Australia Unknown 63 63 Australasia Litvintseva et al. Genetics. 
2006 
K30 Blood Korea Positive 4 4 East Asia Choi et al. FEMS Yeast Res. 
2010,10 
K1 Urine Korea Unknown 5 5 East Asia Choi et al. FEMS Yeast Res. 
2010,10 
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K54 CSF Korea Positive 312 31 East Asia Choi et al. FEMS Yeast Res. 
2010,10 
K37 CSF Korea Positive 23 63 East Asia Choi et al. FEMS Yeast Res. 
2010,10 
WH098 CSF China Positive 5 5 East Asia Dou et al., (2014) 
WH121 Blood China Positive 5 5 East Asia Dou et al., (2014) 
WH122 CSF China Positive 5 5 East Asia Dou et al., (2014) 
WH124 CSF China Positive 5 5 East Asia Dou et al., (2014) 
WH126 CSF China Positive 5 5 East Asia Dou et al., (2014) 
PU27  China Positive 5 5 East Asia Dou et al., (2014) 
PU64  China Positive 5 5 East Asia Dou et al., (2014) 
PU65  China Positive 5 5 East Asia Dou et al., (2014) 
PU147  China Positive 5 5 East Asia Dou et al., (2014) 
PU148  China Positive 5 5 East Asia Dou et al., (2014) 
PU149  China Positive 5 5 East Asia Dou et al., (2014) 
PU150  China Positive 5 5 East Asia Dou et al., (2014) 
PU151  China Positive 5 5 East Asia Dou et al., (2014) 
PU152  China Positive 5 5 East Asia Dou et al., (2014) 
PU153  China Positive 5 5 East Asia Dou et al., (2014) 
PU154  China Positive 5 5 East Asia Dou et al., (2014) 
PU155  China Positive 5 5 East Asia Dou et al., (2014) 
PU156  China Positive 5 5 East Asia Dou et al., (2014) 
PU158  China Positive 5 5 East Asia Dou et al., (2014) 
PU159  China Positive 5 5 East Asia Dou et al., (2014) 
PU160  China Positive 5 5 East Asia Dou et al., (2014) 
PU163  China Positive 5 5 East Asia Dou et al., (2014) 
PU164  China Positive 5 5 East Asia Dou et al., (2014) 
PU167  China Positive 5 5 East Asia Dou et al., (2014) 
PU1  China Negative 5 5 East Asia Dou et al., (2014) 
PU16  China Negative 5 5 East Asia Dou et al., (2014) 
PU18  China Negative 5 5 East Asia Dou et al., (2014) 
PU30  China Negative 5 5 East Asia Dou et al., (2014) 
PU33  China Negative 5 5 East Asia Dou et al., (2014) 
PU38  China Negative 5 5 East Asia Dou et al., (2014) 
PU44  China Negative 5 5 East Asia Dou et al., (2014) 
PU47  China Negative 5 5 East Asia Dou et al., (2014) 
PU49  China Negative 5 5 East Asia Dou et al., (2014) 
PU67  China Negative 5 5 East Asia Dou et al., (2014) 
PU145  China Negative 5 5 East Asia Dou et al., (2014) 
HK_02 Clinical China Unknown 4 4 East Asia Khayhan et al., (2013) 
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HK_01 Clinical China Unknown 6 4 East Asia Khayhan et al., (2013) 
WH003 Sputum China Negative 5 5 East Asia Khayhan et al., (2013) 
WH004 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH005 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH006 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH007 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH008 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH011 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH012 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH013 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH014 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH015 Sputum China Negative 5 5 East Asia Khayhan et al., (2013) 
WH016 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH017 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH019 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH020 Blood China Negative 5 5 East Asia Khayhan et al., (2013) 
WH022 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH023 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH025 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH026 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH027 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH028 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH030 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH031 Lung China Negative 5 5 East Asia Khayhan et al., (2013) 
WH033 Skin China Negative 5 5 East Asia Khayhan et al., (2013) 
WH034 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH035 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH036 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH040 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH041 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH042 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH044 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH047 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH050 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH051 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH054 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH055 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH057 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
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WH058 Skin China Negative 5 5 East Asia Khayhan et al., (2013) 
WH061 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH062 Skin China Negative 5 5 East Asia Khayhan et al., (2013) 
WH063 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH066 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH067 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH068 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH072 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH075 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH076 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH077 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH078 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH079 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH080 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH082 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH083 Blood China Negative 5 5 East Asia Khayhan et al., (2013) 
WH091 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH093 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH094 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH096 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH101 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH102 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH104 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH105 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH106 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH108 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH114 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH115 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH117 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH118 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH119 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
WH120 CSF China Negative 5 5 East Asia Khayhan et al., (2013) 
HK_03 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_04 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_05 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_06 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_07 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_08 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
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HK_09 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_10 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_11 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_12 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_13 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
HK_14 Clinical China Unknown 5 5 East Asia Khayhan et al., (2013) 
9104 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9106 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9107 Unknown Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9108 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9111 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9114 Unknown Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9165 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9166 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9167 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9170 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9172 CSF Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9173 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9174 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9179 Unknown Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9197 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9198 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9199 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9204 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9205 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9211 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9212 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9213 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9217 Unknown Japan Unknown 5 5 East Asia Khayhan et al., (2013) 
9237 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9238 CSF Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9239 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9251 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9254 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9255 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9258 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9259 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9260 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
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9261 Avian guano Japan NA 5 5 East Asia Khayhan et al., (2013) 
9263 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9264 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
9265 Skin Japan Negative 5 5 East Asia Khayhan et al., (2013) 
WH123 CSF China Positive 194 5 East Asia Khayhan et al., (2013) 
PU161  China Positive 296 5 East Asia Khayhan et al., (2013) 
WH095 Ure China Negative 186 5 East Asia Khayhan et al., (2013) 
WH071 CSF China Negative 194 5 East Asia Khayhan et al., (2013) 
WH037 CSF China Negative 31 31 East Asia Khayhan et al., (2013) 
9256 Avian guano Japan NA 31 31 East Asia Khayhan et al., (2013) 
WH001 CSF China Negative 93 31 East Asia Khayhan et al., (2013) 
WH069 CSF China Negative 191 31 East Asia Khayhan et al., (2013) 
PU162  China Positive 63 63 East Asia Khayhan et al., (2013) 
9257 Avian guano Japan NA 23 63 East Asia Khayhan et al., (2013) 
WH125 CSF China Positive 53 174 East Asia Khayhan et al., (2013) 
WH018 CSF China Negative 53 174 East Asia Khayhan et al., (2013) 
WH070 CSF China Negative 53 174 East Asia Khayhan et al., (2013) 
WH073 CSF China Negative 53 174 East Asia Khayhan et al., (2013) 
WH113 CSF China Negative 53 174 East Asia Khayhan et al., (2013) 
WH132 CSF China Positive 195 N/A East Asia Khayhan et al., (2013) 
NIIDCr0013 Clinical Japan Unknown 4 4 East Asia Umeyama et al. Jpn. J. Infect. 
Dis. 2013 
NIIDCr0012 Clinical Japan Unknown 85 5 East Asia Umeyama et al. Jpn. J. Infect. 
Dis. 2013 
NIIDCr0036 Clinical Japan Unknown 230 63 East Asia Umeyama et al. Jpn. J. Infect. 
Dis. 2013 
NIIDCr0029 Clinical Japan Unknown 63 63 East Asia Umeyama et al. Jpn. J. Infect. 
Dis. 2013 
C5 CSF China Unknown 31 31 East Asia Wu et al. Mycoses. 2015 
HLJ2 Blood China Unknown 63 63 East Asia Wu et al. Mycoses. 2015 
IUM 01-2006 Blood Italy Positive 84 5 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 99-5690 CSF Italy Positive 59 31 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 02-2304 CSF Italy Positive 75 31 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 01-3463 Blood Italy Positive 56 63 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 99-5716 CSF Italy Positive 61 63 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 98-3890 CSF Italy Positive 62 63 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 97-4634 Blood Italy Positive 65 63 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 97-4874 CSF Italy Positive 68 63 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 99-5673 CSF Italy Positive 69 63 Europe Cogliati et al. Medical 
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Mycology. 2013 
IUM 99-5719 CSF Italy Positive 138 63 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 97-4877 CSF Italy Positive 55 174 Europe Cogliati et al. Medical 
Mycology. 2013 
IUM 00-1072 CSF Italy Positive 81 174 Europe Cogliati et al. Medical 
Mycology. 2013 
AD1-76 CSF France Unknown 5 5 Europe Desnos-Ollivier et al. mBio. 
2010 
AD4-27A CSF France Unknown 75 31 Europe Desnos-Ollivier et al. mBio. 
2010 
AD4-5 CSF France Unknown 23 63 Europe Desnos-Ollivier et al. mBio. 
2010 
AD1-12 Blood France Unknown 324 63 Europe Desnos-Ollivier et al. mBio. 
2010 
Isolate1 Unknown France Unknown 320 31 Europe http://mlst.mycologylab.org/ 
Isolate2 Unknown France Unknown 321 63 Europe http://mlst.mycologylab.org/ 
Isolate4 Unknown France Unknown 323 63 Europe http://mlst.mycologylab.org/ 
Isolate3 Unknown France Unknown 322 63 Europe http://mlst.mycologylab.org/ 
blg7 Avian guano Belgium NA 5 5 Europe Litvintseva et al. Genetics. 
2006 
blg11 Avian guano Belgium NA 32 31 Europe Litvintseva et al. Genetics. 
2006 
blg12 Air in zoo Belgium NA 23 63 Europe Litvintseva et al. Genetics. 
2006 
fr1 Avian guano France NA 1 63 Europe Litvintseva et al. Genetics. 
2006 
05-0006 CSF Germany Positive 4 4 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
04-0059 CSF Germany Positive 6 4 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
09-0007 CSF Germany Positive 288 5 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
04-0106 CSF Germany #N/A 5 5 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
09-0552 CSF Germany Positive 32 31 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
10-0493 CSF Germany Positive 23 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
10-0457 CSF Germany Positive 69 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
07-0325 CSF Germany Positive 71 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
04-0202 CSF Germany Negative 2 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
10-0484 CSF Germany Unknown 58 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
10-0603 CSF Germany #N/A 63 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
08-0251 CSF Germany #N/A 67 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
09-0829 CSF Germany #N/A 289 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
08-0445 CSF Germany Negative 290 63 Europe Sanchini et al. Med Microbiol 
Immunol. 2014 
05-0070 CSF Germany Positive 174 174 Europe Sanchini et al. Med Microbiol 
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Immunol. 2014 
194_96 Lym node 
biopsy 
Kuwait  Positive 4 4 Middle 
East 
Khayhan et al., (2013) 
1608000894 CSF Qatar Positive 4 4 Middle 
East 
Khayhan et al., (2013) 
1185_04 Endotracheal 
secretion 
Kuwait  Negative 5 5 Middle 
East 
Khayhan et al., (2013) 
201_95 Lumbar 
aspirate 
Kuwait  Negative 5 5 Middle 
East 
Khayhan et al., (2013) 
1609290340 CSF Qatar Negative 5 5 Middle 
East 
Khayhan et al., (2013) 
1607001262 CSF Qatar Positive 5 5 Middle 
East 
Khayhan et al., (2013) 
481_03 CSF Kuwait  Positive 93 31 Middle 
East 
Khayhan et al., (2013) 
1605202443 CSF Qatar Negative 31 31 Middle 
East 
Khayhan et al., (2013) 
1608000352 CSF Qatar Negative 31 31 Middle 
East 
Khayhan et al., (2013) 
177_02 Wound swab Kuwait  Negative 185 31 Middle 
East 
Khayhan et al., (2013) 
8_92 CSF Kuwait  Negative 23 63 Middle 
East 
Khayhan et al., (2013) 
110_99 Blood Kuwait  Negative 69 63 Middle 
East 
Khayhan et al., (2013) 
200_16 Lym node 
biopsy 
Kuwait  Positive 175 174 Middle 
East 
Khayhan et al., (2013) 
2365_08 CSF Kuwait  Negative 174 174 Middle 
East 
Khayhan et al., (2013) 
1589_04 CSF Kuwait  Negative 192 174 Middle 
East 
Khayhan et al., (2013) 
A3 38-20 Avian guano USA NA 1 63 North 
America 
Litvintseva et al. Genetics. 
2006 
A5 35-17 Avian guano USA NA 5 5 North 
America 
Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
A2 102-5 Avian guano USA NA 15 31 North 
America 
Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
A3 1-1 Avian guano USA NA 23 63 North 
America 
Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
A4 1-12 Avian guano USA NA 58 63 North 
America 
Litvintseva et al. Genetics. 
2006 Litvintseva et al. 
PlosOne. 2011 
A1 Avian guano USA NA 2 63 North 
America 
Litvintseva et al. Genetics. 
2006 Simwami et al. PLoS 
Pathogens. 2011 
JS18 Veterinay USA NA 39 31 North 
America 
Singer et al. J Clin Microbiol. 
2014 
JS71 Veterinay USA NA 32 31 North 
America 
Singer et al. J Clin Microbiol. 
2014 
JS25 Veterinay USA NA 64 63 North 
America 
Singer et al. J Clin Microbiol. 
2014 
UFTM 14.48 Urine Brazil Positive 5 5 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.153 CSF Brazil Positive 5 5 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
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UFTM 14.32 Enviromental Brazil NA 5 5 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.132 CSF Brazil Positive 31 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.133 CSF Brazil Positive 31 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.113 CSF Brazil Positive 39 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.96 CSF Brazil Positive 32 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.140 CSF Brazil Positive 32 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.46 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.47 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.49 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.50 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.51 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.52 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.55 Urine Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.61 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.62 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.64 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.66 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.67 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.68 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.69 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.71 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.73 Blood Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.77 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.80 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.81 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.84 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.85 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.89 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.92 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
 274 | P a g e  
 
UFTM 14.93 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.95 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.97 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.99 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.100 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.102 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.104 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.106 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.107 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.108 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.115 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.116 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.119 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.122 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.123 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.125 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.126 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.127 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.128 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.129 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.131 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.137 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.138 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.139 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.142 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.143 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.144 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.145 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.146 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
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UFTM 14.148 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.149 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.150 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.151 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.152 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.156 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.157 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.158 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.160 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.162 CSF Brazil Positive 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.76 CSF Brazil Positive 540 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.44 Enviromental Brazil NA 15 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.94 CSF Brazil Kidney 
transplant/Diabets 
mellitus 
39 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.130 CSF Brazil Crohn's disease 39 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.15 Enviromental Brazil NA 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.16 Enviromental Brazil NA 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.25 Enviromental Brazil NA 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.27 Enviromental Brazil NA 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.29 Enviromental Brazil NA 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.39 Enviromental Brazil NA 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.58 Skin Brazil Kidney transplant 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.65 Blood Brazil Diabets mellitus 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.91 CSF Brazil Unknown 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.101 CSF Brazil Systemic Lupus 
Erythematosus 
93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.110 CSF Brazil Unknown 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.111 CSF Brazil Diabets 
mellitus/Nefritis 
93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.134 CSF Brazil Unknown 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.135 CSF Brazil Unknown 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.154 CSF Brazil Unknown 93 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
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UFTM 14.17 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.18 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.19 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.22 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.23 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.24 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.26 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.30 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.31 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.33 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.34 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.36 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.37 Enviromental Brazil NA 77 31 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.63 CSF Brazil Positive 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.70 Blood Brazil Positive 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.72 Blood Brazil Positive 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.87 CSF Brazil Positive 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.103 CSF Brazil Positive 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.117 CSF Brazil Positive 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.45 Urine Brazil Positive 63 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.57 BAL Brazil Positive 63 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.79 CSF Brazil Positive 63 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.83 CSF Brazil Positive 63 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.121 CSF Brazil Positive 63 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.159 CSF Brazil Positive 63 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.53 Urine Brazil Positive 71 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.98 CSF Brazil Positive 71 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.161 CSF Brazil Positive 71 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.147 CSF Brazil Positive 289 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
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UFTM 14.90 CSF Brazil Kidney transplant 23 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.43 Enviromental Brazil NA 71 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.20 Enviromental Brazil NA 2 63 South 
America 
Ferreira-Paim et al, 
PlosNTD,2017 
UFTM 14.09 Enviromental Brazil NA 15 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.10 Enviromental Brazil NA 31 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.02 Enviromental Brazil NA 93 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.03 Enviromental Brazil NA 93 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.04 Enviromental Brazil NA 93 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.07 Enviromental Brazil NA 93 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.06 Enviromental Brazil NA 77 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.08 Enviromental Brazil NA 77 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.11 Enviromental Brazil NA 77 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
UFTM 14.13 Enviromental Brazil NA 77 31 South 
America 
Ferreira-paim et. al. 
Mycoses. 2011 
br2362 Unknown Brazil Unknown 32 31 South 
America 
Litvintseva et al. Genetics. 
2006 
arg1366 Unknown Argentina Unknown 2 63 South 
America 
Litvintseva et al. Genetics. 
2006 
25_316 CSF India Negative 4 4 South Asia Khayhan et al., (2013) 
25_372 CSF India Positive 6 4 South Asia Khayhan et al., (2013) 
25_373 CSF India Positive 6 4 South Asia Khayhan et al., (2013) 
25_311 CSF India Negative 189 4 South Asia Khayhan et al., (2013) 
25_104 CSF India Positive 77 31 South Asia Khayhan et al., (2013) 
25_244 CSF India Positive 77 31 South Asia Khayhan et al., (2013) 
25_365 CSF India Positive 77 31 South Asia Khayhan et al., (2013) 
25_369 CSF India Positive 77 31 South Asia Khayhan et al., (2013) 
25_61 CSF India Positive 77 31 South Asia Khayhan et al., (2013) 
25_63 CSF India Positive 77 31 South Asia Khayhan et al., (2013) 
25_229 CSF India Positive 31 31 South Asia Khayhan et al., (2013) 
25_357 CSF India Positive 31 31 South Asia Khayhan et al., (2013) 
25_370 CSF India Positive 31 31 South Asia Khayhan et al., (2013) 
25_228 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_237 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_239 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_261 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_272 BAL India Positive 93 31 South Asia Khayhan et al., (2013) 
25_277 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
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25_290 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_292 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_302 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_304 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_308 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_312 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_313 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_334 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_336 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_337 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_341 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_344 BAL India Positive 93 31 South Asia Khayhan et al., (2013) 
25_356 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_358 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_367 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_368 CSF India Positive 93 31 South Asia Khayhan et al., (2013) 
25_105 CSF India Negative 77 31 South Asia Khayhan et al., (2013) 
25_110 CSF India Negative 77 31 South Asia Khayhan et al., (2013) 
25_52 CSF India Negative 77 31 South Asia Khayhan et al., (2013) 
25_53 CSF India Negative 77 31 South Asia Khayhan et al., (2013) 
25_62 CSF India Negative 77 31 South Asia Khayhan et al., (2013) 
25_84 Blood India Negative 77 31 South Asia Khayhan et al., (2013) 
25_14 Clinical India Unknown 77 31 South Asia Khayhan et al., (2013) 
25_40 Unknown India Unknown 77 31 South Asia Khayhan et al., (2013) 
25_18 CSF India Negative 31 31 South Asia Khayhan et al., (2013) 
25_266 CSF India Negative 31 31 South Asia Khayhan et al., (2013) 
25_298 CSF India Negative 31 31 South Asia Khayhan et al., (2013) 
25_355 CSF India Negative 31 31 South Asia Khayhan et al., (2013) 
25_299 CSF India Negative 93 31 South Asia Khayhan et al., (2013) 
25_339 CSF India Negative 93 31 South Asia Khayhan et al., (2013) 
25_371 CSF India Negative 93 31 South Asia Khayhan et al., (2013) 
25_49 CSF India Negative 93 31 South Asia Khayhan et al., (2013) 
25_50 CSF India Negative 93 31 South Asia Khayhan et al., (2013) 
25_86 CSF India Negative 93 31 South Asia Khayhan et al., (2013) 
25_78 Unknown India Unknown 93 31 South Asia Khayhan et al., (2013) 
25_33 CSF India Negative 177 31 South Asia Khayhan et al., (2013) 
25_340 CSF India Negative 187 31 South Asia Khayhan et al., (2013) 
25_328 CSF India Positive 71 63 South Asia Khayhan et al., (2013) 
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25_296 CSF India Positive 174 174 South Asia Khayhan et al., (2013) 
25_17 Blood India Negative 174 174 South Asia Khayhan et al., (2013) 
25_240 CSF India Negative 174 174 South Asia Khayhan et al., (2013) 
25_291 CSF India Negative 40 N/A South Asia Khayhan et al., (2013) 
in2629 CSF India Positive 38 31 South Asia Litvintseva et al. Genetics. 
2006 
11109 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
11112 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
109A Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
109C Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
110C Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
110D Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
130C Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_231 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_253 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_319 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_381 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
96B Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
1111I_08 Blood Thailand Negative 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D12 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D14 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D2 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D27 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D28 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D3 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D31 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D43 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D46 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D69 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D71 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
D73 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
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P6 Clinical Thailand Unknown 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG21 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG26 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG3 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG46 Avian guano Thailand NA 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
2895I_08 Blood Thailand Negative 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
268 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
328 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
544 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
612 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
778 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
2597 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
2606 CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta CSF Indonesia Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
267 CSF Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
2339 CSF Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
2594 CSF Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
3187 CSF Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta (H) Blood Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta (KT) Skin Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta (KT) Skin Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta (P) Blood Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta KLT Skin Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta RTL Skin Indonesia Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
44 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
269 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
1219 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
1_587 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
1_588 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
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1_846 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
2551_07 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_187 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_202 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_315 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_83 Clinical Thailand Unknown 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D1 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D18 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D21 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D22 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D26 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D30 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D33 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D34 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D35 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D36 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D41 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D64 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D76 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG1 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG2 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
PG32 Avian guano Thailand NA 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
20662_07 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
28170_07 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
4500_07 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
50NC2 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
50NC5 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM10 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM11 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
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CM14 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM15 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM16 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM2 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM20 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM24 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM27 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM28 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM29 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM3 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM32 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM34 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM36 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM4 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM45 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM5 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM50 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM52 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM60 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM64 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN49008 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4902 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4904 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4905 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4907 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4909 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4914 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4915 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4927 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
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CN4931 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4932 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4933 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4934 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4936 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4937 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4938 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4949 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4950 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
4_9 Clinical Thailand Unknown 82 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4952 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4954 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4955 BAL Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4956 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4957 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4968 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4970 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5001 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5002 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5003 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5005 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5009 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5011 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5013 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5014 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5017 CSF Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5019 Blood Thailand Positive 4 4 Southeast 
Asia 
Khayhan et al., (2013) 
2461_07 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
2550II_07 Blood Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
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2551_07_CM CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM1 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM12 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM13 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM17 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM18 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM22 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM23 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM25 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM26 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM33 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM37 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM38 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM39 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM40 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM41 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM42 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM43 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM44 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM46 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM47 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM48 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM49 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM51 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM55 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM56 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM57 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM58 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM59 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
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CM6 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM61 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM63 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM7 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CM8 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN49005 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4901 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4903 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4917 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4918 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4919 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4926 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4940 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4941 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4942 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4943 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4944 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4945 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4947 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4964 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4987 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4988 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4989 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4995 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN4998 CSF Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
CN5010 Blood Thailand Positive 6 4 Southeast 
Asia 
Khayhan et al., (2013) 
D9 Avian guano Thailand NA 141 4 Southeast 
Asia 
Khayhan et al., (2013) 
D42 Avian guano Thailand NA 176 4 Southeast 
Asia 
Khayhan et al., (2013) 
110E Avian guano Thailand NA 188 4 Southeast 
Asia 
Khayhan et al., (2013) 
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130D Avian guano Thailand NA 190 4 Southeast 
Asia 
Khayhan et al., (2013) 
40 Avian guano Thailand NA 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
1_488 Clinical Thailand Unknown 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
1_489 Clinical Thailand Unknown 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
189E Avian guano Thailand NA 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN48 Clinical Thailand Unknown 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
D16 Avian guano Thailand NA 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
D4 Avian guano Thailand NA 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
D6 Avian guano Thailand NA 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
PG37 Avian guano Thailand NA 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CM30 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN49004 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN49006 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4906 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4916 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4920 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4921 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4924 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4946 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4948 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4960 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4967 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4977 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4980 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4983 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN4993 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN5008 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN5012 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
CN5015 CSF Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
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CN5018 Blood Thailand Positive 5 5 Southeast 
Asia 
Khayhan et al., (2013) 
D44 Avian guano Thailand NA 193 5 Southeast 
Asia 
Khayhan et al., (2013) 
132 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
597 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
676 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1019 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1051 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1116 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1200 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1206 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1336 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1462 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1571 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
2126 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
3400 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
3594 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
3634 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
Jakarta 1051 CSF Indonesia Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
CR2231 CSF Indonesia Positive 177 31 Southeast 
Asia 
Khayhan et al., (2013) 
CR755 CSF Indonesia Positive 177 31 Southeast 
Asia 
Khayhan et al., (2013) 
CM35 CSF Thailand Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
CN5007 CSF Thailand Positive 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
D15 Avian guano Thailand NA 31 31 Southeast 
Asia 
Khayhan et al., (2013) 
D17 Avian guano Thailand NA 31 31 Southeast 
Asia 
Khayhan et al., (2013) 
D19 Avian guano Thailand NA 31 31 Southeast 
Asia 
Khayhan et al., (2013) 
1048 Unknown Indonesia Unknown 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
3281 Unknown Indonesia Unknown 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
1291_09 Blood Thailand Negative 93 31 Southeast 
Asia 
Khayhan et al., (2013) 
CR0E CSF Indonesia Negative 177 31 Southeast 
Asia 
Khayhan et al., (2013) 
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110A Avian guano Thailand NA 185 31 Southeast 
Asia 
Khayhan et al., (2013) 
264 CSF Indonesia Positive 69 63 Southeast 
Asia 
Khayhan et al., (2013) 
2478 CSF Indonesia Positive 69 63 Southeast 
Asia 
Khayhan et al., (2013) 
34 Avian guano Thailand NA 53 174 Southeast 
Asia 
Khayhan et al., (2013) 
D45 Avian guano Thailand NA 175 174 Southeast 
Asia 
Khayhan et al., (2013) 
CNS1553 CSF Laos Negative 4 4 Southeast 
Asia 
This study 
FS4256/ CNS1444 CSF Laos Negative 4 4 Southeast 
Asia 
This study 
UI_16721 CSF Laos Negative 4 4 Southeast 
Asia 
This study 
CNS456 CSF Laos Negative 6 4 Southeast 
Asia 
This study 
UI_16771 CSF Laos Negative 6 4 Southeast 
Asia 
This study 
BK1 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK111 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK120 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
CNS1017 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1047 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1110 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1129 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1179 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1181 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS133_2 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1379 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS1394 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS199 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS289 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS360 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS365 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS447 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS625 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS681 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
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CNS806 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS814 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS897 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS929 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS955 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS978 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS999 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
HC_ST2296 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
HC_ST352 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
UI_11199 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
UI_29674 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
UI31647_2 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
UI32312 CSF Laos Positive 4 4 Southeast 
Asia 
This study 
CNS245 CSF Laos Unknown 4 4 Southeast 
Asia 
This study 
CNS57 CSF Laos Unknown 4 4 Southeast 
Asia 
This study 
04CN30_001/ UI24618/ 
CNS1285 
CSF Laos Positive 6 4 Southeast 
Asia 
This study 
04CN30_008 / UI21923 / 
CNS1143_2 
CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS_ST1930 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1026 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1085 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1087 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1089 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1125 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1156 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1285 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1302 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1385 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1403 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1413 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
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CNS1419 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1420 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1453 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1474 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS1589 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS198 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS445 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS569 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS573 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS863 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS984 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
ST1931 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
UI_12808 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
UI_14167 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
UI_14344 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
UI_21616 CSF Laos Positive 6 4 Southeast 
Asia 
This study 
CNS626 CSF Laos Positive 306 4 Southeast 
Asia 
This study 
BK14 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK151 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK156 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK163 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK182 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK192 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK193 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK2 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK224 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK225 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK23 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK30 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
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BK35 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK48 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK56 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK57 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK59 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK69 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
CNS595 CSF Laos Unknown 4 4 Southeast 
Asia 
This study 
BK73 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK74 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK80 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK87 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK88 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK89 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BK90 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BMD1392 CSF Vietnam Negative 4 4 Southeast 
Asia 
This study 
BMD1415 CSF Vietnam Negative 4 4 Southeast 
Asia 
This study 
BMD1879 CSF Vietnam Positive 4 4 Southeast 
Asia 
This study 
BMD394 CSF Vietnam Negative 4 4 Southeast 
Asia 
This study 
BK115 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
CNS430 CSF Laos Unknown 6 4 Southeast 
Asia 
This study 
BK116 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK117 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK119 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK124 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK139 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK147 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK15 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK160 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK169 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
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BK171 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK175 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK185 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK190 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK20 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK241 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
CNS128 CSF Laos Negative 5 5 Southeast 
Asia 
This study 
CNS1569 CSF Laos Negative 5 5 Southeast 
Asia 
This study 
BK25 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK26 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK28 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK34 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK38 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK4 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK41 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK42 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK44 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK45 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK49 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK50 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK54 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK58 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK62 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK63 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK76 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK78 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BK94 CSF Vietnam Positive 5 5 Southeast 
Asia 
This study 
BMD101 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1198 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
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BMD1228 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1232 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1291 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1338 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1353 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1452 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1465 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1534 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1592 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1646 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
04CN30_002 / UI24734/ 
CNS1292_3 
CSF Laos Positive 5 5 Southeast 
Asia 
This study 
04CN30_016/ UI14893/ 
CNS605_2 
CSF Laos Positive 5 5 Southeast 
Asia 
This study 
04CN30_019/ UI29069/ 
CNS1415_2 
CSF Laos Positive 5 5 Southeast 
Asia 
This study 
CNS121 CSF Laos Positive 5 5 Southeast 
Asia 
This study 
CNS1396_2 CSF Laos Positive 5 5 Southeast 
Asia 
This study 
CNS517 CSF Laos Positive 5 5 Southeast 
Asia 
This study 
CNS936 CSF Laos Unknown 5 5 Southeast 
Asia 
This study 
BMD1713 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1716 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD1828 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD367 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD368 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD494 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD534 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD673 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD700 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD732 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD761 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD852 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
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BMD854 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD865 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD894 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD899 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD903 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD910 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BMD973 CSF Vietnam Negative 5 5 Southeast 
Asia 
This study 
BK18 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK188 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK189 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK205 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK218 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK219 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK234 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK52 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK71 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK75 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BK96 CSF Vietnam Positive 6 4 Southeast 
Asia 
This study 
BMD745 CSF Vietnam Negative 6 4 Southeast 
Asia 
This study 
BK11 CSF Vietnam Positive 32 31 Southeast 
Asia 
This study 
BK17 CSF Vietnam Positive 32 31 Southeast 
Asia 
This study 
BK27 CSF Vietnam Positive 32 31 Southeast 
Asia 
This study 
BK46 CSF Vietnam Positive 32 31 Southeast 
Asia 
This study 
CNS487 CSF Laos Negative 93 31 Southeast 
Asia 
This study 
CNS1465 CSF Laos Positive 187 31 Southeast 
Asia 
This study 
BK68 CSF Vietnam Positive 32 31 Southeast 
Asia 
This study 
BMD915 CSF Vietnam Negative 32 31 Southeast 
Asia 
This study 
CNS811 CSF Laos Unknown 93 31 Southeast 
Asia 
This study 
BMD942 CSF Vietnam Negative 32 31 Southeast 
Asia 
This study 
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BK154 CSF Vietnam Positive 39 31 Southeast 
Asia 
This study 
BK167 CSF Vietnam Positive 39 31 Southeast 
Asia 
This study 
BK209 CSF Vietnam Positive 39 31 Southeast 
Asia 
This study 
BK12 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK157 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK179 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK213 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK228 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK24 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK33 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK85 CSF Vietnam Positive 93 31 Southeast 
Asia 
This study 
BK109 CSF Vietnam Positive 137 4 Southeast 
Asia 
This study 
BK172 CSF Vietnam Positive 188 4 Southeast 
Asia 
This study 
BK64 CSF Vietnam Positive 188 4 Southeast 
Asia 
This study 
BK129 CSF Vietnam Positive 195 N/A Southeast 
Asia 
This study 
BMD1367 CSF Vietnam Negative 306 4 Southeast 
Asia 
This study 
BK150 CSF Vietnam Positive 338 31 Southeast 
Asia 
This study 
BK153 CSF Vietnam Positive 339 31 Southeast 
Asia 
This study 
BK55 CSF Vietnam Positive 340 31 Southeast 
Asia 
This study 
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Publications 
Parts of this thesis have been included in publications: 
Chapter 1 (Introduction) was included in a review: 
Beardsley, J., Thanh, L.T. & Day, J (2017) A Model CNS Fungal Infection: 
Cryptococcal Meningitis. J. Curr Clin Micro Rpt 2:96. 
(https://doi.org/10.1007/s40588-015-0016-0) 
Preliminary MLST data from Chapter 2 (MLST) was published in this PlosNTD paper in 
2017: 
Day JN, Qihui S, Thanh LT, Trieu PH, Van AD, Thu NH, et al. (2017) Comparative 
genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV 
infected and uninfected patients in Vietnam. PLoS Negl Trop Dis 11(6): e0005628. 
https://doi.org/10.1371/journal.pntd.0005628 
Manuscripts for additional MLST data (Chapter 2) and mouse data (Chapter 3) are being 
prepared for publication.  
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